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Abstract 
Lysosomes and endocytic organelles are intracellular bodies present in eukaryotic 
cells responsible for the degradation of endocytosed extracellular targets. 
Autophagosomes traffic proteins, organelles, and other intracellular components to 
lysosomes to facilitate degradation during the degradative process of autophagy. Multiple 
disorders have been connected to malfunctions in lysosomes (Nieman pick, 
galactosialidosis, Danon disease) and autophagosomes (Alzheimers, Parkinson’s, 
Huntington’s). 
Methods are needed to enrich organelles in order to study their properties without 
contamination from unwanted organelles. Current methods to enrich endocytic organelles 
do not result in highly enriched organelles (differential centrifugation), are time 
consuming and tedious (density gradient centrifugation), and can damage membranes. 
Methods are also needed to determine endocytic and autophagy organelle properties such 
as organelle molecular composition, organelle-specific biotransformation of anti-cancer 
drugs, individual organelle surface properties and marker protein levels, and pH. The 
work described in this thesis develops new techniques to improve our ability to enrich 
endocytic organelles and determine their properties. This work includes: (1) the magnetic 
enrichment of endocytic organelles and determination of pH by capillary cytometry, (2) 
the determination of the biotransformation of N-L-leucyldoxorubicin to doxorubicin, (3) 
the development of a workflow to determine preliminary identifications of enriched 
autophagosome samples and (4) determine temporal changes in individual autophagy 
organelle numbers, surface charge, and LC3-II levels from basal and rapamycin enhanced 
autophagy levels. These methods will improve our understanding of how lysosomes and 
autophagosomes contribute to disease, leading to better therapeutic strategies that may 
improve and lengthen people’s lives. 
Endocytic organelle enrichment was done by trafficking dextran coated magnetic 
iron oxide nanoparticles to lysosomes and endocytic organelles prior to magnetic 
separation. No detectable enzymatic activity from mitochondria and peroxisomes were 
observed in the enriched endocytic organelle fractions suggesting that the enriched 
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lysosomes were in high enrichment. A majority of enriched, individual endocytic 
organelles had an acidic pH as determined by capillary cytometry suggesting the enriched 
endocytic organelle fraction had intact membranes. Enriched endocytic organelle 
fractions were then used to determine the biotransformation of N-L-leucyldoxorubicin to 
doxorubicin. Previous reports had suggested endocytic organelles may be important for 
intracellular biotransformation. About 45% of the biotransformation from uterine 
sarcoma cell post nuclear fraction occurred in the enriched endocytic organelle fraction 
suggesting intracellular biotransformation may be more critical to prodrug activation than 
previously believed. 
Ultra high performance liquid chromatography coupled to near-simultaneous low- 
and high-collision energy mass spectrometry was used to determine preliminary 
identifications of compounds enriched or unique to enriched autophagosome fractions. A 
workflow was developed to detect and confirm features (unidentified compounds with a 
characteristic chromatographic tR and m/z value) in the enriched sample as well as 
making and confirming identifications from online databases. Multiple high-relevancy 
preliminary identifications were made that are relevant to autophagy as supported by 
literature searches. Following validation, these preliminary identifications could prove to 
be important to maintain autophagosome function and autophagy. 
Capillary electrophoresis coupled to laser induced fluorescence detection (CE-
LIF) was used to determine temporal changes in the detected number of individual 
autophagy organelle events (phagophores, autophagosomes, amphisomes, and 
autolysosomes), of GFP-LC3-II levels, and of surface charge by CE-LIF. 
Pharmacological treatment with vinblastine was used to accumulate autophagosomes and 
phagophores from basal and rapamycin enhanced autophagy do detect temporal changes 
in autophagy organelles characteristic of the autophagy level and its autophagy flux. The 
dramatic contrast between time dependent changes in individual organelle properties 
between basal and rapamycin enhanced autophagy conditions demonstrates an 
anticipated complexity of autophagy flux which likely plays critical role in response to 
drug treatments, aging, and disease.  
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Chapter 1 
Thesis Overview 
  
 2 
Lysosomes and endocytic organelles are responsible for degradation of cellular 
components. Lysosomes degrade components by endocytosis, a process which 
internalizes extracellular components. Similarly, autophagy degrades intracellular 
components.  Deficiencies in both endocytosis and autophagy have been associated with 
aging, lysosomal storage diseases, neurodegenerative diseases, and cancer.
1-10
 To 
determine how loss of proper autophagy and endocytic organelle function contributes to 
these different biological states, new methods are needed to enrich lysosome and 
fractions devoid of contaminations from unwanted organelles and to determine endocytic 
and autophagy organelle properties. Currently, the field is limited by methods that cannot 
produce enriched organelle fractions from various biological systems and without 
damaging endocytic organelle membranes. In addition, properties of individual endocytic 
and autophagy organelles such as electrophoretic mobility, fluorescent protein intensity, 
numbers of organelle detected events, pH of enriched organelles, and molecular 
composition have not yet been determined. These studies would provide the scientific 
community with new insights regarding the effects of modified autophagy flux on 
biological systems and the function of endocytosis and autophagy 
There are limitations with the current techniques used to enrich endocytic 
organelles and determine autophagy organelle properties. Current techniques used to 
enrich endocytic organelles can require large amounts of starting material, result in 
fractions with contamination from unwanted organelles, or result in fractions with 
disrupted organelle membranes. The lack of enrichment techniques that overcome these 
limitations prevents studies of endocytic organelle properties such as the capability of an 
organelle to biotransform drugs and prodrugs. 
The dynamic nature of autophagy and the multiple autophagy organelles involved 
make bulk measurements, such as those done by Western blotting, inadequate to 
understand autophagy and its roles in aging and disease. Analytical techniques that 
monitor time-dependent changes in the properties and numbers of individual autophagy 
organelles are highly needed. Temporal measurements are needed to determine the 
properties of autophagy organelles from different autophagy conditions by accumulating 
au 
 3 
tophagosomes and phagophores from basal and rapamycin enhanced autophagy 
conditions. 
Untargeted analysis of autophagosome composition also has not been performed. 
Improved understanding of autophagosome composition could expand the number of 
identified molecules that affect autophagosome function and autophagy levels. The 
analysis of subcellular composition provides insight regarding biological pathways 
occurring in organelles and how these pathways can affect proper organelle function. 
Most studies of organelle composition have been targeted analyses that limit the detection 
of molecular classes such as proteins.  
The goal of this thesis was to develop new techniques to enrich endocytic 
organelles with no detectable organelle contamination and intact endocytic organelle 
membranes and to develop new techniques to determine autophagosome properties. 
Biotransformation of N-L-leucyldoxorubicin to doxorubicin, an anti-cancer prodrug, 
specific to enriched endocytic organelles was determined. A new method was developed 
to monitor temporal changes of individual autophagy organelle numbers and properties. 
Furthermore, a new methodology was developed to gain insights of the small molecule 
composition of enriched autophagosomes by a non-targeted liquid chromatography-
coupled to mass spectrometry method and development of a workflow to make 
preliminary identifications of autophagosome-enriched fractions. 
Chapter 2 begins with an introduction of endocytic organelle and autophagy-
related organelles (organelle with LC3-II). The discussion includes an introduction to 
endocytosis and autophagy, the pathways responsible for degradation of extra- and intra-
cellular components. Techniques and methodologies used to enrich and determine the 
properties of isolated endocytic organelles and autophagosomes are also discussed 
including why techniques were chosen for determination of organelle properties. 
Prior techniques used to enrich endocytic organelles were not capable of 
producing fractions without unwanted organelles, maintain intact endocytic organelle 
membranes, and reduce the experimental time needed to enrich endocytic organelles to 
minimize the loss of enzymatic activity.
11-15
 The work described in Chapter 3 describes a 
 4 
method for enriching magnetically-labeled endocytic organelles. Collected endocytic 
organelle fractions did not have detectable enzymatic activity of both mitochondria and 
peroxisomes. Enriched organelles fractions also had intact membranes as indicated by 
their acidic pH, determined by capillary cytometry. This provides enriched endocytic 
organelle fractions that in future studies can be used for determination of endocytic 
organelle dynamics, metabolomics of endocytic organelles, and endocytic-organelle 
specific anti-cancer prodrug biotransformation as done in the work described in Chapter 
4. 
Previous studies have suggested the anti-cancer prodrug N-L-leucyldoxorubicin 
(LeuDox) is biotransformed to doxorubicin (Dox) outside whole cells
16-18
 until recently 
when LeuDox was discovered to be biotransformed in a fraction containing endocytic 
organelles.
19
 This fraction, however, also likely contained unwanted organelles such as 
mitochondria and peroxisomes because differential centrifugation was used to enrich the 
endocytic organelle fraction. This makes it difficult to determine to what extend the 
endocytic organelles were responsible for the biotransformation.  The work described in 
Chapter 4 discusses the biotransformation of the LeuDox to Dox in highly enriched 
endocytic organelle fractions. Enriched endocytic organelle fractions were treated with 
LeuDox. Micellar electrokinetic chromatography with laser induced fluorescence 
detection (MEKC-LIF) was used to determine concentrations remaining of LeuDox and 
accumulated Dox. Biotransformation of LeuDox to Dox was confirmed to occur in the 
enriched endocytic organelle fraction. The combination of highly enriched organelle 
fractions and excellent limits of detection of MEKC-LIF allowed for the determination of 
LeuDox to Dox biotransformation in the endocytic organelle fraction. This suggests 
endocytic organelles are responsible for intracellular LeuDox biotransformation to Dox 
and suggests the intracellular biotransformation of endocytic organelles needs to be 
accounted for in prodrug and drug design. 
The work described in Chapters 5 and 6 discuss the development of two 
methodologies to determine autophagosome properties. Proteins
6
 and lipids
20
 such as 
LC3,
21
 the Atg proteins,
22-26
 phosphatidylethanolamine,
27
 and ceramide
28
  have been 
previously identified in autophagosomes with targeted approaches. However, the 
 5 
composition of autophagosomes has not been investigated by untargeted techniques 
which can detect additional molecules enriched and provide insight into autophagosome 
composition and autophagy function. The work described in Chapter 5 discusses the 
preliminary identifications of compounds enriched or unique to enriched autophagosome 
fractions by ultra high performance liquid chromatography coupled to simultaneous low- 
and high-collision energy mass spectrometry (UPLC-MS
e
). A data analysis approach was 
developed to ensure that preliminary detected features had extracted ion chromatograms 
(XIC) with chromatographic peak profiles, detect daughter ions supporting database 
identifications, and confirm daughter ions have matching XICs with their parent ions. 
Overall, 187 features (unidentified compounds) and 34 preliminary identifications were 
detected in the enriched autophagosome fractions. These detected molecules will be 
validated and analyzed further in the future to determine their role in autophagosome 
function, their role in autophagy flux, and their role in autophagosome-related diseases. 
Current techniques to monitor autophagy detect LC3-II levels in bulk or whole 
cells.
29-33
 These techniques do not assess temporal changes in individual autophagy 
organelles following pharmacological treatment to accumulate autophagosomes and 
phagophores.  The work described in Chapter 6 determines temporal changes in 
autophagy organelle properties from basal and rapamycin enhanced autophagy by CE-
LIF. Vinblastine was used to accumulate autophagosomes and phagophores. Under basal 
autophagy conditions, there was a net accumulation of organelles, which mostly represent 
autophagosomes; because autolysosomes also degrade, the higher GFP-LC3 fluorescence 
and more positive electrophoretic mobility of individual organelles likely represent 
differences between these two organelle types. When autophagy was enhanced by 
rapamycin treatment, disappearance of autophagy organelles (autolysosomes) prevailed 
over formation of other autophagy organelles, the GFP-LC3 fluorescence of individual 
organelles decreased suggesting accumulation of organelles with lower levels of this 
marker, and the individual electrophoretic mobilities were more negative suggesting that 
organelles formed have a different surface composition.  The dramatic contrast between 
time dependent changes in individual organelle properties between basal and rapamycin-
 6 
driven conditions demonstrates an anticipated complexity of autophagy flux which likely 
plays critical role in response to drug treatments, aging, and disease.   
In conclusion, the developments in this thesis add significantly to the field of 
organelle analysis and may result in new studies to determine the role endocytic and 
autophagy organelles in aging and disease. Endocytic organelle enrichments can be used 
to determine the composition, organelle surface properties, and biotransformation of anti-
cancer drugs specific to endocytic organelles. The determination of intracellular 
biotransformation of drugs and prodrugs and can be applied to other prodrugs that may 
not only be activated both extracellularly and intracellularly. Furthermore, this technique 
may be useful to determine other biotransformations that are attributed to lysosomes and 
other endocytic organelles. The composition of autophagosomes, autophagy organelle 
numbers, and autophagy organelle properties can give new insights of autophagosome 
function and autophagy levels.  
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Chapter 2 
Introduction 
  
 8 
This chapter describes endocytic and autophagy-related organelles including their 
relevant biological properties. Current techniques are described that enrich endocytic and 
autophagy-related organelles as well as techniques that monitor autophagy and detect 
unwanted organelles in enriched organelle samples. Finally, this chapter describes ultra 
high performance liquid chromatography coupled to mass spectrometry (UPLC-MS) and 
capillary electrophoresis coupled to laser induced fluorescence detection (CE-LIF). These 
two techniques were used to preliminarily identify molecules enriched in autophagosome 
fractions (described in Chapter 5) and to determine the characteristics of autophagy flux 
by accumulating autophagosomes and phagosomes from basal and rapamycin enhanced 
autophagy (described in Chapter 6), respectively. 
2.1. Lysosomes and acidic organelles 
Lysosomes are endocytic organelles that degrade extracellular and intracellular 
cargo accumulated by either endocytosis or autophagy, respectively. Lysosomes have an 
acidic pH (~5.0) caused by an accumulation of protons in their lumen. Numerous 
hydrolases, oxidases, and transferases are enzymes localized in the lysosomes responsible 
for lysosome’s degradative properties. These enzymes are responsible for the degradation 
of proteins, polysaccharides, nucleic acids, lipids, and organelles.
2, 34, 35
 Nonfunctioning 
or missing lysosomal enzyme activity or enzymes are responsible for many lysosome-
associated diseases such as Tay-Sachs (missing β-hexosaminidase α-chain), Schindler 
disease type 1 (missing α-N-acetylgalactosaminidase), mannosidosis (missing lysosomal 
α-mannosidase), and Niemann-Pick types a and b (missing sphingomyelin 
phosphodiesterase).
36-39
  
 Endocytosis is responsible for degradation of extracellular components. 
Endocytosis, including phagocytosis, pinocytosis, and macropinocytosis, is categorized 
based on the size ( > 1 μm for phagocytosis) and entry method of the endocytosed cargo 
(binding to specific surface receptors such as clathrin and caveolin or non-selective 
internalization; Figure 2.1).
40, 41
 After internalization, components are trafficked to 
different intracellular routes. Some cargo is trafficked to both sorting and early 
endosomes for cargo marked for recycling while cargo marked for degradation, such as 
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carbohydrates like dextran, traffics to the early endosome, then to the late endosome, and 
finally to the lysosomes. Dextran coated nanoparticles are endocytosed by 
macropinocytosis due to the dextran coating of the particle
42
 and trafficked to late 
endosomes and lysosomes.
43, 44
 These nanoparticles were used in the experiments 
described in Chapter 3 to traffic magnetic dextran coated iron oxide nanoparticles to late 
endosomes and lysosomes to facilitate their magnetic enrichment. The iron oxide 
nanoparticle is magnetic and is attracted to an external magnetic field. This allows for 
organelles sequestered to magnetic nanoparticles to be enriched. Once localized in the 
lysosomes, lysosomal enzymes degrade the dextran coating and iron oxide nanoparticles 
after 6 hours, allowing for enrichment during that time.
45, 46
 
 
Figure 2.1. Relationship between endocytic organelles. Extracellular contents are 
endocytosed in a vesicle. The vesicle then matures to form, in sequential order, early 
endosomes, late endosomes, and lysosomes. Lysosomes are responsible for the 
degradation of both endocytosed and autophagocytosed contents. 
Assessment of individual organelle pH following enrichment of endocytic 
organelles can indicate the lysosome lipid bilayer is intact because organelles with intact 
membranes may retain their acidic pH. The lysosome membrane is composed of a single 
lipid bilayer that contains v-type ATPases.
47
 These ATPases cause accumulation of 
protons in the lysosome that decreases pH. If lysosome membranes are disrupted during 
enrichment, the proton gradient between the cytosol and lysosome lumen is lost and the 
 10 
lysosome pH is increased. Following enrichment with dextran coated magnetic 
nanoparticles, the pH of enriched acidic organelles was determined using the ratio of a 
pH-dependent (fluorescein) and pH-independent (tetramethylrhodamine) fluorophores by 
capillary cytometry (described in Chapter 3).
48
 
Weak bases are able to diffuse through lysosomal membranes into lysosomes and 
become positively charged which prevent their diffusion back to the cytosol.
49
 
Sequestration is due to the pKa of weak bases being increased when compared to the pH 
of acidic organelles, as indicated by the Henderson-Hasselbalch equation (Equation 2.1) 
where [HB] and [B
-
] are the protonated and de-protonated weak base, respectively.  
          
   
     
     Equation 2.1. 
Considering the pH of lysosomes is generally 4-5, a majority of intracellular weak 
bases can be protonated and sequestered in the lysosome. These weak bases are defined 
as lysosomotropic agents,
49
 an example of which is the fluorescent dyes Lysotracker Red 
(pKa = 7.5) which is fluorescent upon protonation and drugs such as chloroquine (pKa = 
8.5). 
Biotransformation of anti-cancer drugs in endocytic organelles is decreased for 
many drugs and cancer cell lines due to the increased pH of endocytic organelles. In 
some cancerous cell lines, the endocytic organelle pH is increased when compared to the 
endocytic organelle pH of non-cancerous cells.
49
 This causes decreased trafficking of 
anti-cancer drugs into endocytic organelles of some cancerous cell lines.
49-52
 Conversely, 
some anti-cancer drugs, such as N-L-leucyldoxorubicin (LeuDox, pKa = 9.6) was 
believed to be biotransformed exclusively in the extracellular space.
16-18, 53
 Recent 
evidence by the Arriaga lab has disputed this by suggesting intracellular LeuDox 
biotransformation occurs; increased biotransformation occurs in endocytic organelles.
19
 
Chapter 4 describes the determination of biotransformation of LeuDox to Dox specific to 
enriched endocytic organelle fractions. 
2.2. Autophagosomes and autophagy-related organelles 
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Autophagosomes are involved in autophagy that, like endocytosis, is responsible 
for the degradation of intracellular cargo.
6, 54
 During autophagy, autophagosomes 
accumulate functional and dysfunctional proteins, nucleic acids, lipids, and organelles. 
Perhaps the most distinct feature of autophagosomes is their double-membrane, lipid-
bilayer.
55, 56
 LC3-II is a protein localized on both sides of the membrane of autophagy-
related organelles and is often used for monitoring either autophagy levels and/or 
autophagy flux in bulk samples.
57, 58
 Lipidation of the isoform LC3-I with 
phosphatidylethanolamine produces the isoform LC3-II causing sequestration to the 
autophagy-related organelles (phagophores, autophagosomes, amphisomes, and 
autolysosomes, Figure 2.2). The work described in Chapter 5 uses LC3-II to monitor 
autophagosome organelle enrichment and the work described in Chapter 6 uses 
fluorescently labeled LC3-II to detect autophagy-related organelle events. 
 
Figure 2.2. Relationship between autophagy organelles. Intracellular contents can be 
engulfed by a phagophore forming an autophagosome. The autophagosome then delivers 
its contents to autolysosomes by either fusion with lysosomes or fusion with endosomes 
to form amphisomes followed by maturation to autolysosomes. Following degradation, 
autolysosomes are recycled to form autophagosomes and lysosomes. 
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Autophagy can be divided into macroautophagy, microautophagy, and chaperone-
mediated autophagy. During macroautophagy, phagophores form around cytosolic targets 
such as proteins and organelles (Figure 6.1). The phagophore membrane can originate 
from different subcellular locations such as the omegasome, which is a portion of the ER, 
mitochondria, Golgi, and plasma membrane. Therefore, autophagy organelles may have 
many different surface compositions.
59-62
 Phagophores then form autophagosomes, 
membrane-bound organelles with internalized intracellular components. 
Autophagosomes then fuse with lysosomes to form autolysosomes where the sequestered 
components are degraded.
63, 64
 This occurs through either (1) direct interaction with 
lysosomes to form autolysosomes where the hydrolases of the lysosome degrade the 
targets or (2) interaction with endosomes to form amphisomes followed by lysosome 
interaction.
65, 66
 Following degradation, lysosomes are recycled form the autolysosome in 
a process defined as autophagic lysosome reformation
67
 In microautophagy, intracellular 
components are delivered to pre-formed autophagosomes.
6, 8
 In chaperone-mediated 
autophagy, intracellular components are delivered directly to lysosomes for degradation.
6, 
68
 Microautophagy and chaperone-mediated autophagy are not investigated in the work 
described in this thesis. 
The Atg proteins are perhaps the best characterized components of autophagy 
organelles. These proteins were discovered in yeast using genetic screens by creating 
mutant cells with genetic knockdowns of Atg genes.
69
 These cell lines had decreased 
protein degradation and electron microscopy was used to observe modified 
autophagosome morphology. Atg (autophagy-related) proteins were later discovered in 
mammalian cells
70
 and led to the identification of protein complexes responsible for 
autophagosome formation.
71, 72
 Lipids conjugated to proteins, such as LC3-II and 
phosphatidylethanolamine,
73
 SNARE proteins, such as Sec9 and Tlg2,
74
 and signaling 
proteins to mark degradation of other organelles,
75
 such as Parkin,
76
 were also 
discovered. These studies used Western blotting, fluorescence confocal microscopy, and 
thin layer chromatography to detect targeted molecules based on prior knowledge of the 
autophagosome composition in yeast and mammalian cells.  
2.3. Techniques used to monitor autophagy flux 
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Autophagy flux is defined as the rate of sequestration of intracellular components 
and the rate of degradation of autophagocytosed cargo. Autophagocytosed cargo is 
degraded and trafficked to lysosomes in organelles possessing LC3-II. The disruption of 
basal autophagy flux (autophagy flux occurring in healthy cells) has been associated with 
Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, increased cancer rates, 
and aging.
6, 8, 9, 77, 78
 
LC3-II has been used to monitor changes in autophagy. Because autophagy 
degradation requires autophagy-related organelles, LC3-II is formed and LC3-I levels 
decrease. Therefore, increased levels of LC3-II is indicative of increased numbers of 
autophagy organelles and increased autophagy levels.
57
 Western blotting,
79
 fluorescence 
confocal microscopy, and flow cytometry have all been used to assess autophagy levels. 
Western blotting qualitatively determines the levels of LC3-I and LC3-II in a biological 
system, however, the technique has limited sensitivity.
29
 Issues also arise due to anti-LC3 
antibodies with varying specificity for LC3-I and LC3-II detection.
29
 Fluorescent-labeled 
LC3-II levels can be monitored by detecting punctates by fluorescence confocal 
microscopy.
31, 32, 65
 Limitations of fluorescence confocal microscopy include discerning 
individual organelle punctates in images (from other organelles and diffuse, fluorescently 
labeled LC3-I) and LC3-I protein complexes which can be misidentified as autophagy-
related organelles.
29, 80
 Finally, flow cytometry has been used to monitor fluorescently 
labeled LC3-II levels in cells. Whole cells are treated with saponin to extract 
fluorescently-labeled LC3-I.
33
 The GFP-LC3 fluorescence remaining following 
extraction is representative of GFP-LC3-II fluorescence and autophagy-related organelle 
levels. Similar limitations exist for flow cytometry as for fluorescence confocal 
microscopy and Western blotting.  
Temporal measurements are used to determine the properties of autophagy 
organelles from different autophagy conditions. Pharmacological treatment with 
vinblastine halts autophagy just before the formation of autolysosomes.
81
 For example, 
vinblastine treatment prevents autophagosomes and amphisomes from fusing with 
lysosomes due to microtubule degradation (Figure 2.2.).
81
 This leads to accumulation of 
autophagosomes, phagophores, and a small number of amphisomes and the 
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disappearance of autolysosomes which are still recycled to lysosomes and LC3-I.
81, 82
 The 
rates of accumulation and disappearance of numbers and properties of accumulated 
autophagy organelles can then be determined for different autophagy conditions.
83
 
Immunoblotting results in an increase in LC3-II signal when autophagosomes were 
accumulated for basal flux.
84
 Enhancement of autophagy results in decreased GFP-LC3-
II levels when compared to basal autophagy determined by immunoblotting.
83
  
Accumulation of autophagosomes by chloroquine treatment caused an accumulation of 
GFP-LC3-II levels as determined by flow cytometry.
33
 The dynamic nature of autophagy 
and the multiple autophagy organelles involved make bulk measurements, such as those 
described above, inadequate to understand autophagy and its roles in aging and disease. 
The work described in Chapter 6 reports the first analysis of autophagy flux by CE-LIF 
and determining the properties of autophagosomes such as LC3-II levels and organelle 
surface charge under basal autophagy and rapamycin enhanced autophagy conditions. 
2.4. Organelle enrichment 
Organelle enrichment is done to eliminate unwanted, contaminating organelles 
and increase the level of desired organelles in collected fractions. In the absence of high 
organelle enrichments, organelle-specific properties cannot be determined. Organelle 
enrichment techniques used in this thesis are centrifugation, immunoenrichment, and 
magnetic-based techniques. Other techniques for organelle enrichment include free flow-
based techniques, fluorescence activated organelle sorting, optical tweezers, and 
dielectrophoresis.
85
 These techniques were not used in this thesis but are reviewed for the 
interested reader in our recent review.
85
 
Differential centrifugation enriches organelles based on organelle sedimentation 
rate and density gradient centrifugation is based on isopycnic sedimentation rate 
(Equation 2.2) where d is the diameter of the organelle, ρ is the density of the organelle 
(ρo) and of the medium (ρm), g is the gravitational force, and μ is the medium viscosity. 
This is a common technique for enrichment of lysosomes and autophagosomes from 
tissue.
13, 14
 From examining Equation 2.2, centrifugation-based enrichments are 
dependent on the size and density of the organelles being enriched. 
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     Equation 2.2. 
Differential centrifugation typically produces three organelle fractions containing 
(1) nuclei and unbroken cells, (2) organelles, and (3) cytosol and cytosolic proteins 
(Figure 2.3). The technique is performed with a buffer that has similar osmolarity to 
isolated organelles and results in enriched organelles with intact membranes. The 
technique is also rapid compared to other enrichment techniques making it a desirable 
technique when high purity is not needed in the enriched fraction. This is often the case 
when specific organelles are labeled such as GFP-LC3 for autophagosomes. This 
technique was used to enrich organelles in the work described in Chapters 3, 5, and 6. 
 
Figure 2.3. Differential centrifugation enrichment of organelles. The method results in 
three enriched organelle fractions: nuclei and unbroken cells, organelles, and cytosol. 
Density gradient centrifugation is another common technique for organelle 
preparation and is similar to differential centrifugation but is done in a density gradient 
medium such as percoll or sucrose.
13
 The gradient medium provides an isopycnic 
enrichment allowing organelles with different sedimentation rates to equilibrate in a 
portion of the density medium. As indicated by Equation 2.2, when the density of a 
medium approaches the organelle density, organelles can equilibrate in a specific portion, 
or band, of a medium. Density gradient centrifugation is capable of high enrichment of 
organelle types due to the gradient medium. 
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Large starting amounts of biological samples are needed for density gradient 
centrifugation due to the loss of material during each sample transfer and wash steps 
needed to remove the gradient medium, which makes the technique difficult to use for 
some cell culture preparations.
29
 Enriched autophagosome and endocytic organelles may 
lose enzymatic activity, membrane integrity, and other functions due to the density media 
used or due to the time needed to perform the technique (density gradient centrifugation 
may exceed 4 hours). 
Density gradient centrifugation with percoll medium was used in the work 
described in Chapter 3 and compared to the magnetic enrichment technique and density 
gradient centrifugation with Nycodenz medium was used to enrich autophagosomes in 
the work described in Chapter 5. Differential centrifugation was used in the work 
described in both Chapters 3 and 5 to remove nuclei and cytosol from un-enriched 
organelle fractions. Differential centrifugation was used in the work described in Chapter 
6 to prepare an enriched autophagy-related organelle fraction and remove cytosol which 
contains GFP-LC3-I protein. 
In the past decade, an influx of literature has been published discussing affinity-
based enrichment techniques (Figure 2.4).
85
 A majority of these techniques are immuno-
based techniques with magnetic separations. Antibodies are raised against an organelle-
specific protein and are conjugated to a molecule that facilitates its removal from the 
organelle suspension such as magnetic particles. After binding of the antibody to its 
organelle-specific protein, an external magnetic field can be applied causing separation of 
the magnetic fraction containing the targeted organelle. Immuno-enrichment provides 
excellent specificity for targeting organelles due to the antibody-protein interaction but is 
dependent on availability of antibodies for organelle-specific proteins. In addition to 
using the technique to enrich an organelle, it can also be used to remove an organelle 
from an enriched fraction. Determination of organelle electrophoretic mobility (the 
migration time of an organelle in an applied electric field during capillary 
electrophoresis) or organelle pI (isoelectric point of an organelle based on the many 
compounds localized on an organelle surface) are not ideal for immuno-based enrichment 
because antibodies can change these characteristics.  Removal of antibodies while 
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maintaining the membranes of organelles is difficult. This technique was used in the 
work described in Chapter 5 to remove mitochondria from an autophagosome-enriched 
fraction. 
 
Figure 2.4. Immuno-enrichment of organelles with magnetic separation. Organelles 
(large gray spheres) are enriched by antibody-coated particles. Antibodies (Y-shaped 
molecules) are bound to magnetic particles (black spheres). 
Various enrichment techniques have been developed for endocytic organelles and 
autophagosomes. Because endocytosis is able to internalize extracellular cargo and traffic 
the cargo to lysosomes, magnetic nanoparticles are capable of being trafficked directly to 
endocytic organelles. The use of magnetic nanoparticles to enrich acidic organelles on 
magnetic columns has excellent specificity, however, this technique has either caused 
damage to the endocytic organelle membrane due to the electromagnetic column
15
 or 
endocytic organelle pH was not determined after enrichment.
11
 This limits the endocytic 
organelle properties that can be investigated including prodrug biotransformation and 
examination of individual organelle pH. The work described in Chapter 3 utilizes 
dextran-coated iron oxide nanoparticles that are endocytosed to produce highly enriched 
endocytic organelle fractions. To ensure enriched organelles had intact membranes, 
organelle pH was determined by capillary cytometry. 
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Recent developments have also been made in autophagosome enrichment.
81
 
Enrichment was optimized by vinblastine treatment which prevents autophagosome 
fusion with autolysosomes and increased autophagosome yield. Glycyl-L-
phenylnapthylamide, a substrate for a lysosome-specific enzyme, was used to cause 
osmotic rupture of lysosomes. A significant decrease in lysosome level was detected by 
Western blotting and accumulation of autophagosomes and amphisomes was attributed to 
vinblastine treatment. Vinblastine and glycyl-L-phenylnapthylamide were both used in 
the work described in Chapter 5 to increase autophagosome yield and remove unwanted 
lysosomes in enriched autophagosome fractions. Magnetic immunoaffinity-based 
selection of mitochondria was also used to remove unwanted mitochondria in enriched 
autophagosome fractions. 
2.5. Organelle analysis 
Methods are needed to determine organelle enrichment and to determine organelle 
properties such as pH, molecular composition, and surface charge, amongst others. In this 
thesis work, enzymatic assays, Western blotting, fluorescence confocal microscopy, and 
capillary cytometry with laser induced fluorescence detection were used to assess 
organelle enrichment. Two new methods were also developed using ultra high 
performance liquid chromatography coupled to low- and high-collision energy mass 
spectrometry (UPLC-MS
e
) and CE-LIF to determine molecules enriched in 
autophagosomes (work described in Chapter 5) and autophagy flux (work described in 
Chapter 6), respectively. This section discusses techniques used for assessing organelle 
purity and instrumentation used to develop new methods for determining autophagosome 
composition and autophagy flux.  
2.5.1. Examination of organelle enrichment 
Enzymatic assays were used to quantify organelle enrichment and were used in 
the work described in Chapter 3 to determine that endocytic organelles were enriched in 
endocytic organelle fractions while mitochondria and peroxisome activity were not 
detectable. Substrates are modified by organelle-specific enzymatic reactions that 
indicate the presence of the organelle. The para-nitrophenylphosphatase (pNPP) assay 
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was used to determine the presence of lysosomes by the degradation of para-nitrophenol 
phosphate. The succinate dehydrogenase (SD) assay was used to determine the presence 
of mitochondria by the reduction of blue-colored dichloroindophenol. The catalase assay 
was used to determine the presence of peroxisomes by the degradation of hydrogen 
peroxide.  
Western blotting is a technique used to detect organelle specific proteins in 
organelle enriched samples to confirm enrichment of the desired organelle and detect 
contamination from unwanted organelles. Western blotting was used in the work 
described in Chapter 5 to confirm organelle enrichment and detect contaminating 
organelles. Western blots have improved sensitivity for detecting very low levels of 
organelle contaminations compared to enzymatic assays but give limited quantitation due 
to their limited dynamic range (Section 2.3.). 
2.5.2. Fluorescence confocal microscopy 
Fluorescence confocal microscopy was used in this thesis as a benchmark 
technique for detecting organelles in intact cells (work described in Chapters 3 and 6), 
confirming that transfected proteins expressed fluorescence with the desired organelle-
specific protein (work described in Chapter 6), and evaluating colocalization of 
endocytosed particles in organelles (work described in Chapter 3). Organelles were 
fluorescently labeled by transfection with plasmids containing genes for organelle-
specific proteins conjugated to fluorescent fusion proteins such as green fluorescent 
protein (GFP), by fluorescent dyes that are sequestered into specific organelles such as 
LysoTracker in endocytic organelles, and by immuno-labeling with primary and 
fluorescently labeled secondary antibodies. Various fluorophores were used in this thesis 
work (Table 2.1). In the work described in Chapter 3, fluorescently labeled dextran 
coated iron oxide nanoparticles were confirmed to traffic to endocytic organelles by 
monitoring fluorescent overlap with LysoTracker Red fluorescence.
46
 Statistical 
parameters such as the Manders, Pearson’s Correlation, M2 coefficient, and ICQ 
correlation were used to determine overlap of LysoTracker Red fluorescence and 
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AlexaFluor 568 dextran-coated iron oxide nanoparticles to confirm the nanoparticles had 
localized in the endocytic organelles.
86
 
Fluorescence confocal microscopy was used as previously discussed to examine 
autophagy levels
30-32
 and to determine endocytic organelle pH.
48, 87
 Fluorescence confocal 
microscopy has disadvantages including limited throughput to detect multiple organelles, 
limited organelle resolution preventing individual organelle detection after cell lysis, and 
the need for z-scans to confirm observation of single organelles.
29, 88
 These disadvantages 
make fluorescence confocal microscopy difficult to determine individual organelle 
properties and make other techniques, such as CE-LIF, more advantageous 
 
Table 2.1. Fluorophores used in thesis.  
2.5.3. Capillary electrophoresis with laser induced fluorescence detection 
CE-LIF is used in this thesis for determination of LeuDox biotransformation 
(work described in Chapter 4) and individual autophagy-related organelle analysis (work 
described in Chapter 5). For organelle analysis, isolated organelles are injected into a 
Fluorophore Organelles Conjugation Excitation (nm) 
/Emission (nm) 
AlexaFluor488 Endocytic Dextran coated 
iron oxide 
nanoparticles 
495 /519  
Lysotracker Red Endocytic None 577 /590  
Tetramethylrhodamine  Endocytic Dextran 550 /580  
Fluorescein Endocytic Dextran 480 /520  
Green Fluorescent Protein 
(GFP) 
Autophagosomes GFP-LC3 fusion 
protein 
395 and 470 /510 
AlexaFluor568 Autophagosomes Anti-LC3 
secondary 
antibody 
578 /603  
4’6-diamidino-2-
phenylindole (DAPI) 
Nucleus None 358 /461  
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coated fused-silica capillary and separated in an electric field. The separation of 
organelles by CE-LIF is dependent on the surface charge of the organelle while other 
forces such as deformation of the ionic cloud surrounding the organelle have a limited 
effect as shown by the Arriaga lab.
89
 Following separation, organelles exit the capillary 
and are detected with laser induced fluorescence detection. 
CE-LIF injections (either electrokinetic or pressure-driven) can be as low as 
nanoliters, requiring small amounts of sample.
90
 CE-LIF also has excellent limits of 
detection which approach sub-zeptomolar levels for fluorescent particles and 
organelles.
90
 The combination of low injection volume, excellent limits of detection, and 
high throughput allows for individual organelle detection, which, in turn, allows for the 
diversity of organelles to be determined.
90
 
The fused silica surface of capillaries is capable of adsorbing organelles due to the 
negative charge of the capillary and hydrophobic interactions with the basic proteins 
located on organelle surfaces.
91
 To prevent this unwanted interaction, both permanent and 
transient coatings of poly(vinyl alcohol) have been used.
91
 Both types of coatings reduce 
organelle-capillary interactions, however, transient coatings require reapplication in-
between separations.
91
 Poly(vinyl alcohol) was used as a permanent coating in the work 
described in Chapter 6 and a temporary coating was used in the work described in 
Chapter 3. The sheath flow-LIF detector provides excellent limits of detection (Figure 
2.5).
92-94
 Following separation, organelles enter a sheath-flow cuvette which focuses 
organelles into a narrow fluid stream. Excitation of fluorescently-labeled organelles 
occurs in the sheath flow cuvette. Two-channel fluorescence detection is possible by use 
of a dichroic mirror that splits different fluorescent wavelengths into perpendicular paths. 
Notch filters are used to reject a portion of the light spectrum removing interference from 
specific wavelengths of light, such as the wavelength of light of the laser. In the work 
described in this thesis, the notch filter rejected light from the 488-nm excitation laser. 
Band pass filters are used to filter and remove wavelengths of light not specific to the 
fluorophore being detected ensuring that only the desired wavelength is detected. This 
also removes light scattering from both Raleigh and Raman sources, which are also 
removed by notch filters. Light scattering is also removed spatially by pinhole filters, and 
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LIF detection at a 90° angle to excitation. Photomultiplier tubes are used to detect the 
emitted fluorescence. Data is digitized by a data board that allows for data points to be 
collected at 200 Hz. This data acquisition rate allows for multiple data points to be 
acquired for a single organelle peak and allowing organelle peak profiles to be well 
characterized. Overall, the combination of the sheath flow cuvette, notch and band pass 
filters, and data acquisition capabilities allows for fluorescence detection of single 
organelles.  
 
Figure 2.5. CE-LIF instrument design.  
A similar instrument setup was used to examine the pH of enriched endocytic 
organelle fractions in the work described in Chapter 3 defined here as capillary 
cytometry. Isolated organelles are flowed through the capillary so determination of 
individual organelle fluorescence intensity can be determined. In the work described in 
Chapter 3, only the ratio of pH-dependent and pH-independent fluorescence emission is 
needed to determine individual endocytic organelle pH values. 
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2.5.4. Micellar electrokinetic chromatography 
Micellar electrokinetic chromatography (MEKC) was used in the work described 
in Chapter 4 to separate N-L-leucyldoxorubicin and doxorubicin. CE buffers include 
charged species that create a diffuse layer on the capillary surface which is partially 
responsible for electroosmotic flow. In MEKC, the buffer also contains detergents that 
form micelles. The concentration of detergents exceeds the critical micelle concentration 
ensuring micelles are formed. The micelles allow for analytes with similar mass/size 
ratios, such as N-L-leucyldoxorubicin and doxorubicin, to be separated based upon their 
hydrophobicity. Different analytes may have different hydrophobicity and therefore 
partition into micelles with different rate constants. Since micelles have an 
electrophoretic mobility, an analyte that is partitioned into a micelle at a higher rate can 
be separated from an analyte that is either not partitioned or partitions at a lower rate into 
a micelle.  
2.5.5. Organelle heterogeneity analysis 
Organelle heterogeneity can be assessed with CE-LIF due to the capability of 
detecting individual organelles. Organelle heterogeneity is described as the range of 
values detected for individual organelle property measurements. Previously, 
heterogeneity was determined using other techniques such as transmission electron 
microscopy
95
 and fluorescence confocal microscopy.
48
 These techniques are not high 
throughput, however, and are limited in the properties of organelles that can be 
determined. CE-LIF instrumentation can determine the properties (fluorescent-protein 
level, electrophoretic mobility, pH) of individual organelles. Furthermore, thousands of 
organelles can be detected by CE-LIF. The Arriaga lab has examined the heterogeneity of 
mitochondria,
93, 96-103
 nuclei,
104
 and endocytic organelles.
48, 87, 105-107
 Heterogeneity of 
mitochondria electrophoretic mobility,
93, 96
 DNA copy numbers,
101
 pI,
103
 levels of 
reactive oxygen species,
106
 cytoskeleton binding,
99
 and nuclei electrophoretic mobility
104
 
have all been determined. The heterogeneity of endocytic organelles’ fluorescent 
intensity and electrophoretic mobility was determined following labeling by endocytosed 
fluorescent microspheres.
107
 Individual pH measurements of acidic organelles were 
 24 
performed by CE-LIF from multiple cells
48
 and from single cells using AlexaFluor488-
bound dextran.
48, 87
 The heterogeneity of doxorubicin levels in endocytic organelles, 
mitochondria, and nuclei was also determined.
106
 To date, no studies have examined 
individual autophagy-related organelles properties by CE-LIF. The work described in 
Chapter 6 discusses the first determination of individual autophagosome properties (GFP-
LC3-II levels and electrophoretic mobility). Thousands of organelles were detected.  
2.5.6. Liquid chromatography coupled to mass spectrometry 
Liquid chromatography coupled to mass spectrometry (LC-MS) is an attractive 
technique for studying the biological composition of samples. LC-MS provides excellent 
coverage of features (unidentified compounds with a characteristic chromatographic tR 
and m/z value) enriched in a biological system. UPLC has increased pressure (flow rates 
exceeding 7 mm/sec) and decreased particle size (1.7 μm) packed in the column to 
improve resolution of adjacent chromatographic peaks allowing improved detection of 
features compared to high performance liquid chromatography (5-6 mm/sec flow rates; 
3.5-10 μm particle size).108 Following chromatographic separation, features are detected 
by mass spectrometry. Electrospray ionization (ESI) is used to ionize analytes producing 
multiply-charged ions. ESI is well suited for studying the biological composition of 
samples as  minimal daughter ions are produced which allows compounds to be intact 
and studied in the mass spectrometer.
109
 Quadrupole mass spectrometers with time of 
flight mass analyzers are commonly used for proteomic and metabolomic experiments 
due to their combination of mass accuracy and ability to fragment parent ions into 
daughter ions.
110
 
MS
e
 acquires both low- and high-collision energy mass spectra.
111
 Parent ions are 
continuously emitted from the quadrupole and enter the helium collision-induced 
dissociation cell. This cell alternates between low collision energy and high collision 
energy resulting in low- and high-collision energy mass spectra for all parent ions eluting 
from the UPLC column and entering the quadrupole at a given time. High collision 
energy results in fragmented parent ions and produces daughter ions specific to their 
parent ion. MS
e 
does not produce daughter ions for a specific parent ion but rather 
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produces numerous daughter ions for any parent ions eluted from the quadrupole at a 
given time. The advantages of this method include reduced experiment time compared to 
MS
2
 and production of daughter ions that provide evidence for preliminary 
identifications. One drawback is that daughter fragments can be produced from multiple 
parent ions. Extracted ion chromatograms of parent and daughter ions can be compared. 
If the profiles of extracted ion chromatograms are identical, the daughter can be assigned 
to a parent ion. The instrument used in the work described in Chapter 5 is shown in 
Figure 2.6. UPLC-MS
e
 was used in the work described in Chapter 5 to preliminarily 
identify features  from enriched autophagosome samples. 
 
Figure 2.6. Block diagram of quadrupole-time of flight mass spectrometer used in the 
work described in Chapter 5. 
2.5.7. Biological composition of autophagosomes 
Most studies investigating the composition of autophagosomes have focused on 
targeted proteins as described in 2.3.
69-76
 Non-targeted techniques have been used to 
determine the molecular composition of other enriched organelle fractions such as both 
chloroplasts and mitochondria,
112
 vacuoles,
113
 both mitochondria and vacuoles,
114
 
mitochondria,
115-118
 and lipid droplets by liquid chromatography coupled to mass 
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spectrometry.
119, 120
 Despite the study of other enriched organelle fractions, non-targeted 
techniques have not been applied to enriched autophagosome fractions. The work 
described in Chapter 5 describes the first study of autophagosome composition with an 
untargeted approach by UPLC-MS
e
. 
2.6. Summary 
The work described in Chapter 3 discusses the development of a technique using 
dextran coated magnetic nanoparticles to enrich endocytic organelles with no detectable 
peroxisomes or mitochondria and with a majority of enriched endocytic organelles with 
acidic pH indicating endocytic organelle membranes are intact. The work described in 
Chapter 4 uses the technique described in Chapter 3 to determine endocytic organelle-
specific biotransformations of N-L-leucyldoxorubicin to doxorubicin to by MEKC-LIF.  
The work described in Chapter 5 uses UPLC-MS
e 
to determine the composition of 
enriched autophagosome fractions. The work described in Chapter 6 uses CE-LIF to 
determine the number of detected autophagy-related organelle events and their properties 
from basal autophagy and rapamycin-enhanced autophagy.  
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Chapter 3 
Individual organelle pH determinations of magnetically-enriched endocytic 
organelles via laser-induced fluorescence detection 
 
Reproduced with permission from Analytical Chemistry, 2011, 83, 7331-7339. Chad P. 
Satori, Vratislav Kostal, and Edgar A. Arriaga. “Individual Organelle pH Determinations 
of Magnetically Enriched Endocytic Organelles via Laser-Induced Fluorescence 
Detection”. Copyright © 2011 American Chemical Society. 
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at the University of Minnesota Institute of Rock Magnetism. The authors would like to thank the 
Lee Penn laboratory for access to their x-ray diffraction equipment and the Christy Haynes 
laboratory for access to light scattering equipment. 
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The analysis of biotransformations that occur in lysosomes and other endocytic 
organelles is critical to studies on intracellular degradation, nutrient recycling and 
lysosomal storage disorders. Such analyses require bioactive organelle preparations that 
are devoid of other contaminating organelles. Commonly used differential centrifugation 
techniques produce impure fractions and may not compatible with micro-scale separation 
platforms. Density gradient centrifugation procedures reduce the level of impurities but 
may compromise bioactivity. Here we report on simple magnetic setup and a procedure 
that produce highly enriched bioactive organelles based on their magnetic capture as they 
traveled through open tubes. Following capture, in-line laser-induced fluorescence 
detection (LIF) determined for the first time that each magnetically retained individual 
endocytic organelles have an acidic pH. Unlike bulk measurements, this method was 
suitable to describe the distributions of pH values in endocytic organelles from L6 rat 
myoblasts treated with dextran-coated iron oxide nanoparticles (for magnetic retention) 
and fluorescein/TMRM-conjugated dextran (for pH measurements by LIF). Their 
individual pH values ranged from 4 to 6, which is typical of bioactive endocytic 
organelles.  These analytical procedures are of high relevance to evaluate lysosomal-
related degradation pathways in aging, storage disorders and drug development. 
3.1. Introduction 
Lysosomes are organelles that degrade endocytosed material
121
 such as 
proteins,
3, 122
 lipids,
123
 fatty acids,
124
 and carbohydrates.
122
 These organelles play 
important roles in drug metabolism, biotransformation, reactive oxygen species 
production, autophagy, and lysosomal storage disorders.
125-128
 Lack of lysosomal function 
can lead to many diseases (e.g. Fabry’s,129 Gaucher’s,130 and Niemann-Pick disease).127 
Lysosomes are also important in Alzheimer’s disease,131 because it has been shown that 
degradation of β-amyloid inside lysosomes may lead to novel disease treatments. 
Investigating such roles and biological function of lysosomes usually involves 
studies done on enriched isolated lysosomes, devoid of other contaminating organelle 
types. For instance, proteomic studies aiming at identifying lysosomal proteomes usually 
require extensive lysosomal isolation procedures prior to proteomic analysis.
132-134
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Another example is the detection of reactive oxygen species in lysosomes that requires 
these organelles to be functional and free of contaminating mitochondria.
106, 125, 135
 Lastly, 
many xenobiotics, such as penicillin G, tilmicosin, and vitamin E may be accumulated 
and biotransformed in the lysosomes, but confirmation that these processes occur in the 
lysosomes requires enriched functional lysosomes, devoid of contaminants in which 
similar processes may occur.
136-138
 In the absence of high enrichment of a specific 
organelle, direct links cannot be made. 
The most common methods to isolate and enrich lysosomes are differential 
centrifugation and density-gradient centrifugation. Differential centrifugation separates 
organelles based upon their sedimentation rate.
139
 It is relatively quick (~ 2 hours), but 
peroxisomes and mitochondria are present as contaminants. Density-gradient 
centrifugation in self forming gradients of colloidal particles separates organelles 
directly
13, 14
 or after loading of the lysosomes with compounds such as dextran,
140
 iron,
141
 
and gold
142
 to change their sedimentation rate. These methods often require multiple 
centrifugation and sample cleanup steps that can lead to a lengthy experimental time (~6 
hours) and the potential dissipation of the acidic pH within lysosomes and other 
endocytic organelles. 
143
 Free flow electrophoresis has been shown to separate lysosomes 
based on their electrophoretic mobility, however it requires specialized 
instrumentation.
144
 
Magnetic isolation based on antibody-coated paramagnetic beads, which is 
commonly used to isolate proteins and cells,
145-148
 is another approach to isolate 
organelles such mitochondria, peroxisomes, and autophagosomes.
149-151
 Magnetic 
isolation of lysosomes after endocytosis of dextran-coated superparamagnetic iron oxide 
nanoparticles (FeDex) has also been reported
11, 15, 151
 and used to investigate 
pharmacological properties in bulk.
15, 152
 These studies did not evaluate directly whether 
such organelles retained an acidic pH during the isolation procedure. Magnetic isolation 
of particles in microfluidic channels
153
 and capillary
154
 have been used to isolate and 
concentrate particles used in protein digestions
153
, triglyceride analysis
155
 and 
immunoassays,
156
 but have not been applied to organelle studies. 
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Here, we report on the analysis of the pH of individual magnetically-enriched 
endocytic organelles after their release from a magnetic retention in an open tube. The 
post-nuclear fraction of L6 cells that had endocytosed both FeDex and 
fluorescein/TMRM-conjugated dextran was delivered through a fused silica capillary. 
This capillary passed through a custom-built on-line magnetic isolation device and ended 
at a post-column dual-channel laser induced fluorescence detector (LIF). For each 
individual organelle detected, the ratio of its fluorescence signals at each channel was 
used to determine its pH. Acidic pH values of the magnetically retained individual 
organelles suggested that magnetic isolation in an open tube is suitable to prepare 
functional endocytic organelles. Future magnetic purification of acidic organelles in open 
tubes would be highly beneficial to investigate the role of lysosomal activity in aging, 
storage disorders and metabolism. 
3.2. Experimental 
3.2.1. Reagents 
Dulbecco’s Modified Eagle Medium (DMEM) high glucose cell medium was 
obtained from Gibco. Bovine calf serum was obtained from Omega Scientific (Tarsana, 
CA). Gentamycin, iron (III) chloride hexahydrate, dextran from Leuconostoc 
mesenteroides, 1,10-phenanthroline, hydroxylamine hydrochloride, poly-L-lysine, 
magnesium chloride hexahydrate, protease inhibitor, dimethyl sulfoxide, 2,6-
dicholoroindophenol, sodium azide, succinic acid disodium salt, Triton X-100, titanium 
oxysulfate sulfuric acid complex hydrate, cacodylate, glutaraldehyde, osmium tetroxide, 
polyvinyl alcohol, propylene oxide, 3-sn-phosphatidyl-L-serine, L-α-
phosphatidylcholine, L-α-phosphatidylethanolamine, iron (II) chloride tetrahydrate, 
imidazole, and dichloroindophenol (DCIP) were obtained from Sigma-Aldrich (St. Louis, 
MO). Ammonium hydroxide, hydrochloric acid, potassium hydroxide, and hydrogen 
peroxide were obtained from Mallinckrodt (Phillipsburgh, NJ). Fluorescein, 
tetramethylrhodamine (TMRM), para-nitrophenylphosphate (pNPP), fluorescein/TMRM-
conjugated dextran (70,000 MW) (FTD), LysoTracker Red, and AlexaFluor488-
conjugated dextran (10,000 MW, referred thereafter as AlexaFluor488-dextran) were 
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obtained from Invitrogen (Carlsbad, CA). Sodium acetate trihydrate, 4,6-diamidino-2-
phenylindole, and sulfuric acid were obtained from Fisher Scientific (Pittsburgh, PA). 
Bovine serum albumin was obtained from Roche (Basel, Switzerland). Ethanol was 
obtained from Pharmco-AAPER (Brookfield, CT). Phosphate buffered saline (10 PBS) 
is obtained from BioRad (Hercules, CA). UltraPure brand sucrose (99.9%) was obtained 
from MP Biomedicals, Inc. (Illkirch, France). Iron (96.0% pure) was obtained from VWR 
(Radnor, PA). Water was purified with a Millipore Synergy UV System (18.2 mΩ/cm, 
Bedford, MA). 
A nigericin stock solution (1 mM) was made by mixing 5 mg nigericin with 6.89 
mL water. Potassium phosphate solution (used with nigericin; 900 mM) was made by 
adding 3.92 g of the reagent to 20 mL of water. The pH was then adjusted to 6.1 with 
concentrated NaOH and brought to 25 mL. Buffer N, used for cell handling for enzyme 
assay procedures, was made by adding 27.01 g mannose (300 mM) and 240 mg MgCl2 
(5.0 mM) to 50.0 mL of 10× PBS. The solution was then diluted to 450 mL with water. 
The pH was adjusted to 7.4 with concentrated NaOH and brought to 500 mL. Buffer M, 
used for cell handling for magnetic isolation procedures for determination of the pH of 
the retained organelles, was made by adding 19.12 g mannitol (210 mM), 11.98 g sucrose 
(70 mM), 596 mg 4-(2-hydroxyetheyl)-1-piperazineethanesulfonic acid (5 mM), and 731 
mg ethylenediaminetetraacetic acid (5 mM) to 450 mL water. The pH was adjusted to 7.4 
with concentrated NaOH and brought to 500 mL. The catalase assay solution was made 
the day of the experiment by adding 50 mg bovine serum albumin, 5 mL 0.2 M imidizole 
(pH 7.6), 1 mL 10 % w/v Triton X-100, 100 µL of 37 % H2O2, and was brought to 50 
mL. The catalase stop buffer was made in a fume hood by adding 2.25 g TiOSO4 to 300 
mL 2 N H2SO4. Once dissolved, the solution was brought to room temperature. A 
200mL aliquot of the solution was added to 200 mL of 2N H2SO4. This solution was 
then diluted to 1 L. Unless noted otherwise, solutions were diluted with deionized water. 
The synthesis of FeDex was prepared as described previously,
11
 except for 
preparation of AlexaFluor 488-FeDex, that used a mixture of 5 mg of AlexaFluor488 
dextran and 2 g of dextran. After synthesis, the particles were dialyzed against water in a 
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Fisher 4.8 nm seamless cellulose membrane for 48 hours at 4 °C. The dialysis water was 
exchanged after 24 hours. FeDex was filtered with a 0.22-µM filter under vacuum to 
remove large aggregates and impurities. FeDex (~ 4 mg/mL) was stored at 4 °C in water 
and used within 2 months. 
FeDex particles were characterized by transmission electron microscopy (TEM), 
x-ray diffraction, light scattering and hysteresis loop measurements. For TEM 
characterization, FeDex particles were imaged on lacey carbon/formvar copper 200 mesh 
grids (Ted Pella Inc, Redding CA) on a JEOL 1200 transmission electron microscope. 
TEM does not display the dextran coating and revealed iron cores with irregular 
morphology with long-axis length of 7.4 ± 2.2 nm (average ± standard deviation, n=30; 
range: 4.3 - 14.4 nm), which are similar to those previously observed (8.7 ± 2.1 nm).
11
 
For x-ray diffraction, 80 mg FeDex were analyzed in a Pananalytical X’Pert PRO MRD 
x-ray diffraction instrument. Using the Scherrer equation the calculated crystalline 
volume was 16.5 ± 8 (average ± standard deviation, n=7), which is consistent with the 
dimensions observed by TEM. For light scattering, 4.0 mg/mL FeDex in water were 
analyzed in a Brookhaven Instruments 90Plus/BI-MAS particle sizing instrument. The 
average particle size was 61.2 ± 0.7 (average ± standard deviation, n = 3 trials). This is a 
hydrodynamic determination that includes the total particle dimensions, including the 
thickness of the dextran coating. Hysteresis loop measurements were done in a Princeton 
Measurements Alternating Gradient Magnetometer (23° C, 0T - 2.2T, 1 × 10-11 Am2, 
Princeton, NJ). The FeDex particles were superparamagnetic and were at 97% of their 
maximum magnetic moment (160.7 µAm2) when exposed to the maximum magnetic 
field obtained with the magnets used here. 
3.2.2. Cell culture and homogenate preparation with differential centrifugation 
The rat myoblast L6 cells (ATCC, Manassas, VA) were maintained in DMEM 
supplemented with 10% bovine serum and 0.01% gentamycin at 37 °C and 5% CO2. 
Cells were subcultured upon reaching 95% confluence in a 1:40 ratio. L6 cells were 
treated with nanoparticles FeDex (2.0 mg/mL) for 30 minutes in DMEM. Trypsin in PBS 
(0.5%) was used to release cells from T-flasks for subculture or collection of cells. Cells 
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used for determination of individual organelle pH values were treated with 
fluorescein/TMRM-conjugated dextran (2 mg/mL) for 18 hours before cell 
homogenization. 
In most of the studies described here, after their release by trypsinization cells 
were harvested by centrifugation at 1,000g for 10 minutes and washed twice with 3 mL 
of buffer N. This was repeated a second time. Cells were then treated with 1% (v/v in 
DMSO) protease inhibitor cocktail and homogenized in a Dounce homogenizer (0.0025” 
clearance, Kontes Glass, Vineland, NJ) with 100 strokes. About 10% of the whole cell 
homogenate volume was retained for enzyme assays. The remaining 90% of homogenate 
was centrifuged at 600g for 10 minutes to remove the nuclear fraction and unlysed whole 
cells. The resulting supernatant was the post nuclear fraction (PNF) and contained 
lysosomes, mitochondria, peroxisomes, endosomes, and cytosol. For differential 
centrifugation studies, the PNF was centrifuged at 13,000g for 10 minutes to form a pellet 
that contained lysosomes among other organelles. The supernatant containing mainly 
cytosol and cytosolic proteins was removed with a pipette. The pellet was diluted with 
1.1 mL of buffer N and then used in enzyme assays. In addition the whole cell 
homogenate fraction was diluted and characterized in a similar fashion. 
3.2.3. Fluorescent microscopy of L6 cells 
Cells seeded in a LabTek 4 chambered coverslip were labeled with Lysotracker 
Red (50 µM) for 45 minutes at 37 °C. After 15 minutes, cells were labeled with 
AlexaFluor488-FeDex (3 mg iron/mL) for the remaining 30 minutes at 37 °C. After 
labeling, the tray was washed twice by removing media, adding PBS with a pipette, 
removing the first wash solution, and replacing with 300 μL of PBS. 
All images were taken with an Olympus IX81 inverted microscope (Melville, 
NY) equipped with an Olympus IX2-DSU disk scanning unit and a 60 (NA 1.45) oil 
immersion objective. A mercury lamp (Addison, TX) was used as the excitation source. 
AlexaFluor488 and Lysotracker Red fluorescence were detected respectively with filter 
sets GFP (excitation 460-500 nm; dichroic 505 nm; emission 510-560 nm) and RFP 
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(excitation 510-560 nm; dichroic 565 nm; emission 572-649 nm) (Chroma (Rockingham, 
VT). Imaging was done with a C9100-01 CCD camera (Hamamatsu, Bridgewater, NJ). 
CImaging Simple PCI 5.3 (Compix Inc., Cranberry Township, PA) software was used to 
control the microscope, image acquisition and processing. The levels of background 
fluorescence, AlexaFluor 488 cross talk, and Lysotracker Red cross talk were determined 
by observing unlabeled controls and samples labeled with only AlexaFluor488-FeDex or 
Lysotracker Red, respectively. The values of the crosstalk were undetectable and 3.6 ± 
1.1 % (average ± standard deviation), respectively. 
Image J-W Version 1.43s (National Institutes of Health) was used to calculate the 
Manders colocalization coefficients (M1 and M2) and the ICQ correlation coefficient 
(Section A-1). M1 and M2 range from zero to one representing total to total lack of 
colocalization of fluorophores.
86
 ICQ values range from 0.5 to -0.5 representing same to 
opposite correlation, respectively, of the fluorescence intensities of the two fluorophores. 
3.2.4. Enzyme assays 
Enzyme assays specific to lysosomes, mitochondria, and peroxisomes were used 
to determine the abundance of these organelle types. The initial change of absorbance 
versus time was the enzymatic activity. After correcting for dilutions, the total specific 
activity (S.A.) was calculated as the ratio of enzymatic activity to protein concentration in 
the original sample. The relative activity (R.A.) of a sample was calculated as the ratio of 
its S.A. relative to the S.A. of the whole cell homogenate. The yield of a method was 
calculated as ratio of the total enzymatic activity in a recovered fraction over the total 
enzymatic activity of the PNF used in the fraction isolation procedure (i.e., differential 
centrifugation or magnetic isolation). Lysosomal abundance was determined with the 
pNPP assay.
157
 First 150 µL of 25 mM pNPP and then 150 µL of the sample were added 
to a well of a 96-well plate (F96, Nunc, Rochester, NY). Absorbance readings at 405 nm 
( = 1.80 × 104 cm-1 M-1)158 were taken every 8 seconds for 15 minutes. Measurements 
were done in triplicate. LOD’s for enzymatic assays were determined by calculating the 
enzymatic activity and protein concentration equivalent to three standard deviations 
above baseline. The LOD of the pNPP assay was 700 pmol pNPP/min/mg protein. 
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Mitochondrial abundance was determined with the succinate dehydrogenase assay.
159
 The 
following reagents were added sequentially to a well of a 96-well plate: 130 µL of buffer 
N, 25 µL of 40 mM sodium azide, 25 µL of 200 mM succinate, and 25 µL aliquot of 
0.050 mM DCIP. Then, 80 μL of the sample were added and thoroughly mixed. 
Absorbance readings at 600 nm ( = 1.88 × 104 cm-1 M-1)160 were taken every 8 seconds 
for 15 minutes. The LOD of the succinate dehydrogenase assay was 1.0 nmol 
succinate/min/mg protein. Peroxisomal abundance was determined with the catalase 
assay.
161
 A 50 µL aliquot of organelle sample was mixed with a 12 µL aliquot of the 
catalase assay solution. Samples were incubated for 8 minutes and then treated with a 205 
µL aliquot catalase stop solution to quench the reaction and allows for remaining 
hydrogen peroxide to react with titanium (IV) oxysulfate. A 250 µL aliquot of the total 
solution was added to a well in a 96-well plate and read at 405 nm ( = 3.97 × 105 cm-1 
M-1).
162
 The LOD of the catalase assay was 7.6 nmol/min/mg protein. Protein 
concentrations were determined using the bicinchoninic acid protein assay (BCA kit, 
ThermoScientific, Wilmington, MA) according to the manufacturer’s instructions. 
3.2.5. On-line magnetic isolation device 
Neodymium borate magnets (2.0  2.0 sq. in.; magnetized through their 0.5-inch 
thickness; K&J Magnetics, Inc., Jamison, PA) were modeled with Vizimag 3.18 software 
(Figure 3.1). The relative permeability of each magnet was set to 1.10 and the magnetic 
strength was set to 1.32 Tesla to match the manufacturer’s values. The best configuration 
found had four magnets per pole (Figure 3.1A). For 1-cm gap, the predicted field was 817 
mT. We adopted such configuration and positioned each set of magnets on an aluminum 
mount equipped with a high-precision micrometer to adjust the gap between zero and ten 
centimeters (Figure 3.1B). The magnetic field was measured with a hand held 
Gaussmeter (GM08, Hirst, Cornwell, United Kingdom) that fitted when the gap between 
the magnets was 1 cm or larger (Figure 3.1C). For 1-cm gap the measured magnetic field 
was 758 mT. 
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Figure 3.1. Characterization of magnet configuration. (A) Magnetic simulations of a 
cavity defined by two sets of four magnets each. This configuration shows a field 
strength of 817 mT when the gap is 1 cm. The simulation was done with Vizimag 
software. (B) On-line magnetic isolation device. (C) Field strength measurements at the 
center of the magnet cavity. Triangles and squares represent the experimental and the 
simulation data, respectively. Simulation data fitted the equation y = 0.0058x2 – 0.11x + 
0.67 and predicted magnetic field strengths of 650 and 670 mT for gaps equivalent to 
those used for PEEK tubing and fused-silica capillary, respectively. Experimental data 
fitted the equation y = 0.012x2 – 0.19x + 0.93 and predicted magnetic field strengths of 
900 and 930 mT for gaps equivalent to those used for PEEK tubing and fused-silica 
capillary, respectively. 
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3.2.6. Magnetic isolation procedures for enzymatic assays 
A syringe pump (Model number 210, KDS Scientific, Holliston, MA) delivered ~ 
100 µL of PNF from a 1-mL Hamilton RN syringe to PEEK tubing (#1531, IDEX Health 
and Science, Oak Harbor, WA) passing through the on-line magnetic isolation device. 
The syringe needle (22 g) was connected to the tubing with an adapter (VISF-2 and U-
411, Chrom Tech, Inc, Apple Valley, MN). The PEEK tubing was positioned between the 
two magnet poles and held in place by reducing the gap until to the magnets slightly 
squeezed the tubing. The length of the tubing in the magnetic zone was 5.1 centimeters, 
which represents a volume of 2.6 μL within the tubing. 
Following delivery of 15 µL of PNF through the tubing for loading of magnetic 
material into the magnetic zone, 25 μL of buffer N were delivered to wash off unretained 
material. The eluted volumes from the loading and wash steps contained unretained 
material. Upon completion of the wash step at 1.3 cm/min linear flow rate, the PEEK 
tubing was removed from the magnet gap. Then the previously retained magnetic 
material was eluted with at least 125 µL of buffer N. This elution step took under 9.5 
minutes. The collected material was analyzed with the enzymatic assays described above. 
The linear velocity for the loading and elution steps was 21.9 cm/min. The linear 
velocities used for the wash step were 0, 0.6, and 1.32 cm/min, but only 1.32 cm/min was 
adequate to remove mitochondria and peroxisomes (Figure A.2). 
3.2.7. Magnetic isolation procedures for determination of the pH of the retained 
organelles 
To detect the pH of organelles, we used the setup shown in Figure 3.2. Fused-
silica capillary replaced the PEEK tubing described above. A fused silica capillary (49-
μm I.D., 150-μm O.D., 80-cm long, coated with 2% polyvinyl alcohol91) was immersed 
in a vial containing either the PNF or buffer N and pressurized at 4 psi with an argon 
tank. The linear flow velocity in the capillary was 7.7 cm/min. The magnetic separator 
was placed 40 cm from the injection end. The capillary position was fixed within the 
magnet gap because two pieces of tape at each side of the magnet cavity prevented it 
from moving (Figure 3.2A), wooden dowels confined it to the middle of magnet gap 
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(Figure 3.2B), and the gap was adjusted to match the capillary O.D. A capillary length of 
5 cm was within the magnet gap and define an internal capillary volume of ~ 100 nL 
where magnetic capture occurred. When loading the capillary with PNF the plug length 
was ~ 5 cm long, matching the length of the capillary within the magnet gap. After 
loading the PNF, one capillary volume (1.6 µL) of buffer M was used to displace the 
PNF to the magnet gap and to wash off unretained material at a linear flow rate of 7.7 
cm/min. Then, the capillary was removed from the magnet gap and retained organelles 
were mobilized by the pressure driven-flow. Upon completion of this step the capillary 
was flushed with methanol to reduce carry over into the next experimental run. 
 
Figure 3.2. Detail of the on-line magnetic isolation device. (A) Tape ensured that the 
capillary did not shift along the capillary’s length in the magnetic separator. (B) Wooden 
dowels attached to the magnetic housing kept the capillary in the middle of the magnetic 
housing. The star represents the gap adjusted to hold snug the PEEK tubing (gap ~ 1.59 
mm) or the fused-silica capillary (gap ~ 0.150 mm). (C) An LIF detector placed ~ 40 cm 
after the device. Detection and excitation conditions are described in the Experimental 
section. 
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The detection end of the capillary was connected to a post-column LIF detector 
that has been previously described (Figure 3.2C.).
89
 Briefly, the 488-nm argon-ion laser 
line was used for excitation. A 560 nm dichroic mirror (XF2016, Omega Optical, 
Brattleboro, VT) was used to reflect green fluorescence. A 635 ± 25 nm filter (XF3015, 
Omega Optical,) was used to select tetramethylrhodamine (TMRM) fluorescence and a 
530 ± 10 nm filter (XF3017, Omega Optical) was used to select fluorescein and 
AlexaFluor488 fluorescence, respectively. Photomultiplier tubes were biased at 1,000V. 
The LOD of fluorescein was ~ 9 zmol. Fluorescently labeled organelles were detected as 
individual events as they eluted out during washing of the non-retained material and 
elution of the magnetically retained material. Events also occurred during the washing 
with buffer M and before elution of the fluorescently labeled organelles. These random 
false positives occurred at a low rate (0.049 ± 0.004 events/s). The non-retained 
fluorescent organelles (e.g. endocytic organelles with low FeDex contents but detectable 
levels of fluorescein/TMRM-conjugated dextran) appeared first at a rate of 0.17 ± 0.14 
events/s. The retained fluorescent organelles (e.g. endocytic organelles with both FeDex 
and fluorescein/TMRM-conjugated dextran) appeared after ~100 s delay after removal of 
the capillary from the magnet. The yield of retained organelles was calculated as the ratio 
of the number of events in the retained zone to the number of events in both the 
unretained and retained zone. 
Fluorescent data was analyzed using Igor Pro (WaveMetrics, Inc. Lake Oswego, 
OR). Broad bands corresponding to freely diffusing species were eliminated with a 
median filter. Individual organelle peak analysis was done with the custom-written 
program “coincidence analysis”.163 The average peak base width for peaks used in 
coincidence analysis was 24 ± 3 ms (n = 10,374) for TMRM peaks and 32 ± 3 ms (n = 
10959) for fluorescein peaks. Peak intensities were corrected for spectral crosstalking 
(i.e, red-to-green ~ 16% and green-to-red ~ 6%). Peaks detected at the same time (± 20 
msec) by the two PMTs of the LIF detector were used to calculate pH as previously 
reported
48
 using a pH calibration curve of FTD-loaded liposomes with different internal 
pH’s (Section A-3). Peak overlap between individual events defined by statistical overlap 
theory
164
 was not significant for all the magnetically retained organelles and for most of 
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the non-retained organelles. For histogram distributions of individual pH values the bin 
width (2.0 pH units) was determined as the cubic root of total number of retained 
organelles, plus one.
165
 This value is larger than the error of individual pH values 
calculated by error propagation (Section A-3). Because pH distributions are non-
parametric, previously described Q-Q plots
166
 were used for comparison of distributions. 
3.2.8. Safety considerations 
Biosafety level 1 was observed in all procedures involving L6 cells. Biological waste was 
treated with bleach prior to disposal. Used cell culture supplies were autoclaved prior to 
disposal. 
3.3. Results & Discussion 
Fluorescence confocal microscopy measurements confirmed endocytosis of 
FeDex by L6 cells and was used to assess localization of FeDex in endocytic organelles 
based on the colocalization of LysoTracker Red and AlexaFluor488-bound FeDex 
(Figure 3.3. and Figure A.1.). LysoTracker Red accumulates in acidic organelles because 
the dye’s amine functional groups become protonated in acidic environments, which 
causes retention within the lumen of acidic organelles.
107, 167
 Based on the M2 Manders 
coefficient, 93% AlexaFluor488 fluorescence was colocalized with Lysotraker Red 
fluorescence. The remaining 7% may correspond to AlexaFluor 488 found in the cytosol 
(i.e., released from the lysosomes upon dextran degradation) or organelles with 
undetectable levels of LysoTracker Red (e.g., early endosomes). Based on the M1 
Manders coefficient, 74% of the LysoTracker Red fluorescence was colocalized with 
AlexaFluor488 fluorescence. This is not surprising because endocytosis of 
AlexaFluor488-bound FeDex is expected to distribute to endocytic organelles (late 
endosomes, lysosomes)
46, 168
 excluding other non-endocytic acidic organelles (e.g. 
Golgi). ICQ suggested a positive correlation in the abundances of AlexaFluor488-bound 
FeDex and LysoTracker Red (ICQ = 0.34). Based on the fluorescence microscopy results 
and considering dextran’s role as a lysosomal and endocytic organelle marker,168, 169 we 
concluded that FeDex particles were mainly localized in late endocytic organelles, 
including lysosomes. 
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Figure 3.3. Intracellular colocalization of FeDex with acidic organelles. (A) Overlay of 
confocal fluorescent images of L6 myocytes after endocytosis of AlexaFluor488-FeDex 
(Green) and treatment with LysoTracker Red (Red). Scale bar = 10 μm. (B) Boxplots of 
colocalization statistics of 45 cells. The M1 statistic represents the fraction of red 
fluorescence pixels with green colocalization. The M2 statistic represents the fraction of 
green fluorescence pixels with red colocalization. The ICQ statistic is > 0 indicating that 
intensities of both fluorophores are correlated. The ICQ statistic ranges from -0.5 to 0.5. 
3.3.1.Subcellular composition of magnetically isolated material 
Organelle specific enzyme assays are commonly used to determine composition, 
enrichment (i.e. R.A), and yields of subcellular fractions.
136
 We utilized the pNPP, 
succinate dehydrogenase, and catalase assays to compare the subcellular fractions 
prepared by (i) magnetically retaining organelles from PNF flowing through PEEK 
tubing or (ii) differential centrifugation. While the subcellular fraction prepared by 
differential centrifugation was positive for all the enzymatic markers tested here (i.e., 
lysosomes, mitochondria, peroxisomes), the fraction that was magnetically isolated had 
only lysosomal markers present (R.A. = 1.7 ± 0.5, average ± Std. Dev., n=3 independent 
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tests); other markers were below their limits of detection (Table 3.1). The R.A. for 
differential centrifugation for lysosomes was 1.2 ± 0.6 (average ± Std. Dev., n=3 
independent tests). While the magnetic isolation procedure appears to have a higher yield 
than differential centrifugation, these values are not statistically different (p=0.05). 
Density gradient centrifugation has also been used for purification of lysosomal 
fractions.
13, 14
 Unfortunately, this procedure did not provide sufficient material to perform 
the organelle marker assays used here (data not shown). 
Organelle Differential Centrifugation 
(R.A.) 
Magnetic Isolation 
(R.A.) 
Lysosome 1.2 ± 0.6 1.7 ± 0.5 
Mitochondria 1.4 ± 0.5 <0.2 
Peroxisome 1.7 ± 0.4 <0.1 
 
Table 3.1. Enrichment and composition of organelle fractions. The abundance of each 
organelle type was determined using organelle-specific enzymatic markers. The relative 
abundance (R.A.) for each fraction was calculated a described in the Experimental. The 
para-nitrophenylphosphatase assay was used to determine lysosomal abundance (LOD = 
700 pmol p-nitrophenol/min/mg protein). The succinate dehydrogenase assay was used to 
determine mitochondrial abundance (LOD = 1.0 nmol DCIP/min/mg protein) as used for 
mitochondria. The catalase assay was used to determine peroxisomal abundance (LOD = 
7.6 nmol Ti(IV)peroxysulfate/min/mg protein). 
The lysosomal yield of the magnetic isolation procedure was 18 ± 6% (average ± 
Std. Dev., n = 3 independent tests). The yield for differential centrifugation was 42 ± 10 
(average ± Std. Dev., n = 3 independent tests). While the magnetic isolation procedure 
appears to have a lower yield than differential centrifugation, these values are not 
statistically different (p=0.05). When the goal is to isolate large amounts of material, the 
yield could be further improved by coiling the tubing within the magnet gap,
170
 design of 
 43 
other magnet geometries,
153
 and further optimization isolation procedure. On the other 
hand, the current design is highly suitable when working with limited amounts of 
material (e.g., 5 µL of PNF). 
3.3.2. Determination of the individual pH of magnetically isolated organelles 
Lysosomes and other late endocytic organelles require an acidic pH to maintain 
biological activity.
121
 For lysosomes to be enriched and to be of possible use for 
metabolic and biotransformation in vitro studies, their functionality must be retained. The 
first step to assess their biofunctionality is the determination of their pH. Determining the 
pH value of isolated organelles in bulk does not describe the ranges in pH values found in 
isolated endocytic organelles at the different stages of their maturation. Knowing the 
distribution of pH values is critical to associate pH with the overall bioactivity of the 
isolated organelles. Detection of the pH of individual organelles addresses this issue. We 
previously reported an LIF detection scheme to measure the pH of individual 
organelles.
48
 In order to use this detection scheme, here we combine magnetic 
purification with the analysis of pH of individual organelles based on LIF detection. 
Organelles that were magnetically isolated and then detected had both FeDex 
nanoparticles and FTD. Since FTD has two fluorophores (Alexa 488 and TMRM) each 
with distinct pH dependence, While FeDex allows for magnetic retention, the ratio of 
fluorescence signals of FTD (Alexa 488 and TMR) are used calculate the pH of 
individual organelles (Section A.3). 
The instrumental setup used for pH determinations consisted a fused silica 
capillary (50 µm. I.D.), which replaced the PEEK tubing, connected to a post-column LIF 
detector (Figure 3.2C). The LIF detection of individual organelles produced narrow 
events (i.e., 24 and 32 ms wide at their base for fluorescein and TMRM detection, 
respectively), with a separate fluorescence signal detected at each PMT for each 
fluorophore (Figure 3.4B). While the PNF was being loaded and before loaded sample 
reached the detector, only a small number of random events were detected (regions (i) 
and (ii) in Figure 3.4A). When the PNF material began reaching the LIF detector, 
organelles began to appear (region (iii) in Figure 3.4A). These events are the non-retained 
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organelles and decreased in frequency as washing with Buffer M proceeded. Once the 
frequency of appearance of events decreased to 0-5% of that of the most crowded region, 
the capillary was removed from the magnet gap. As expected, the frequency of events 
increased, indicating that the magnetically retained events were reaching the LIF detector 
(region (iv) in Figure 3.4A). This region lasted only 50-60 seconds and had a low number 
of events (~ 20), consistent with the small volume of capillary exposed to the magnetic 
field (Figure 3.2A). The combined results of three runs had 83 events (yield ~ 2.6% of 
the total number of events) detected after removal of the capillary from the magnetic 
field. The yield was lower than that calculated based on organelle markers because here 
we used a higher linear flow rate than that used for the PEEK tubing-based experiments 
(7.7 cm/min for fused silica capillary; 1.3 cm/min for PEEK tubing). As indicated in 
Figure A.2, the recovery decreased as the flow rate increases. The numbers of non-
specific absorption and random events (12% and 4% of the detected events in region (iv), 
respectively) were not a problem because the non-specific absorption events are also 
endocytic organelles with pH values indicative of their bioactivity; the random events 
were rare and did not affect the interpretation of the pH results. Thus, we used the 
detected events in region (iv) to assess the pH of the magnetically isolated organelles. 
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Figure 3.4. LIF detection of individual organelles loaded with FTD. (A) Detection of 
fluorescein (upper trace) and TMRM (lower trace). Both traces were modified with a 
median filter to remove broad bands corresponding to free fluorophores (Figure A.4).
107
 
The four regions shown in this plot include: (i) Detection while PNF was loaded and 
before organelles reached the LIF detection; (ii) dead time during the exchange of PNF 
for buffer M; (iii) detection of events from organelles that were not magnetically 
retained; (iv) detection of events that were magnetically retained. Before detection of 
events in region (iv) the frequency of events had been decreased to 0 – 2.3% of the event 
density observed at the beginning of region (iii). (B) Expanded view from 3.4A indicates 
that events are narrow as expected from the rapid passage of organelles through the LIF 
laser and they contain FTD because they are detected simultaneously in both channels. 
As a reference, we determined the distribution of the pH of individual endocytic 
organelles in the PNF of L6 cells, treated only with FTD and prepared by differential 
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centrifugation (Figure 3.5A). The observed range of individual pH was 4-6, which is 
consistent with the expected pH of lysosomes and late endocytic organelles.
171
 We also 
determined a distribution of pH of individual endocytic organelles in the PNF prepared 
from L6 cells treated with nigericin and FTD (Figure 3.5B). Nigericin dissipates the 
luminal pH in acidic organelles that acquire the pH of their surroundings.
172
 The Q-Q plot 
of the distributions shown in Figure 3.5B confirmed that nigericin-treated organelles had 
an overall increase in pH (Figure A.5A). 
We also investigated the effect of FeDex on the LIF determination of pHs of 
individual organelles. The presence of FeDex caused a systematic increase in pH (1.7 ± 
0.1 pH units) relative those organelles from cells treated only with FTD (Table A.1, 
Figure A.5B). This may be the result from scattering or fluorescent quenching by the iron 
oxide nanoparticle.
173
 This shift was used as a correction factor for pH values of 
individual organelles obtained from FeDex-treated L6 cells. After correction, both the pH 
of the retained (Figure 3.5C) and the eluted organelles (Figure A.5C) were consistent 
with previous literature reports.
171
 Most importantly, the determination of the individual 
pH of magnetically retained organelles revealed how pH distributions shifted relative to 
the distribution of the organelles in the PNF (Figures 3.5C and 3.5A, respectively). This 
slight shift may indeed correspond to uncorrected biases caused by the FeDex particles or 
the additional time needed to carry out the magnetic isolation (~30 min) during which the 
pH gradient may begin to dissipate. On the other hand, a Q-Q plot comparing the 
individual pH values of magnetically retained and non-retained organelles in the same 
PNF revealed that their pH distributions are practically unbiased by the magnetic 
isolation procedure (Figure 3.5D). 
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Figure 3.5. Individual organelle pH distributions. (A) The pH of organelles in a PNF 
from L6 cells not treated with FeDex (B) Same as in A, except for treatment with 
nigericin prior to cell homogenization. (C) The pH of magnetically retained organelles. 
(D) Q-Q plot of pH distributions of magnetically retained versus unretained organelles in 
the same run. 
3.4. Conclusions 
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The magnetic isolation system described here was effective at isolating enriched 
lysosomes and endocytic organelles containing FeDex particles. Based on organelle 
enzyme markers, common contaminants in differential centrifugation preparations such 
as mitochondria and peroxisomes were not observed. Laser-induced fluorescence 
detection of the individual pH of magnetically retained organelles demonstrated that 
magnetic isolation does not influence the distribution of pH values relative to non-
retained organelles. We found a pH for isolated organelles of 4 – 6, which is 
characteristic of lysosomes and endocytic organelles retaining acidic pH. 
Future applications of the work described here include evaluation of different 
subpopulations of magnetically enriched organelles. This could be achieved with on-line 
magnetic capture of organelles followed by capillary electrophoresis coupled to LIF 
detection
48
 or isolectric focusing of the organelles based upon either free flow 
electrophoresis
174
 or within a capillary with LIF detection
103
. Future improvements also 
includes designing alternate open tube configurations (e.g. coiled
170
 or parallel lines
15
) or 
microfabricating magnetic geometries that are more conducive to attaining higher 
organelle yields.
175
 The advantages of newly proposed configurations could be easily 
explored using physical modeling using software packages such as ANSYS (fluid 
dynamics) and Maxwell (magnetism).
176
 The device could also be used to magnetically 
isolate other subcellular compartments using magnetic beads coated with organelle-
specific antibodies.
145-151
 The bioactivity of such organelles could be evaluated using 
previously reported
177
 or novel individual organelle assays. Lastly, the work described 
here has a great potential to become the basis for future magnetic purifications of 
endocytic organelles that are highly needed to investigate the role of lysosomal function 
in aging, storage disorders and metabolism. 
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Chapter 4 
Magnetically Enriched Endocytic Organelles from Uterine Sarcoma Cells 
Biotransform the Prodrug N-L-Leucyldoxorubicin into Doxorubicin 
 
Brandon Meyer synthesized N-L-leucyldoxorubicin, performed separations of drug and prodrug 
standards, and assisted in biotransformation experiments. Joseph J. Dalluge assisted with mass 
spectrometry. This work was supported by NIH grant T32 GM8347 and by the University of 
Minnesota's Undergraduate Research Opportunities Program (B.M.).  
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The biotransformation of N-L-leucyldoxorubicin (LeuDox) to the anti-cancer drug 
doxorubicin (Dox) occurs in the extracellular space, however, biotransformation may also 
occur intracellularly in endocytic organelles. In this study, magnetically enriched 
endocytic organelle fractions from human uterine sarcoma cells were treated with 
LeuDox, of which 10 % was biotransformed to Dox. This percentage accounts for 45% of 
the total LeuDox biotransformation observed in the post-nuclear fraction. This suggests 
endocytic organelles play a key role in the intracellular biotransformation of LeuDox to 
Dox. This technique allows for the determination of intracellular biotransformation of 
drugs and prodrugs. This process can be applied to other prodrugs that may not only be 
activated by metalloproteases and other extracellular enzymes, but also intracellularly. 
Furthermore, this technique may be useful to determine other biotransformations that are 
attributed to lysosomes and other endocytic organelles. 
4.1. Introduction 
Doxorubicin (Dox) is an anthracycline used to treat multiple hematological and 
solid tumors for decades.
178-180
 Dox enters the nucleus of mammalian cells and inhibits 
cell replication by binding to both DNA and topoisomerase 2α and 2β forming the 
topoisomerase 2-doxorubicin-DNA cleavage complex, triggering cell death.
181, 182
 
Despite its high anti-cancer activity, severe cardiac and liver toxicity are examples of its 
severe side effects.
183-189
 Cytotoxicity is both dose- and time-dependent
190
 and is caused 
in healthy cardiocyte cells by binding between Dox and topoisomerase 2β. Binding leads 
to both DNA double-strand breaks and increased apoptosis which causes modification to 
the cellular transcriptome which in turn causes critical errors in both mitochondriogenesis 
and  in mitochondrial metabolic function.
182
  
Prodrugs increase drug efficacy and can target cancerous cells by adding a 
molecular signature to the active drug.
191
 Prodrugs are practically inactive and are 
expected to release the drug once it reaches its targeted tissue or subcellular area. The 
prodrug is then cleaved forming the active drug. N-L-leucyldoxorubicin (LeuDox) is a 
Dox prodrug synthesized by conjugating L-leucine to the primary amine of Dox.
138
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Relative to Dox, reports have reported LeuDox is less cytotoxic and has higher tolerated 
dose than Dox.
16, 192-195
  
It is accepted that the biotransformation of LeuDox to Dox occurs in the 
extracellular space. This was attributed to both the high rate of biotransformation of 
LeuDox
16
 and the low cellular update of LeuDox.
16, 18, 196
 In support of these studies, 
aminopeptidases, cathepsins, and metalloproteinases that are capable of LeuDox 
biotransformation into Dox have been identified in the extracellular space.
197, 198
 It has 
also been hypothesized that LeuDox can be biotransformed to Dox intracellularly making 
intracellular activation of LeuDox a potentially important therapeutic route. 
Lysosomotropic amines, such as Dox and LeuDox, are weak bases which can diffuse into 
lysosomes and become protonated when their pKa is higher than the acidic pH of 
lysosomes, sequestering the amine in the lysosome.
172
 The presence of enzymes, such as 
cathepsins, in the lysosome has the potential of activating LeuDox to Dox.
2, 199
 One major 
caveat though is that some cancer cells have lysosomes with abnormally high pH, which 
would decrease sequestration of lysosomotropic amines into lysosomes such as 
LeuDox.
49
  
 
Figure 4.1. Structures of LeuDox and Dox. 
Investigating the role of lysosomes and endocytic organelles in intracellular 
LeuDox biotransformation requires highly enriched fractions devoid of other 
contaminating organelle types. Previous studies used enriched, lysosomal enzymes from 
rat liver to show lysosome enzymes are capable of this biotransformation,
197, 200, 201
 
however, these studies could not evaluate if LeuDox enters intact lysosomes. To address 
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this issue, we previously investigated LeuDox biotransformation occurring in whole 
MES-SA human uterine sarcoma cells. Following LeuDox treatment and cell 
homogenization, we determined the Dox and LeuDox contents in the enriched organelle 
fractions.
138
 The biotransformation of LeuDox into Dox in the enriched endocytic 
organelle fraction suggested that some of these organelle types, likely lysosomes, may be 
capable of the biotransformation of LeuDox into LeuDox.  This study did not rule out the 
possibilities that LeuDox biotransformation into Dox may occur extracellularly or in 
other subcellular compartments, from which Dox traffics to organelles found in the 
enriched organelle fractions. In addition, the presence of other organelle types in the 
enriched endocytic organelle fraction prevented us from ruling out the participation of 
these other organelles in the LeuDox biotransformations.  
Here we confirm that the biotransformation of LeuDox to Dox occurs in 
endocytic organelle fractions containing intact lysosomes and late endosomes. We 
magnetically enriched endocytic organelles from MES-SA cells using an approach in 
which the isolated endocytic organelles retain its acidic pH and in which other 
contaminating organelle types (i.e., mitochondria and peroxisomes) are absent  (work 
described in Chapter 3).
88
 Following treatment with LeuDox, the enriched fraction was 
analyzed by micellar electrokinetic chromatography coupled to laser induced 
fluorescence detection (MEKC-LIF), a technique previously used to monitor the 
biotransformation of LeuDox to Dox.
138
 LeuDox to Dox biotransformations took place in 
the magnetically enriched endocytic organelle fractions containing intact lysosomes and 
late endosomes. This technique allows for the determination of intracellular 
biotransformation of drugs and prodrugs and can be applied to other prodrugs that may 
not only be activated both extracellularly and intracellularly. Furthermore, this technique 
may be useful to determine other biotransformations that are attributed to lysosomes and 
other endocytic organelles. 
4.2. Material and Methods 
4.2.1. Reagents 
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McCoy’s 5A with L-glutamine was obtained from Fisher Scientific (Pittsburgh, 
PA). Bovine calf serum was obtained from Omega Scientific (Tarsana, CA). Gentamycin, 
protease inhibitor, iron(III) chloride hexahydrate, iron(II) chloride tetrahydrate, dextran 
from Leuconostoc mesenteroides, 1,10-phenanthroline, imidazole, 
cetyltrimethylammonium bromide (CTAB), tert-butoxycarbonyl-L-leucine succinimide 
ester (Boc-Leu-OSu), methanol, triflouroacetic acid, sodium hydroxide, sucrose, 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), and tricine were obtained 
from Sigma-Aldrich (St. Louis, MO). Ethylenediaminetetraacetic acid (EDTA), 
hydrochloric acid, and potassium hydroxide were obtained from Mallinckrodt 
(Phillipsburgh, NJ). Fluorescein was obtained from Invitrogen (Carlsbad, CA). Bovine 
serum albumin was obtained from Roche (Basel, Switzerland). Ethanol was obtained 
from Pharmco-AAPER (Brookfield, CT). Phosphate buffered saline (10 PBS, 13.7 M 
NaCl, 270 mM KCl, 800 mM Na2HPO4, and 200 mM KH2PO4, pH 7.4) was obtained 
from BioRad (Hercules, CA). Iron (96.0% pure) was obtained from VWR (Radnor, PA). 
Pyridine, Silica Gel 150, acetonitrile and chloroform were obtained from Mallinckrodt 
(Phillipsburg, NJ, USA). Trimethylsilyl iodide (TMSI) was obtained from TCI America 
(Portland, OR, USA). Doxorubicin HCl (Dox) was obtained from Meiji Seika Kaisha 
(Tokyo, Japan). Deionized water was purified with a Millipore Synergy UV System (18.2 
mΩ/cm, Bedford, MA). 
Buffer A, used for cell handling, was made by adding sucrose (34.23 g; 200 mM), 
Tris-HCl (790 mg; 10 mM), and EDTA (20 mg; 0.1 mM) to 450.0 mL of deionized 
water. The pH was adjusted to 7.4 with NaOH and HCl and diluted to 500 mL with 
deionized water. CTAB buffer, used for MEKC-LIF, was made by adding CTAB (730 
mg; 4 mM) and tricine (4.5 g; 40 mM) to 450 mL DI. The pH was adjusted to pH 8.5 
with NaOH and HCl and diluted to 500 mL with DI. 
Dextran coated iron oxide nanoparticles were prepared as described previously.
11
 
Following synthesis, coated nanoparticles were dialyzed against water in a Fisher 4.8 nm 
seamless cellulose membrane for 48 h at 4 °C. The dialysis water was exchanged after 24 
hour. Coated nanoparticles were filtered with a 0.22-µM filter under vacuum to remove 
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large aggregates and impurities. Coated nanoparticles (4 mg/mL) were stored at 4 °C in 
water and used within 2 months of synthesis.  Nanoparticles were characterized by 
transmission electron microscopy (TEM), x-ray diffraction, light scattering and hysteresis 
loop measurements as described previously.
88
 
For the synthesis of LeuDox, Dox (5.0 mg, 9.2 μmole) and Boc-Leu-OSu (4.0 
mg, 12 μmole) in pyridine (1.0 mL) was first stirred at 25 °C for 24 hour. Solvent was 
then removed at 60 °C on a rotating evaporator. The residue was dissolved in 
chloroform:methanol (10:1) and purified by silica gel chromatography with 
chloroform:methanol (10:1) as the eluent. Boc-Leu-Dox (3.0 mg, 46% yield) was 
obtained as a red-colored product. Boc-Leu-Dox (1.5 mg, 2.0 μmole) and TMS-I (800 μg, 
4.0 μmole) in chloroform (200 μL) were reacted under nitrogen at 25 °C for 6 min. Next, 
deionized water (3 μL, 1.7 × 10-4 mole) was added to quench the excess TMS-I in the 
reaction mixture. Semi-preparatory HPLC with a gradient elution in a C18 column (10-
µm particle size, 250  10.00 mm, Phenomenex, Torrance, CA) was used for 
purification. The mobile phase composition changed linearly from 100% water (0.1% 
trifluoroacetic acid) to 100% acetonitrile (0.1% trifluoroacetic acid) over 35 min and was 
maintained for another 35 min. Solvent was then removed at 60° C on a rotating 
evaporator. Leu-Dox (908 μg, 59% yield) was obtained as a red-colored powder product. 
4.2.2. Cell culture 
The human uterine sarcoma MES-SA cells (ATCC, Manassas, VA) were 
maintained in McCoy’s 5A media with L-glutamine supplemented with 10% bovine 
serum and 0.01% gentamycin at 37 °C and 5% CO2. Cells were subcultured to maintain 
upon reaching 95% confluence. Trypsin in PBS (0.5%) was used to release cells from T-
flasks. MES-SA cells were treated with nanoparticles (2.0 mg/mL) for 30 min in 
McCoy’s 5A media with L-glutamine supplemented with 10% bovine serum and 0.01% 
gentamycin at 37 °C and 5% CO2. 
4.2.3. Differential centrifugation 
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Cells were harvested by centrifugation at 1,000g for 10 min and washed twice 
with 3 mL of 137 mM NaCl, 2.70 mM KCl, 8.00 mM Na2HPO4, and 2.00 mM KH2PO4, 
pH 7.4 (1x PBS). This was repeated a second time. Cells were then treated with 1% (v/v 
in DMSO) protease inhibitor cocktail and homogenized in a Dounce homogenizer 
(0.0025” clearance, Kontes Glass, Vineland, NJ) with 100-150 strokes. The resulting 
solution was the whole cell homogenate (WCH) and 10% was kept for protein assays. 
The remaining 90% of WCH was centrifuged at 600g for 10 min to remove nuclei and 
unlysed whole cells. The resulting supernatant was the post nuclear fraction (PNF) and 
contained lysosomes, mitochondria, peroxisomes, endosomes, and cytosol. For 
biotransformation experiments, 6 µL of the PNF was aliquoted into 1.5 mL Eppendorf 
microcentrifuge tubes. 
4.2.4. Biotransformations of LeuDox in MES-SA cells 
MES-SA cells were treated with LeuDox to determine the amount of LeuDox 
biotransformed in living cells. MES-SA cells (1.2 × 10
6
; 25 mL) were treated with 
LeuDox (889 µg; 47 µM) for 1 h at 37 °C. Cells were harvested and lysed. The PNF 
fraction was collected and treated with MEKC buffer (20 µL). 
4.2.5. Biotransformation of LeuDox in MES-SA post-nuclear fractions 
A post-nuclear fraction (PNF) of MES-SA cells was treated with LeuDox to 
determine the amount of LeuDox biotransformed in MES-SA PNF. MES-SA cells (1.2 × 
10
6
) were harvested and lysed. The PNF fraction (200 µL) was collected and treated with 
LeuDox (7.12 µg; 47 µM) at 37° C for 1 hour at 200 rpm with the Eppendorf AG 
thermomixer (Eppendorf, Hamberg, Germany). The sample was then quenched by adding 
an equal volume of MEKC buffer (200 µL). 
4.2.6. Enrichment of lysosomes and endocytic organelle fractions 
The enrichment of lysosome and endocytic organelle fractions was done as 
previously described.
88
 In brief, neodymium borate magnets (2.0  2.0 sq. in., magnetized 
through their 0.5-inch thickness, K&J Magnetics, Inc., Jamison, PA) were arranged in 2 
sets of 4 magnets on an aluminum mount equipped with a high-precision micrometer to 
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adjust the gap between the two magnet sets from zero to ten centimeters. A syringe pump 
(Model number 210, KDS Scientific, Holliston, MA) delivered ~ 100 µL of PNF at 21.9 
cm/min to PEEK tubing (#1531, IDEX Health and Science, Oak Harbor, WA) positioned 
between the middle of two sets of magnets and held in place by a tight gap. The length of 
the tubing in the magnetic zone was 5.1 centimeters, which represents a volume of 2.6 
μL. 
To trap magnetic material, 12 µL of PNF was flowed through PEEK tubing held 
within the gap of the magnetic device. After trapping of the magnetic material, buffer A 
(20 μL; 1.3 cm/min) was then flowed through to remove unretained material. The PEEK 
tubing was removed from the magnet zone and the retained magnetic material was eluted 
with buffer A (20 µL; 212 cm/min). The non-retained fraction had a final volume of 32 
µL and the retained magnetic fraction had a final volume of 20 µL. 
The PNF, non-retained, and magnetic retained organelle fractions were treated 
with LeuDox (1.51-7.57 ng; 10-50 μM) immediately after collection. Samples were 
mixed by repeated aspiration and of the mixture with a pipette. Samples were incubated 
in a thermomixer (37° C, 1 hour, 200 rpm). Samples were then removed and treated with 
equal volume MEKC buffer (32 µL or 20 µL), vortexed for 30 s, and either frozen at -
20°C for next day analysis or immediately characterized by MEKC-LIF.  
4.2.7. Controls for LeuDox biotransformations 
A control experiment was done to ensure that the magnetic nanoparticles used 
here were not catalyzing the biotransformation of LeuDox to Dox. An excess of FeDex 
(20 mg/mL; 20 µL) relative to that used for magnetic enrichment was treated with 
LeuDox (1.51 ng; 10 μM) and incubated in a thermomixer (37° C, 1 h, 200 rpm). 
Thereafter, the control mixture was treated with an equal volume of MEKC buffer, 
vortexed for 30 s, and either frozen for future analysis or immediately characterized by 
MEKC-LIF.  
Buffers may cause hydrolysis of LeuDox to Dox. Buffer A and PBS were treated 
with LeuDox (1.51-7.57 ng; 10-50 μM). Buffer A or PBS treatments were then incubated 
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in a thermomixer (37° C, 1 h, 200 rpm) and quenched with equal volume of MEKC 
buffer, vortexed for 30 s, and either frozen for future analysis or immediately 
characterized by MEKC-LIF.  
PNF fractions were treated with Dox to ensure Dox was not biotransformed into 
an additional product with a similar migration time to LeuDox. Dox may biotransform to 
Doxorubicinol.
138, 202
 Overlap would cause an increased fluorescence signal for LeuDox 
resulting in incorrect determination of the moles of LeuDox. PNF (2.5 × 10
7
 cells; 200 
μL) was treated with Dox (5.11 μg; 47 μM). The sample was then incubated in a 
thermomixer (37° C, 1 h, 200 rpm) and quenched with equal volume of MEKC buffer, 
vortexed for 30 s, and either frozen for future analysis or immediately characterized by 
MEKC-LIF.  
4.2.8. MEKC-LIF analysis of LeuDox biotransformations 
The custom-built instrument used for this work has been previously described.
89
 
Dox standard (1.0 × 10
-7
 M) was prepared by serial diluting of Dox stock solution (1.0 × 
10
-3
 M in methanol) in MEKC buffer. Leu-Dox standard (1.0 × 10
-6
 M) was prepared by 
dissolving Leu-Dox (760 μg) in 400 μL of methanol then diluting 100-fold in MEKC 
buffer. Rhodamine 123 standard (R123; 1 × 10
-9
 M) was prepared by serial diluting a 
R123 stock solution in methanol (1.0 × 10
-3
 M) in MEKC buffer. Uncoated, 50-μm i.d., 
42-cm long fused-silica capillary (Polymicro; Phoenix, AZ) was conditioned with 100 
mM NaOH, deionized water, and MEKC buffer under external pressure (20-25 kPa) for 
30 min each prior to the first sample injection. Separations were performed at -400 V/cm 
because this MEKC buffer reverses electroosmotic flow.
138
 Fluorescence excitation was 
done with a 488-nm line argon-ion laser powered at 12 mW (Milles Griot; Irvine, CA). 
Fluorescence emission was selected with a 635 ± 27.5 nm filter (Omega Optical; 
Brattlesboro, VT) and detected with an R1477 photomultiplier tube (R1477 Hamamatsu 
Photonics, Hamamatsu, Japan) biased at 1,000V. Data was digitized by a NiDaq I/O data 
board (PCI-MIO-16XE-50, National Instruments, Austin, TX), and operated by Labview 
5.1 software (National Instruments). 
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Data was analyzed using Igor Pro (WaveMetrics, Inc. Lake Oswego, OR). The 
limit of detection (LOD) for R123, Dox, and LeuDox was calculated as described below: 
LOD =   
 
 
              Equation 4.1. 
where   was the standard deviation of the baseline, I was the intensity of the 
standard, [C] was the injected standard’s concentration, and Vi was the volume injected. 
The LODs of R123, Dox, and LeuDox were 2 × 10
-19
, 2 × 10
-18
, and 1 × 10
-17
 moles, 
respectively. While the optical components and filters were not optimized as well as 
previous reports leading to increased LODs (e.g. 61 zmol Dox
203
), the sensitivity 
achieved for Dox and LeuDox was still improved compared to high performance liquid 
chromatography methods previously used to determine levels of Dox and LeuDox.
16
 
The resolution (Rs) between Dox and LeuDox was calculated as 
                         Equation 4.2. 
where tm is the migration time and w is the peak width at half the maximum 
intensity. Rs between Dox and LeuDox peaks were 2.4. 
The migration time (tm) of analytes in MEKC varies from run-to-run and calls for 
methods to correct for such variations.
204
 The migration time of Dox was corrected using 
the retention time of one standard (R123) and LeuDox itself because it was present in all 
the samples. The corrected migration time of Dox (tx) was calculated as: 
    
 
 
    
 
 
 
 
 
     
 
 
   
 
     Equation 4.3. 
   
 
     
 
 
     
 
    
 
 
    
     Equation 4.4. 
where     is the observed tm of Dox,       is observed tm of R123, tm,1 is the average 
tm of R123,       is observed tm of LeuDox, and tm,2 is the average tm of LeuDox. 
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The mole percent of LeuDox biotransformed into Dox in either the retained (R) or 
unretained (U) fraction was calculated as shown below: 
        
      
     
      
      
     
     
           
        
        
 
 
  
  
      
     
      
      
     
     
           
        
        
 
 
   
   
     Equation 4.5. 
where ADox and ALeuDox are the respective areas of peaks for Dox and LeuDox 
observed for a given sample; while ADox,S and ALeuDox,S are the respective areas of peaks 
for Dox and LeuDox standards when  mDox,S and mLeuDox,S moles of Dox and LeuDox, 
standards, respectively, were injected and analyzed in a separate run. ‘Ctl’ is the 
biotransformation in a control fraction which only contains buffer and LeuDox to account 
for non-specific biotransformation. 
4.2.9. Safety considerations 
Biosafety level 2 was observed in all procedures involving MES-SA cells. 
Biological waste was treated with bleach prior to disposal. Used cell culture supplies 
were autoclaved prior to disposal. 
4.3. Results  
4.3.1. MEKC-LIF analysis of LeuDox to Dox biotransformations  
Previous studies have suggested LeuDox is biotransformed into Dox in endocytic 
organelles including lysosomes and acidic organelles.
138, 197, 200
 To investigate whether 
this is indeed the case, we treated magnetically enriched endocytic organelles with 
LeuDox and monitored the reaction products by MEKC-LIF. Prior work demonstrated 
that such magnetic enrichment procedure was adequate to prepare endocytic organelles 
with an expected acidic pH, which suggests that they are functional and that the 
preparation was devoid of other unwanted organelles.
88
  
The basic test for biotransformation of LeuDox to LeuDox was separation of 
these two species by MEKC-LIF. Analysis of standards showed two peaks in the 
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electropherograms (Figure 4.2). The difference in their electrophoretic mobility was 4.6 × 
10
-5 
cm
2
×s
-1
×V
-1
, which is similar to a previously reported value (5.2× 10
-5
 cm
2
×s
-1
×V
-
1
).
138
 LeuDox appeared either as a single peak or as major peak with an unresolved, 
minor peak, which is consistent with a previous report previously (Figure 4.2).
138
 The 
sporadic appearance of the minor peak may be explained by the stereoisomeric nature of 
LeuDox (Figure 4.1).
204
 Stereoisomers may have small differences in electrophoretic 
mobility, which are barely resolved only on some days; day-to-day variation in MEKC-
LIF is commonplace. Further evidence supporting that both peaks are LeuDox are a clean 
mass spectrum (Figure B.1.) and the major and minor peak decrease in magnitude during 
formation of Dox. Therefore, for quantification purposes, both areas of these two peaks 
were included when calculating the moles of LeuDox (Equation 4.5.). Most importantly, 
all major species R123 (standard), Dox, and LeuDox were fully resolved thereby 
enabling a quantification of the transformation of LeuDox into Dox.  
 
Figure 4.2. MEKC-LIF separation of LeuDox and Dox standards. Separation conditions: 
uncoated, 50-μm i.d., 42-cm long fused-silica capillary, -400 V/cm, MEKC buffer 
consisted of 4 mM CTAB, 40 mM tricine in deionized water, pH 8.5. Detection 
conditions: excitation with a 488-nm line argon-ion laser powered at 12 mW; emission 
was detected at 635 ± 27 nm. LeuDox (1.0 × 10
-6
 M concentration, tm = ~430 s), Dox (1.0 
× 10
-7
 M concentration, tm = ~360 s), Rhodamine 123 (1 × 10
-9
 M, tm = ~225 s). 
Buffers or magnetic particles used for endocytic organelle enrichment may cause 
biotransformation of LeuDox into Dox.
191
 We confirmed that Dox formation is due only 
to biotransformation of LeuDox in endocytic organelles and not to other hydrolysis 
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caused by material that could become in contact with LeuDox during the procedure. Dox 
formation was not detected when LeuDox was mixed with the homogenization buffer or 
PBS prior to MEKC-LIF analysis (Figure 4.3). Furthermore, Dox formation was not 
observed when magnetic nanoparticles in homogenization buffer were treated with 
LeuDox prior to MEKC-LIF analysis. These controls demonstrate that the 
biotransformation of LeuDox to Dox was likely caused by the endocytic organelles.  
 
Figure 4.3. Controls for LeuDox to Dox biotransformations. (A) LeuDox in 
homogenization buffer (5 × 10
-4
 M LeuDox, tm = ~430 s). (B) LeuDox in the presence of 
magnetic nanoparticles (20 mg/mL) suspended in homogenization buffer. Treatment time 
was 1 h. See Figure 4.2. for additional information. 
One of the Dox metabolites in MES-SA cell lines is Doxorubicinol.
138, 202
 If 
Doxorubicinol was formed, it may be detected and overlap with LeuDox peaks. 
Therefore, we performed a control experiment to determine whether Dox is metabolized 
to other products such as Doxorubicinol that have overlapping migration times with 
LeuDox. Overlapping products would bias the quantitation of LeuDox in a sample. To 
investigate this possibility, we treated the post-nuclear fraction with Dox. No 
biotransformation products with similar migration times to those of LeuDox were 
observed. The only indication of biotransformation of Dox was a broad band with peak 
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maximum at tm = ~340 s. The difference in observed mobilities between Dox and the 
unidentified peak was the same as reported by Wang et al. for the differences between 
Dox and Doxorubicinol mobilities (6.2 × 10
-5
 cm
2
×s
-1
×V
-1
).
138
 Thus, it is unlikely that 
Dox metabolism is forming compounds that bias the analysis of LeuDox is suggests the 
fluorescence levels detected for LeuDox in MES-SA cells and in enriched subcellular 
fractions prepared from this cell line (Figure 4.4).  
 
Figure 4.4. Biotransformation of Dox in PNF. The PDF was treated with Dox (4.7 × 10
-6
 
M for 1 h, tm = 400 s) and the only peak observed at tm = ~335 s did not overlap with the 
LeuDox peak (tm = ~450-500 s). See Figure 4.2. for additional information.  
4.3.2. Biotransformations of LeuDox in MES-SA cells and MES-SA PNF 
The biotransformation of LeuDox into Dox was 9.5% in living MES-SA cells. A 
parallel analysis using PNF instead of living MES-SA cells showed 23% of LeuDox is 
biotransformed into Dox in the PNF of these cells; a previous study reported that  ~ 26% 
LeuDox biotransforms into Dox in the PNF of MES-SA cells.
138
 The higher 
biotransformation of LeuDox in the PNF was anticipated because LeuDox can more 
readily access endocytic organelles when these have been released from whole cells. One 
caveat in these studies is that other organelles present in the PNF may be contributing to 
the biotransformation of LeuDox. 
4.3.3. Biotransformation of LeuDox in magnetically enriched and non-enriched 
endocytic organelle fractions 
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The biotransformation of LeuDox into Dox in magnetically enriched and non-
enriched endocytic organelle fractions was determined by MEKC-LIF (Figure 4.5.). 
Because the biotransformation did not occur in the presence of only buffers or magnetic 
particles, LeuDox biotransformation was attributed to endocytic organelles. Dox was 
successfully identified as a peak with migration time of 326 ± 30 s, (average ± st.dev, n = 
2 independently prepared endocytic organelle fractions). The mole percent of LeuDox 
biotransformed to Dox was 10% (n=2) and 13% (n=2) in this magnetic enriched and non-
retained fractions, respectively. This suggests 45% of the biotransformation occurred in 
the enriched organelle fraction. 
 
Figure 4.5. Biotransformations of LeuDox in the PNF of magnetically enriched 
endocytic organelle fraction. Fractions were treated with 5 × 10
-4
 M LeuDox for 1 hr, (A) 
Post-nuclear fraction (B). Non-enriched fraction. (C) Enriched fraction. See Figure 4.2. 
for additional information. 
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4.4. Discussion 
In this study, we determined that 45% of the intracellular biotransformation of 
LeuDox into Dox occurs in a magnetically enriched fraction which contains endocytic 
organelles including lysosomes. We previously reported that the organelles in this 
fraction maintain an acidic pH (~ 4-6) and do not have detectable levels of mitochondria 
or peroxisomes.
88
 Because the hydrolytic properties of endocytic organelles are unique to 
late endosomes and lysosomes and the enzymes involved require an acidic pH, we 
concluded that the LeuDox biotransformation into Dox occurs intracellularly in 
lysosomes and possibly in late endosomes.  
The magnetic enrichment method did not capture all the endocytic organelles, 
which explains why LeuDox biotransformation was also observed in the non-retained 
fraction. Although we cannot rule out biotransformations caused by other organelle types 
(e.g. mitochondria) in the non-retained fraction, prior work indirectly suggested it is 
indeed endocytic organelles in the non-retained fraction that cause LeuDox 
biotransformation. In this prior work, the magnetically enriched and non-retained 
fractions had 18% and 82% of the endocytic organelles in the post-nuclear fraction, 
respectively.
88
 Using this proportion of endocytic organelles in the two fractions, we 
anticipated that biotransformation of LeuDox in the magnetically retained and non-
retained fractions would occur in similar proportions. Surprisingly, 45% of LeuDox 
transformation occurred in the magnetically retained fraction; this percentage increases to 
95% when accounting for the endocytic organelle yield. This suggests that the retained 
organelles maintain higher specific biotransformation activity than those that were not 
retained.   
A previous study treated living MES-SA cells with LeuDox for 12 hours and then 
determined that the fraction containing acidic organelles, prepared by differential 
centrifugation, biotransformed ~63% LeuDox into Dox.
138
 This ratio is larger than the 
percentage determined in the magnetically retained fraction reported here (45%), which is 
not surprising because the current incubation with LeuDox lasted only 1 h.
138
 
Furthermore, the previous report treated living MES-SA cells with LeuDox raising the 
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possibility that LeuDox biotransformation occurred either extracellularly or in other 
subcellular locations; Dox produced could then traffic to endocytic organelles and 
become sequestered. In this study, direct treatment of the magnetically enriched 
endocytic organelle fraction ruled out this possibility and confirmed that LeuDox 
biotransformation occurs in the endocytic organelle fraction. 
An aspect of the method that can be improved in the future is the functional status 
of endocytic organelles that have been magnetically isolated. Currently, incubation of 
LeuDox with endocytic organelles is adequate for 2-3 hours after isolation. Reduction of 
the duration of magnetic isolation time and stabilization of the functional status of the 
isolated organelles for longer times would extend the capabilities of the procedure 
described here. This could be done by providing ATP to enriched organelles to allow for 
proton gradients to be maintained for endocytic organelles.
205, 206
 Reduction of the 
duration of the endocytic organelle technique could be done with more powerful magnets 
which would allow for increased flow rates of the biological sample.
207
 Finally, a 
modified geometry of the magnetic apparatus could result in increased yields of 
endocytic organelles.
15, 170, 175
 
4.5. Conclusions 
This report demonstrated that intracellular biotransformation of LeuDox to Dox 
occurs in endocytic organelles, likely in lysosomes and late endosomes. Overall, the 
research describe here can determine the role of intracellular activation in the design of 
novel prodrugs. This technique may also be useful to determine other biotransformations 
that are attributed to lysosomes and other endocytic organelles. Intracellular 
biotransformation information may be critical in the future development of prodrugs with 
increased efficacy. Since we have shown LeuDox is biotransformed intracellularly in 
endocytic organelles, it may be advantageous to incorporate a liposome into LeuDox 
formulation, analogous to Dox and the liposome-form Doxil
®
. Doxil enter cells via 
nontargeted endocytosis allowing for Dox to be release in endocytic organelles.
208
 A 
similar approach for LeuDox could also result in increased intracellular activation.   
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This methodology described here can also be applied to other prodrugs that may 
not only be activated by metalloproteases and other extracellular enzymes, but also 
intracellularly. Furthermore, this technique may be useful to determine other 
biotransformations that are attributed to lysosomes and other endocytic organelles. 
Although only MES-SA cells were used here, the potential of other cell lines (e.g. CCRF-
CEM and CEM/C2 human leukemia cells
106
) to activate intracellularly LeuDox and other 
prodrugs could be investigated with the methodology described here. Ultimately, the 
methodology could be extended to animal tissues such as Balb/c nude mice
209
 and 
rabbit,
195
 as well as human tissues such as ovarian cancer,
210, 211
 or samples acquired 
during clinical trials.
196
  
In order to determine prodrug biotransformations from tissue, new techniques 
may need to be developed. Isolated tissues could be treated with nanoparticles similar to 
the treatment of cells with nanoparticles as described previously.
88
 If this technique does 
not produce a sufficient yield of enriched endocytic organelles, magnetic 
immunoenrichment techniques may need to be developed for tissue. An antibody against 
a lysosome-enriched protein could be bound to a magnetic particle. Following binding 
between the antibody and protein, an external magnetic field can be used to enrich the 
magnetic particle with bound organelles.
212, 213
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Chapter 5 
A Workflow for Preliminary Identification of Small Molecules Enriched in 
Autophagosomes and Activated Mast Cells Using UPLC-MS
E
, Chemometrics, and 
Mass Spectral Evaluation 
Joseph Koopmeiners developed the home-written programs for the linear mixed model. 
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enriched autophagosomes from rat liver tissue. Thane Taylor assisted in the removal of 
mitochondria in autophagosome enriched fractions from rat myoblast cell culture. 
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Fellowship, Revson Foundation Fellowship), T.H.T. and M.M.H. (NIH Chemistry 
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The high sensitivity, selectivity, and mass accuracy of LC/MS using high-
resolution mass analyzers have made it a method of choice for the generation of 
metabolic signatures and databases. Failure to evaluate database identifications that are 
based solely on accurate mass measurements, however, may lead to erroneous 
identifications. This report describes a workflow based on ultra high performance liquid 
chromatography (UPLC) coupled to acquisition of low- and high-collision energy mass 
spectra (MS
e
) for preliminary feature (a sample-specific chemical entity characterized by 
a unique constitution of chromatographic retention time, m/z and intensity) identification 
in the following biological systems: (a) rat liver autophagosomes; (b) rat myoblast 
autophagosomes; (c) chemically activated murine mast cells. The developed workflow 
consists of 5 steps: (1) UPLC/MS
e
 profiling of the systems of interest; (2) chemometric 
analysis to determine candidate features characteristic of these biological systems; (3) 
confirmation of candidate features via evaluation of extracted ion chromatograms (XICs); 
(4) database searching to provide potential identifications of confirmed features; (5) mass 
accuracy confirmation, evaluation of fragmentation patterns from MS
e
 spectra, and 
precursor-product XIC alignment to provide preliminary identifications of evaluated 
features. For rat liver-enriched autophagosome fractions, 114 confirmed features were 
determined from which 23 preliminary identifications were made. For rat myoblast-
enriched autophagosome fractions, 130 confirmed features were determined from which 
12 preliminary identifications were made. Chemometric approaches determined 2,656 
confirmed features from activated mast cells from which 14 preliminary identifications 
were made. Precedent literature supports the biological relevance of many of the 
preliminary identifications made for the biological systems studied here. 
5.1. Introduction 
Liquid chromatography coupled to mass spectrometry (LC/MS) employing high 
resolution mass analyzers is often the method of choice for the analysis of compounds in 
biological systems due to its high sensitivity, selectivity, and mass accuracy.
214-216
 A 
rapid and robust method for biological chemical profiling studies by LC/MS is 
UPLC/MS
e
.
215, 217-219
 UPLC/MS
e
 employing an orthogonal quadrupole-time-of-flight 
mass spectrometer can provide rapid, high peak-capacity separations with simultaneous 
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acquisition of low- and high-collision energy mass spectra with excellent mass accuracy 
for both parent and fragment ions. This combination allows more comprehensive 
validation of detected features (sample-specific chemical entities characterized by a 
unique constitution of chromatographic retention time, m/z and intensity) without the 
requirement to perform additional precursor-selected MS/MS experiments on those 
features.  
The large amount of data generated by LC/MS(MS)-based profiling experiments, 
including UPLC/MS
e
, requires the use of multivariate chemometric approaches for the 
detection of chemical entities specific to a given biological system. Orthogonal partial 
least squares with discriminate analysis (OPLS-DA) is a chemometric approach that 
classifies potential features into one of two comparative biological fractions.
220-223
 
Disadvantages of OPLS-DA include the failure to detect candidate features that are not 
well grouped into one of the two biological fractions due to a group-averaging effect 
from discriminate analysis.
224
 Alternate approaches to using OPLS-DA for detecting 
candidate features include the t-test and linear mixed model (LMM) which compare the 
average intensity of XICs between samples
225
 Both approaches provide similar 
information but the LMM is also able to partition the total variance into the biological 
and analytical variance when instrumental replicates are present.
225
 The LMM is more 
powerful than the t-test, resulting in an increased number of detected candidate features, 
but is susceptible to model misspecification, which can result in inaccurate selection of 
candidate features and potential omission of some candidate features unique to a sample 
that have increased variation.
224
 Incorrectly applied chemometric approaches in 
combination with misidentification of confirmed features by databases, the only criterion 
for which is the measured accurate mass of precursor ions, can result in the inadvertent 
determination of false-positive candidate features. Applying multiple chemometric 
approaches to a given data set can increase coverage for the detection of candidate 
features and can compensate for the limitations of detection for each individual 
chemometric approach.  
Despite the advantages of LC/MS-based approaches combined with chemometrics 
for metabolite profiling studies, there are potential pitfalls.
226-228
 Slight changes in 
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chromatographic retention times can result in misassignment of sample-specific features. 
Chemometric approaches used to detect candidate features with extracted ion 
chromatograms (XIC) near the peak intensity threshold may not be true positives. Ion 
suppression of chemical species due to co-eluting compounds can cause an inaccurate 
assessment of analyte relative abundance, cause increased variation in XIC quantification 
in replicate analyses, or cause complete loss of detection. Identification of confirmed 
features by database searches based solely on accurate mass measurement of precursor 
(parent) ions may lead to incorrect structural assignments.
228
 In addition, for MS
e
 
analyses, co-eluting species can result in complex low- and high-collision energy mass 
spectra that may limit the ability to confirm the precursor-product relationships for a 
given feature. These disadvantages are often multiplied by the inability to perform ideal 
numbers of replicate LC/MS examinations. 
The numerous caveats regarding chemometric analysis and database searching 
summarized above make the evaluation of both chemometric-determined candidate 
features and database identifications imperative. As such, a workflow has been developed 
to evaluate and confirm the determination and preliminary identification of features 
resulting from chemometric analysis of UPLC/MS
e
 analyses of complex biological 
samples combined with structural database searching (Figure 5.1.). The workflow 
includes (1) untargeted UPLC/MS
e
 profiling of the systems of interest; (2) application of 
chemometrics to identify candidate features characteristic of these biological systems; (3) 
confirmation of identified features via evaluation of extracted ion chromatograms (XICs), 
referred to as Checkpoint 1 (Figure 5.1.); (4) database searching to provide potential 
identifications of confirmed features; (5) mass accuracy confirmation, evaluation of 
fragmentation patterns of each feature from simultaneously acquired high-collision 
energy mass spectra, and precursor-product XIC alignment to provide determinant 
identifications of confirmed features, referred to as Checkpoint 2 (Figure 5.1.). This 
workflow has been employed in a proof-of-principle study to identify compounds 
specific to autophagosomes. These are organelles that facilitate the degradation of 
intracellular components via a biological process called autophagy. Abnormal autophagy 
has been associated with multiple disease states including Parkinson's disease,
71, 229, 230
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Huntington's disease,
229
 and Alzheimer's disease.
230, 231
 To demonstrate broad 
applicability of the described approach for comparison of dissimilar biological systems at 
the molecular level, it has also been applied to the characterization of chemically 
stimulated mast cells that are known to play an important role in allergic/inflammatory 
response.
232
 
 
Figure 5.1. Workflow for determination, confirmation, and preliminary identification of 
features from UPLC/MS
e
 data. 
5.2. Materials and Methods 
5.2.1. Reagents 
Metrizamide was purchased from Amresco (Solon, OH). Vinblastine sulfate, 
sucrose, gentamycin, Trizma-hydrochloric acid, potassium chloride, sodium chloride, d-
glucose, calcium chloride, protease inhibitor cocktail (for mammalian cell and tissue 
extracts, in DMSO solution), sodium hydroxide, and magnesium chloride were from 
Sigma Aldrich (St. Louis, MO). Glycyl-L-phenylnaphthylamine was from Bachem 
(Torrance, CA). Methanol was from Fisher Scientific (Fairlawn, NJ). Dichloromethane 
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was from Mallinkrodt (Phillipsburg, NJ). Ultra LC/MS-grade methanol, acetonitrile, and 
water were from JT Baker (Center Valley, PA). Formic acid was from EMD (Darmstadt, 
Germany). Penicillin-streptomycin solution (PS) was from Life Technologies (Grand 
Island, NY). Anti-TNP IgE antibody was from BD Biosciences (San Jose, CA). CXCL10 
was from Shenandoah Biotechnology (Warwick, PA). Dubelco’s Modified Eagle 
Medium (DMEM) high glucose cell medium, bovine calf serum, and fetal bovine serum 
were from Thermo Scientific (Waltham, MA). 
5.2.2. Enrichment of autophagosomes from rat liver 
Male Wistar rats (200–250 g) were obtained from Jackson Laboratory. 
Autophagosomes were isolated from rat liver after 6 h starvation using a protocol 
modified from the literature.
233
 Livers were harvested, minced and homogenized using a 
Teflon homogenizer prior to separation by differential centrifugation. A pellet containing 
the nuclear fraction and (up to 30%) unbroken cells was produced first. The supernatant 
was centrifuged at 100,000g and the pellet contained non-enriched organelles. 
Autophagosome fractions were enriched by differential centrifugation followed by 
discontinuous density metrizamide gradients as previously described.
20, 233
 
5.2.3. Enrichment for autophagosomes from rat myoblast cell culture  
L6 rat myoblast cells were cultured in 450 mL DMEM with 50 mL fetal bovine 
serum, and 100 μL gentamycin. For the enrichment of autophagosomes, cells were first 
treated with vinblastine sulfate dissolved in 0.9% sodium chloride at a final concentration 
of 50 μM in DMEM solution for 2 hours. Homogenization buffer consisted of 250 mM 
sucrose in deionized water (Millipore Synergy UV system, 18.2 mΩ/cm, Bedford, MA) 
adjusted to pH 7.2 with 100 mM sodium hydroxide. Cells were collected in 
homogenization buffer and centrifuged twice at 1,000g for 10 min. The cell pellet was 
resuspended in 1 mL homogenization buffer and 1% protease inhibitor cocktail. Cells 
were lysed with a Dounce homogenizer (clearance, 0.0025 in, Kontes Glass, Vineland, 
NJ). An organelle pellet was formed from the lysate with sequential 600g (to remove 
nuclei and cell debris) and 16,100g (to remove cytosol and cytosolic proteins) differential 
centrifugation steps. The resulting post-nuclear fraction was the control, non-enriched 
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fraction. To enrich for autophagosomes, mitochondria were immuno-removed with the 
Mitochondria Isolation Kit (MACS, Miltenyi Biotec, Auburn, CA) according to the 
manufacturer’s procedure using the homogenization buffer described above. Lysosomes 
were osmotically lysed with 500 nM glycyl-L-phenylnapthylamine for 8 min at 37 °C at 
200 rpm on a thermomixer. Following treatment, the fraction was centrifuged for 30 min 
-at 16,100g. The resulting organelle pellet was defined as the enriched autophagosome 
fraction. Protein quantitation was done with the Pierce BCA protein assay kit (Thermo 
Fisher, Rockford, IL) according to the manufacturer’s procedure. 
5.2.4. Extractions of autophagosome samples 
A two step protocol for polar and nonpolar extractions was used for extractions of 
enriched autophagosome fractions.
234
 Fractions were treated with 1.5 mL ice cold 1:1 v/v 
methanol:deionized water. Pellets were resuspended with a syringe, vortexed for 30 s, 
and incubated for 5 min. Samples were centrifuged at 16,100g for 10 min to pellet any 
non-extracted materials. The supernatant, defined as the polar extraction, was removed 
and kept on ice. The remaining pellet was treated with 1.5 mL ice cold 1:3 v/v 
dichloromethane:methanol. The pellet was resuspended with a syringe, vortexed for 30 s, 
and incubated for 5 min. The sample was centrifuged for 16,100g for 10 min to pellet any 
non-extracted materials. The supernatant, defined as the non-polar extraction, was 
removed and kept on ice. Extracted samples were vacuum concentrated overnight at 
room temperature to remove extraction solvent. Sample extracts were stored under 
nitrogen at 4° C until analysis. 
5.2.5. Stimulation of mast cells  
Murine peritoneal mast cells (MPMCs) were isolated via peritoneal lavage 
following euthanasia by CO2 asphyxiation. Lavage was performed using approximately 8 
mL per mouse of cell culture media composed of ice-cold high-glucose DMEM 
supplemented with 10% (v/v) BCS and 1% (v/v) PS, and 6-7 mL lavage fluid were 
recovered per mouse. After isolation, cells were pelleted at 450g, resuspended in fresh 
media, and cultured overnight on a confluent monolayer of NIH/3t3 fibroblasts 
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(purchased from American Type Culture Collection, Manassas, VA) with 0.5 µg/mL 
anti-TNP IgE. 
MPMCs were washed three times with 37 C Tris buffer (12.5 mM Trizma-HCl, 
150 mM NaCl, 4.2 mM KCl, 5.6 mM glucose, 1.5 mM CaCl2, and 1.4 mM MgCl2, pH 
7.4) to remove cell culture media, serum proteins, and cell debris. MPMCs were treated 
either with Tris buffer (2 cultures prepared) or with Tris buffer containing 200 ng/mL 
CXCL10 for 2 hr (2 cultures prepared). Each pair of cultures was then treated with either 
Tris buffer or Tris buffer containing 100 ng/mL TNP-ova for 2 hr. These treatments in 
series created four different activation conditions: (1) Tris buffer followed by Tris buffer, 
(2) Tris buffer followed by TNP-ova, (3) CXCL10 followed by Tris buffer, and (4) 
CXCL10 followed by TNP-ova. 
Supernatants were collected and filtered using PTFE 0.2 µm centrifugal filter 
units at 14,000g for 5 min, then stored overnight at -80 °C. Prior to UPLC/MS
e
 analysis, 
samples were concentrated to 100 µL, and salts and proteins were precipitated via the 
addition of 1 mL ice cold ethanol. Samples were then centrifuged at 12,000g for 10 min, 
and supernatants were vacuum concentrated to approximately 30 µL. Tris buffer/TNP-
ova and CXCL10/TNP-ova samples were reconstituted to 300 µL with LC/MS-grade 
water and analyzed by UPLC/MS
e
. Tris buffer/Tris buffer and CXCL10/Tris buffer 
samples were stored at -80 °C, then reconstituted to 300 µL with LC/MS-grade water 
prior to UPLC/MS
e
 analysis. 
 Samples were resuspended prior to UPLC/MS
e
 analysis as previously 
described.
234
 Briefly, both polar and nonpolar extracts were resuspended in 200 μL 1:1 
v/v methanol:deionized water. Samples were vortexed for 30 s to resuspend the pellet 
followed by sonication for 30 min. The sample was centrifuged for 16,100g for 10 min to 
remove any non-resuspended materials. 
5.2.6. UPLC/MS
e 
conditions 
A Waters Acquity UPLC coupled to a Waters Synapt G2 HDMS quadrupole 
orthogonal acceleration time of flight mass spectrometer was used for UPLC/MS
e
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analysis. The reversed-phase column used was a Waters HSS T3 C18 2.1 mm x 100 mm 
column (1.7 m diameter particles) operated at 35C. The following 28 min linear 
gradient separations were employed at a flow rate of 0.40 mL/min using a mobile phase 
consisting of A: water containing 0.1% formic acid and B: acetonitrile containing 0.1% 
formic acid. The gradient profile for samples from polar extractions was: 3% B, 0 min to 
5 min; 3% B to 97% B, 5 min to 18 min; 97% B, 18 min to 21 min; 97% B to 3% B, 21 
min to 23 min; 3% B 23 min to 28 min. The gradient profile for nonpolar extractions was: 
30% B, 0 min to 5 min; 30% B to 97% B, 5 min to 18 min; 97% B, 18 min to 21 min; 
97% B to 3% B, 21 min to 23 min; 3% B, 23 min to 28 min. Dead time was 0.68 min for 
the polar separation and 0.54 min for the non-polar separation as determined by injection 
of acetone. Simultaneous low- and high-collision energy (CE) mass spectra were 
collected in centroid mode over the range m/z 50-1200 every 0.1 s during the 
chromatographic separation. MS
e
 parameters in positive electrospray ionization mode 
were as follows: capillary, 2.0 kV; sampling cone, 35.0 V; extraction cone, 5.0V; 
desolvation gas flow, 800 L/h; source temperature, 100 C; desolvation temperature, 350 
C; cone gas flow, 20 L/h; trap CE, off (low CE collection), trap CE ramp 15V-65V (high 
CE collection); lockspray configuration consisted of infusion of a 5 g/mL solution of 
leucine-enkephalin and acquisition of one mass spectrum (0.2 s scan, m/z 100-1200) 
every 10 s. Three lockspray m/z measurements of protonated leucine-enkephalin were 
averaged and used to apply corrections to measured m/z values during the course of the 
analysis. All MS
e
 parameters were identical in negative ionization mode except the 
following: capillary, 2.5 kV; sampling cone, 30.0 V; extraction cone, 4.0V. 
5.2.7. UPLC/MS
e 
data analysis and workflow 
Waters MarkerLynx was used for mining chromatographic and mass spectral 
data using three-dimensional peak integration and data set alignment to determine 
potential features. The parameters were set to achieve determination of 1000-2000 
potential features specific to a given biological system. Data extraction parameters within 
Markerlynx were set as follows: extracted ion chromatogram tolerance was ±20 mDa, 
peak width assessment was done at half-height of the peak, peak-to-peak baseline noise 
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was 8.0 counts, marker intensity threshold was 100 counts, mass window was ±20 mDa, 
and the retention time window was ±0.10 min. 
Chemometric analysis was used for determination of candidate, system-specific 
features from UPLC/MS
e
 data. The LMM and t-test approaches were implemented in the 
R programming language using a home-written script and OPLS-DA was used within 
Waters MarkerLynx.235 Candidate features (Figure 5.1.) were selected by comparing 
their relative abundance, as measured by XIC intensity, between control and either 
enriched or stimulated fractions. Experiments with no biological replicates but with three 
instrumental replicates (rat liver autophagosomes) were analyzed using the two-sample t-
test for unequal variances. Experiments with both three biological replicates and three 
instrumental replicates each (rat skeletal autophagosomes and activated mast cells) were 
analyzed using LMM.
225
 Analysis for the t-test and LMM was performed on the log-
transformed scale and differences between biological samples were described by the ratio 
of geometric means. Multiple comparisons were accounted for by controlling the false 
discovery rate, which was calculated using the approach described in Benjamani and 
Yekutieli.
236
 For autophagosome-enriched samples, potential features with a false 
discovery rate of 10% or less were selected as candidate features and for activated mast 
cells, features with a false discovery rate of 1% or less were selected as candidate features 
for Checkpoint 1 (Figure 5.1.). For determining candidate features with OPLS-DA, 
selected potential features were at the edges of the OPLS-DA-generated S plot (Figure 
5.2.). An S plot is one option available for visualization of OPLS-DA data.
237
 The 
enrichment of the preliminary feature in a biological system is plotted on the x-axis and 
correlation of enrichment is plotted on the y-axis. Features that were > │0.001│for 
coefficient 2 (x-axis) and >│0.90│for correlation (y-axis) were selected for checkpoint 1 
(Figure 5.1.). 
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Figure 5.2. OPLS-DA-generated S-Plot from OPLS-DA chemometric approach for 
identification of rat liver autophagosome-specific candidate features. Candidate features 
are indicated by circles. Features approaching x = -0.004 are specific to autophagosome-
enriched while features approaching x = 0.003 are specific to the control. Squares 
indicate the features selected in the autophagosome-enriched and control samples. 
Confirmed features were determined at Checkpoint 1 (Figure 5.1.). All candidate 
features were examined with XICs from the low-collision energy mass spectra for a given 
m/z value with a 5 ppm mass tolerance. The candidate feature was rejected if the XIC 
appeared as a noise spike, had a very low signal-to-noise ratio (< 2), or if the XIC was not 
characterized as having a true chromatographic peak profile. 
Database identifications were made using online database searches. All XIC-
confirmed features for the autophagosome-enriched samples were selected for database 
searching. Due to the large number of confirmed features for activated mast cells, the top 
250 confirmed features for the LMM and all confirmed features for the OPLS-DA were 
selected for database searching. Online databases included the Chemical Entities of 
Biological Interest, Human Metabolome Database, and Lipid MAPS databases with a 
mass tolerance of < 10 mDa. The ChemSpider database was used with the same mass 
tolerance when candidate features did not result in matches in the other databases. 
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Searches were made for the neutral mass values corresponding to [M+H]
+
 and [M-H]
-
 
ions. All database identifications were selected for Checkpoint 2 (Figure 5.1.). 
Features with database identifications were evaluated at Checkpoint 2. 
Checkpoint 2 consists of (1) XIC alignment of coeluting ions to verify the presence of 
putative precursor ions corresponding to the database-identified species; (2) 
corroboration of identity by comparison of fragmentation patterns observed in the high-
collision energy mass spectra of each precursor with simulated fragmentation patterns 
calculated in silico using Waters MassFragment software;  (3) manual precursor-
product XIC alignment. MassFragment parameters were set as follows: the 20 most 
intense m/z species from the high-collision energy mass spectra were compared to 
theoretical fragments with a tolerance of 10 mDa. Double bond equivalence values were 
between -10 to 50, electron count was set to "both", maximum H deficit was 6, fragment 
number of bonds was 4, and scoring parameters were for aromatic (6), multiple (4), ring 
(2), phenyl (8), other (1), H-deficit (0), hetero modifier (0.5), alpha penalty (5), and max 
score (16). Preliminary identifications supported by the evaluation criteria described here 
are reported using their database identification number (CE:18337).
238
 
5.2.8. Safety considerations 
All Biosafety Level 2 guidelines were followed when working with cell culture 
and tissue. Biological waste was bleached for 30 min prior to disposal. 
5.2.9. Animal considerations 
All rat studies for autophagosome enrichment were conducted under an animal 
study protocol approved by the Albert Einstein College of Medicine Animal Institute 
Animal Care and Use Committee. Calorically restricted rats were allowed free access to 
water. All mice for mast cells were raised and euthanized according to an animal study 
protocol #0806A37663 approved by the University of Minnesota Institutional Animal 
Care and Use Committee. 
5.3. Results and Discussion 
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Chemometric analysis of complex data sets such as those generated by 
UPLC/MS
e
 experiments expedites the determination of system-specific chemical 
features.
239
 While chemometric approaches in concert with database searches have 
become essential to improving efficiency in systems biology research, there is the 
likelihood that some candidate features may be false positives and/or misidentified. 
Additionally, database identifications based only on mass accuracy measurements of 
detected precursor ions are often erroneous.
228
 As such, evaluation of chemometrics-
determined features and subsequent database-identified compounds becomes imperative 
to assigning reliable preliminary identifications. A detailed description of a workflow 
(Figure 5.1.) developed to appraise chemometric outputs and database identifications and 
ensure reliable determination of confirmed features and their preliminary identities 
follows. The application of this workflow toward preliminary identification of 
biologically relevant compounds specific to autophagy and mast cell stimulation is 
highlighted. 
The developed workflow is comprised of the following: (1) untargeted 
UPLC/MS
e
 profiling of the systems of interest; (2) application of chemometrics to 
identify candidate features characteristic of these biological systems; (3) confirmation of 
candidate features via evaluation of extracted ion chromatograms (XICs); (4) database 
searching to provide potential identifications of confirmed features; (5) mass accuracy 
confirmation, evaluation of fragmentation patterns of each feature from acquired low- 
and high-collision energy mass spectra, and precursor-product XIC alignment to provide 
preliminary identifications of confirmed features. 
This workflow was first applied to the analysis of two different enriched 
autophagosome samples, a “gold standard” of enrichment of autophagosomes prepared 
from rat liver tissue by density gradient centrifugation
20, 233
 and a fraction of 
autophagosomes prepared from rat myoblast cell culture by differential centrifugation, 
immuno-depletion of mitochondria and osmotic lysis of lysosomes. For the rat liver 
sample, unwanted organelle types were removed by differential and density gradient 
centrifugation. Western blotting analysis revealed no detectable lysosome contamination 
(Figure C.1.). For the rat myoblast sample, cells were treated with vinblastine, which 
 80 
increases the number of autophagosomes.
81
 Mitochondria and lysosome levels were 
decreased from an enriched organelle pellet by immuno-depletion of mitochondria and 
glycyl-L-phenylnaphthylamine (GPN) lysis of lysosomes,
81
 respectively. Western 
blotting analysis revealed no detectable mitochondria and a highly reduced level of 
lysosome in the enriched autophagosome fraction (Figure C.2.) consistent with previous 
published results for rat hepatocyte cells.
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Manual examination of total ion chromatograms resulting from UPLC/MS
e 
analysis of extracts of enriched autophagosomes as compared to a total organelle control 
proved inadequate to detect autophagosome-specific, XIC-confirmed features. As such, 
three chemometric approaches (OPLS-DA, t-test, and LMM) were used to maximize the 
number of detected candidate features specific to rat liver enriched autophagosomes and 
rat myoblast cell culture enriched autophagosomes. Applying multiple chemometric 
approaches to a given data set can increase coverage for the detection of candidate 
features, compensate for the limitations of detection for each individual chemometric 
approach, and provide additional confirmation of the validity of preliminary 
identifications. Of the 63 XIC-confirmed features determined with OPLS-DA for the 
enriched autophagosome samples, 34 were also detected with the LMM and t-test. Of the 
401 confirmed features determined with OPLS-DA for the mast cell samples, 328 were 
also determined with the LMM. 
5.3.1. Features and identifications from rat liver 
For the enriched autophagosome fraction from rat liver tissue, multiple 
chemometric approaches detected 114 candidate features (Table C.1.). Confirmation of 
candidate features via evaluation of XICs (Checkpoint 1, Figure 5.1.) yielded 76 
confirmed features (67% of detected candidate features). The percentage of common 
confirmed features determined with multiple chemometric approaches averaged 17% 
(Table C.1.). An online database search of the 76 confirmed features yielded 46 potential 
database identifications (Table C.1.). The percentage of common XIC-confirmed features 
identified with multiple chemometric approaches averaged 17% (Table C.1.). Checkpoint 
2 scrutinized the online database identifications by manual examination of low- and high-
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collision energy mass spectra and matching observed fragmentation patterns with 
simulated fragmentation patterns for the identified compound (determined using Waters 
MassFragment), as well as precursor-product XIC alignment. Overall, 23 preliminary 
identifications were made following Checkpoint 2 (Table 5.1., Figure. C.3A.). Rejection 
of potential database identifications resulted primarily from one or both of the following 
criteria: (1) lack of supporting fragmentation pattern data from acquired high-collision 
energy mass spectra (MS
e
) and/or (2) inconclusive precursor-product XIC alignment in 
complex spectra resulting from analyte coelution. While it is understood that these 
tentatively rejected identifications may in fact be valid, additional experiments including 
true precursor-selected MS/MS analysis, and/or UPLC/MS/MS analysis of standards, if 
available, will be required to make identifications.  Figure 5.3. illustrates data supporting 
the identification of one such autophagosome-specific compound, 1-hexadecanoyl-sn-
glycero-3-phosphoethanolamine (PE(16:0/0:0); LMGP02050002, Figure 5.3A.). Figure 
5.3B. and 5.3C. show aligned low- and high-collision energy extracted ion 
chromatograms for m/z 454.294 in the analysis of an autophagosome-enriched fraction of 
rat liver, respectively. A trend plot (Figure 5.3D.) for the observed precursor ion indicates 
the relative abundance of this compound in the autophagosome-enriched fraction (Aps, 
Figure 5.3D) versus the non-enriched fraction (control, ctl, Figure 5.3D). Trend plot data 
was used to .calculate the fold-enrichments provided in Table 5.1. Figure 5.3E. and 5.3F. 
illustrate the low collision energy mass spectrum and high collision energy mass 
spectrum of PE(16:0/0:0), respectively. Elemental compositions, m/z values, and mass 
errors of observed fragment ions corresponding to theoretical fragment ions generated in 
silico using MassFragment are depicted in Figure 5.3G. 
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System
1
 Ext
2
 ESI
3
 m/z TR p-value FE
4
 Chem
5
 PI
6
 
Mass 
Error 
(ppm) 
Liver NP + 288.295 9.14 1.49 × 10
-5
 P/A t-test, OP HMDB00269* 1.7 
Liver NP + 288.295 8.85 8.62 × 10
-6
 P/A t-test, OP HMDB00269* 1.7 
Liver NP + 415.214 10.52 1.24 × 10
-3
 1.85 t-test, OP CHEBI31547 0.5 
Liver NP + 601.438 17.80 1.08 × 10
-4
 1.68 t-test, OP LMGL02010051 7.4 
Liver NP + 623.451 17.76 1.09 × 10
-4
 1.74 t-test, OP LMGP01011228 0.2 
Liver NP + 755.525 17.42 6.34 × 10
-4
 1.86 t-test LMGP01010604 2.7 
Liver NP + 265.109 7.68 3.39 × 10
-4
 P/A t-test CS124129 0.6 
Liver NP + 244.268 8.89 N.A. 2.18 OP CS59037 1.9 
Liver Polar + 361.276 15.10 9.73 × 10
-5
 P/A t-test LMST03020020 0.6 
Liver Polar + 454.294 14.55 4.91 × 10
-6
 11.6 t-test, OP LMGP02050002 2.0 
Liver Polar + 522.355 14.98 1.81 × 10
-4
 P/A t-test HMDB10385 0.1 
Liver Polar + 524.371 15.99 2.58 × 10
-5
 2.82 t-test, OP LMGP01050123 0.2 
Liver Polar + 570.352 14.34 2.52 × 10
-6
 P/A t-test HMDB10403 0.6 
Liver Polar + 300.294 13.11 4.23 × 10
-5
 P/A t-test CHEBI16393 1.3 
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Liver Polar + 367.143 0.54 3.19 × 10
-5
 P/A t-test CHEMBL421556 0.1 
Liver Polar + 415.213 13.85 1.77 × 10
-4
 3.23 t-test, OP CS8129200 0.2 
Liver Polar + 674.460 17.63 3.47 × 10
-4
 P/A t-test LMGP01010523 2.3 
Liver Polar + 415.213 13.41 N.A. 1.93 OP CS9677319 0.4 
Liver Polar + 482.324 15.90 N.A. 30.2 OP HMDB11130 0.0 
Liver Polar + 496.341 14.62 N.A. 2.60 OP HMDB10382 0.2 
Liver Polar + 520.339 13.99 N.A. 2.69 OP HMDB10386 0.1 
Liver Polar + 568.338 14.05 N.A. 9.22 OP HMDB10404 0.3 
Liver NP - 346.157 3.45 1.53 × 10
-18
 79.3 LMM, OP CHEBI51939 0.4 
Liver NP - 655.426 16.76 1.39 × 10
-31
 63.1 LMM, OP HMDB11155 6.8 
Myoblast NP + 286.273 9.88 3.78 × 10
-88
 P/A LMM LMSP01040002 0.4 
Myoblast NP + 288.291 9.26 6.80 × 10
-39
 P/A LMM, OP LMSP01040003 0.4 
Myoblast NP + 545.312 16.76 1.44 × 10
-24
 29.7 LMM CS8228689 0.3 
Myoblast Polar + 273.168 9.11 6.65 × 10
-5
 P/A LMM CS9087911 1.1 
Myoblast Polar + 412.161 11.97 1.38 × 10
-20
 59.4 LMM CS21513528 1.1 
Myoblast Polar + 454.211 11.14 6.36 × 10
-6
 44.7 LMM CS4644673 0.4 
Myoblast Polar + 472.183 11.72 6.30 × 10
-12
 40 LMM CS10484174 0.1 
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Myoblast Polar + 520.162 14.25 2.17 × 10
-7
 24.1 LMM CHEBI63717 3.5 
Myoblast Polar + 692.289 15.46 6.58 × 10
-5
 53.6 LMM CHEBI62469 4.1 
Myoblast Polar + 777.322 15.89 0 P/A LMM, OP CHEBI16314 5.0 
MCN (vs. 
MCTN) 
NA - 265.171 14.87 N.A. P/A OP CHEBI47781 0.2 
MCTN 
(vs. MCN) 
NA - 241.180 14.52 7.06 × 10
-175
 381 LMM HMDB10730 0.2 
MCTN 
(vs. MCN) 
NA - 447.132 12.66 4.24 × 10
-86
 514 LMM CS4644613 0.7 
MCTN 
(vs. MCN) 
NA + 437.249 8.02 1.48 × 10
-3
 1480 LMM, OP CHEBI57835 1.1 
MCTN 
(vs. MCN) 
NA + 247.086 9.30 0 502 LMM CHEBI38130 1.7 
MCTN 
(vs. MCN) 
NA + 353.117 9.15 0 1190 LMM, OP CHEBI61220 0.0 
MCTN 
(vs. MCN) 
NA + 355.064 9.24 1.49 × 10
-217
 834 LMM, OP CHEBI18337 0.4 
MCTN 
(vs. MCN) 
NA + 409.162 12.69 0 1220 LMM, OP CS59230 0.9 
MCTN 
(vs. MCN) 
NA + 481.261 8.31 0 2200 LMM, OP CHEBI2535 1.7 
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MCTN 
(vs. MCN) 
NA + 525.289 8.47 0 1550 LMM, OP CS20121381 0.3 
MCTN 
(vs. MCN) 
NA + 569.313 8.61 0 1010 LMM, OP CS382892 0.4 
MCB (vs. 
MCCX) 
NA - 265.146 15.12 1.06 × 10
-119
 875 LMM, OP CHEBI45599 0.3 
MCCX. 
(vs. MCB) 
NA + 525.291 8.36 1.53 × 10
-3
 1530 LMM, OP CS20121381 0.0 
MCB (vs. 
MCCX) 
NA + 234.207 8.90 4.44 × 10
-274
 2200 LMM, OP CS16127 0.2 
MCB (vs. 
MCCX) 
NA + 247.085 9.30 0 532 LMM CS4522006 4.3 
MCB (vs. 
MCCX) 
NA + 357.088 10.76 5.06 × 10
-282
 1660 LMM, OP CHEBI61723 0.0 
Table 5.1. Preliminary identifications made from the biological systems studied here. 
1
-Liver = enriched autophagosomes from liver; 
myoblast = enriched autophagosomes from rat myoblasts; MCN = mast cells, non-activated; MCTN = TNPova-activated mast cells; 
MCCX = CXCL10-activated mast cells; MCB = Both CXCL10- and TNPova-activated. 
2
-Extractions performed were either nonpolar 
(NP) or polar (see materials & methods). NA = no extraction made. 
3
-ESI analysis was performed in positive (+) and negative (-) 
ionization modes. 
4
-Fold-enrichment = average intensity of analyte in experimental sample vs. control; P/A = present/absent. 
5
-
Chemometric analysis applied to acquired UPLC/MS
e
 data; OP = OPLS-DA. 
6
-Preliminary identification provided in accordance with 
the metabolomic standards initiative. *-Denotes structural isomers detected. 
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Figure 5.3. Preliminary identification of m/z 454.294 (PE 16:0/0:0) in autophagosome 
enriched fractions of rat liver (TR = 14.55 min, p-value = 4.91 x 10
-6
). (A) Structure of PE 
16:0/0:0; (B) Low-collision energy XIC for m/z = 454.294; (C) High-collision energy 
XIC for m/z = 454.294; (D) Trend plot for m/z = 454.294 in control (Ctl) versus 
autophagosome-enriched (Aps) samples; (E) Low-collision energy mass spectrum at TR = 
14.55 min; (F) High-collision energy mass spectrum at TR = 14.55 min; (G) Elemental 
compositions, m/z values, and mass error of observed fragment ions corresponding to 
theoretical fragment ions generated in silico using Mass Fragment. 
Many of the preliminary identifications for the rat liver autophagosome-enriched 
samples (Table 5.1., Figure C.3A.) appear to have biological relevance to autophagy. 
Since publications concerning autophagosome composition are limited, assessment of the 
relevance of preliminary identifications is difficult. Preliminary identification of 
PE(16:0/0:0) is of interest because it is a member of the phosphatidylethanolamine (PEA) 
family. PEA is a critical factor in autophagy due to its conjugation with Atg8 in the 
protein complex required for autophagosome formation.
73, 241
 Sphinganine 
(HMDB00269), a sphingolipid base, represents another compelling preliminary 
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identification as sphingolipids have previously been shown to stimulate 
macroautophagy
242, 243
 and accumulate in biological systems such as Niemman Pick C 
disease that also accumulate autophagosomes.
244, 245
 While the biophysical function of 
sphingolipids in autophagy has not yet been fully determined, ceramide, a closely related 
compound to sphinganine, induces membrane curvature and formation of lipid rafts.
246
 
Based on our preliminary identification, it may be possible that sphinganine plays a 
similar structural role in autophagosomes. 
Preliminary identifications also consisted of multiple lysophospholipids and 
glycerophospholipids including LysoPC(18:1(11Z)) (HMDB10385),  PC(18:0/0:0) 
(LMGP01050123), LysoPC(22:5(7Z, 10Z, 13Z, 16Z, 19Z)) (HMDB10403), and 
LysoPC(18:2(9Z, 12Z)) (HMDB10386) (Table 5.1.). Lysophospholipids are involved in 
membrane fusion and elongation in macroautophagy
247
 and alteration of these 
lysophospholipids causes disruption of autophagy-related organelle membranes by 
modifying lipid biosynthesis.
248
 Lysophospholipids, such as PE 16:0/0:0 
(LMGP02050002) are also important in membrane synthesis during autophagosome 
membrane elongation in macroautophagy.
247
 Autophagy may also play a role in vitamin 
D regulation making the preliminary identification of 1α,23-dihydroxy-24,25,26,27-
tetranorvitamin D3 (LMST03020020), a vitamin D3 metabolite, intriguing.
249
 While the 
methodology and workflow presented here has proven invaluable as a tool to provide a 
first distillation of complex data sets and preliminary identifications of confirmed 
features, this does not preclude the need for comprehensive validation of these 
identifications via true precursor-selected MS/MS analysis, as well as UPLC/MS/MS of 
commercially available standards. In addition, examination of the quantitative effect of 
modified autophagy flux on levels of these preliminary identifications will further 
validate the association of these chemical entities with autophagosomes, providing 
insight into the function of diseases associated with autophagy
7-10, 250
 as well as the 
composition and origin of autophagosome membranes.
59, 62, 251
 
5.3.2. Features and identifications from rat myoblast cell culture 
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For the enriched autophagosome fractions from rat myoblast cell culture, 
chemometric approaches detected 130 candidate features. Overall, 112 XIC-confirmed 
features remained following Checkpoint 1 (Table C.1.). The percentage of common 
confirmed features identified with multiple chemometric approaches averaged 20% 
(Table C.1.). A database search of the confirmed features resulted in 69 potential 
database identifications. Of these potential database identifications, 12 were preliminary 
identifications following Checkpoint 2 (Table 5.1, Figure C.3B.). Figure 5.4. illustrates 
data supporting identification of the rat myoblast autophagosome-specific compound 3-
{(4Z)-4-[(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)hydrazono]-5-oxo-
4,5-dihydro-1H-pyrazol-3-yl}-4-hydroxy-1-methyl-2(1H)-quinolinone (Figure 5.4A., 
identified as CS10484174 in the ChemSpider database). Figure 5.4B. and 5.4C. show 
aligned low- and high-collision energy extracted ion chromatograms for m/z 472.183 in 
the analysis of an autophagosome-enriched fraction of rat myoblasts. A trend plot 
showing relative fold-enrichment of CS10484174 in autophagosomes is illustrated in 
Figure 5.4D. Figure 5.4E. and 5.4F. illustrate the low- and high-collision energy mass 
spectra of CS10484174, respectively. Elemental compositions, m/z values, and mass 
errors of observed fragment ions corresponding to theoretical fragment ions of 
CS10484174, generated in silico using MassFragment are depicted in Figure 5.4G. 
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Figure 5.4. Preliminary identification of m/z 472.183 (3-{(4Z)-4-[(1,5-Dimethyl-3-oxo-
2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)hydrazono]-5-oxo-4,5-dihydro-1H-pyrazol-3-yl}-
4-hydroxy-1-methyl-2(1H)-quinolinone , CS10484174) in autophagosome enriched 
fractions of rat myoblast (TR = 11.72 min, p-value = 6.30 x 10
-12
). (A) Structure of 
CS10484174; (B) Low-collision energy XIC for m/z = 472.183; (C) High-collision 
energy XIC for m/z = 472.183; (D) Trend plot for m/z = 472.183 in control (Ctl) versus 
autophagosome-enriched (Aps) samples; (E) Low-collision energy mass spectrum at TR = 
11.72 min; (F) High-collision energy mass spectrum at TR = 11.72 min;  (G) Elemental 
compositions, m/z values, and mass error of observed fragment ions corresponding to 
theoretical fragment ions generated in silico using Mass Fragment. 
Preliminary identifications of the rat myoblast-enriched autophagosomes again 
consisted of sphinganine (HMDB00269) as well as sphingosine, another type of 
sphingolipid. Other potentially interesting identifications include PA(P-
16:0e/18:2(9Z,12Z) (HMDB11155) which is an intermediate product of ether lipid 
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metabolism according to the HMDB.
252
 While this preliminary identification has not been 
explicitly detected in autophagosomes, autophagy is a well known pathway for lipid 
metabolism.
253
 Other preliminary identifications such as the carbohydrate α-L-Fucp-(1-
>2)-β-D-Galp-(1->3)-β-D-GlcpNAc-(1->3)β-D-Galp  (Chemical Entities of Biological 
Interest ID CHEBI:62469) and N-formylmethanofuran (CHEBI16314) were detected. 
These and other preliminary identifications made here are not known to be associated 
with any organelle. As such, validation via precursor-selected MS/MS, comparative 
analysis with synthetic standards, and quantitative correlation with autophagy will be 
required. 
The percentage of database identifications made here is consistent with previous 
GC- and LC/MS-based metabolomic analyses of organelles. For rat liver-enriched 
autophagosomes, ~61% of confirmed features yielded potential database identifications. 
For rat myoblast cells, ~62% of confirmed features yielded potential database 
identifications. By comparison, Krueger et al. report that database identifications were 
made for ~46% of features from Arabidopsis thaliana leaf organelles using the KEGG 
(focus on nucleotide metabolites), KNApSAcK (focus on plant secondary metabolites), 
and an in-house database,
114
 and a metabolite profiling study by Benkebilia et al. report 
database identifications for ~50% of features from subcellular soybean fractions using the 
NIST 02 Mass Spectral Library.
113
 As databases continue to develop, percentages of 
database identifications and their reliability may increase but the importance of 
evaluation of such identifications using the criteria described here will remain high. 
5.3.3. Features and identifications from activated mast cells 
To further expand the application of the developed workflow to the identification 
of biological features, UPLC/MS
e
 analysis and the developed workflow was applied to 
the analysis of chemical secretions detected from activated mast cells. Of 2,656 detected 
candidate features, 1,661 were XIC-confirmed features following Checkpoint 1 (Table 
C.1.) meaning ~37% of the candidate features were removed. The percentage of common 
confirmed features identified with multiple chemometric approaches averaged 25% 
(Table C.1.). Since the number of confirmed features was large, preliminary 
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identification was attempted for only the 250 most statistically significant (based on p-
value) confirmed features from the LMM chemometric approach and the 65 confirmed 
features detected by OPLS-DA. In total, 114 potential database identifications were 
made. The percentage of potential identifications made from online databases was ~36% 
for activated mast cells secretions. Overall, 14 of the potential database identifications 
were determined to be preliminary identifications following Checkpoint 2 (Table 5.1, Fig. 
C.3C.). Data supporting one such identification, the activated mast cell-specific 
compound 5-amino-6-(5’-phosphoribosylamino) uracil, is illustrated in Figure 5.5.  
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Figure 5.5. Preliminary identification of m/z 355.064 (-amino-6-(5’-
phosphoribosylamino)uracil, CHEBI18337) in TNPova-activated mast cell secretions (TR 
= 9.25 min, p-value = 1.49 x 10
-217
). (A) Structure of CHEBI18337; (B) Low-collision 
energy XIC for m/z = 355.064; (C) High-collision energy XIC for m/z = 355.064; (D) 
Trend plot for m/z = 355.064 in non-activated (NA) versus TNPova-activated (Aps) 
samples; (E) Low-collision energy mass spectrum at TR = 9.25 min; (F) High-collision 
energy mass spectrum at TR = 9.25 min;  (G) Elemental compositions, m/z values, and 
mass error of observed fragment ions corresponding to theoretical fragment ions 
generated in silico using Mass Fragment. 
Interesting preliminary identifications were also made for activated mast cells. 3-
oxotetradecanoic acid (HMDB10730) is a known fatty acid involved in lipid synthesis. 
Glutathionylspermidinium (CHEBI57835) is particularly interesting in light of a recent 
study of mast cell granules in which it was found that, in addition to well-characterized 
amines such as serotonin and histamine, mast cell granules also contain polyamines such 
as spermidine, and these polyamines have roles in granule homeostasis.
254
 Although 
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glutathionylspermidinium was not a compound detected in mast cell granules, it could be 
formed by an extracellular enzymatic reaction, and further studies should be performed 
on the potential importance of spermidine compounds in inflammation and mast cell 
function. D-pantetheine 4’-phosphate (CHEBI61723), a metabolite associated with 
coenzyme A biosynthesis, has a role in fatty acid biosynthesis, as well as enzymatic 
synthesis of peptides and additional biologically active metabolites according to the 
ChEBI database.
255
 D-pantetheine 4’-phosphate was enriched in mast cell samples 
exposed to CXCL10 and TNP-ova versus TNP-ova alone, which highlights the need for 
further studies into the function of mast cells in inflammatory diseases such as asthma. 
Benzylpenicilloic acid (CHEBI61220) is a metabolite of the antibiotic penicillin, which 
was present in the cell culture conditions,
256
 suggesting that this antibiotic metabolite was 
endocytosed by the mast cells during culturing, and subsequent secretion of this species 
took place upon mast cell activation and degranulation by TNP-ova.  
5.4. Conclusions 
LC/MS analysis of complex biological systems can detect thousands of potential 
features in a biological sample. Without chemometric analysis and examination of 
subsequent database identifications, however, chemical identities of the features may be 
incorrectly assigned, which compromises the biological relevance of the study. The 
workflow described here is applicable to a wide range of biological samples and results in 
more reliable, higher confidence preliminary identifications of system-specific features. 
This approach can be applied to any LC/MS profiling of dissimilar biological samples. In 
this study, a number of preliminary identifications specific to enriched autophagosome 
and activated mast cell fractions were made using UPLC/MS
e 
analysis combined with 
outputs from chemometric analyses, database search results, and evaluation of mass 
spectral data. Compounds identified in this way may prove to be essential to the 
composition and function of autophagosome organelles or as potential chemical 
messengers released during degranulation of mast cells. 
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Chapter 6 
Describing the Temporal Nature of Autophagy at the Individual Organelle Level by 
Capillary Electrophoresis with Laser Induced Fluorescence Detection 
Vratislav Kostal assisted in the transformation and selection of transfected cells. The 
LC3-GFP plasmid was a generous gift from the Professor Do-Hyung Kim laboratory 
from the University of Minnesota-Twin Cities. This work was funded by NIH grant 
AG020866. 
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Autophagy is a molecular pathway responsible for the degradation of intracellular 
cargo involving sequential formation of phagophores, autophagosomes and 
autolysosomes. These are known as autophagy organelles. The dynamic nature of 
autophagy and the multiple types of autophagy organelles present at a given time make 
current measurements, such as those done by Western blotting, insufficient to understand 
autophagy and its roles in aging and disease. Capillary electrophoresis coupled to laser 
induced fluorescence detection (CE-LIF) has been used previously to count and 
determine properties of individual organelles, but has never been used on autophagy 
organelles or for determination of temporal changes of such properties. Here we used CE-
LIF to determine the number of autophagy organelles, their individual GFP-LC3 
fluorescence intensities, and their individual electrophoretic mobilities from L6 cells 
expressing GFP-LC3 under basal and rapamycin-driven autophagy conditions. Under any 
of these two conditions, CE-LIF provided an individual organelle-based snapshot of 
autophagy. Furthermore to determine time-dependent changes of individual organelle 
properties, we treated cells with vinblastine which interrupts autophagy prior to formation 
of autolysosomes. Differences in organelle numbers and changes in both GFP-LC3 
fluorescence levels and electrophoretic mobilities of individual organelles that occurred 
during the duration of the vinblastine treatment were determined. This provided the first 
report of the temporal nature of the autophagy process at the individual organelle level. 
These temporal observations point to differences in the properties of accumulating 
autophagosomes and disappearing autolysosomes. Surprisingly for rapamycin-enhanced 
autophagy, the temporal trends of individual organelle properties upon treatment with 
vinblastine were the opposite of the trends observed under basal autophagy conditions. 
These observations demonstrate that individual organelle analysis by CE-LIF is a 
powerful technology to investigate the complexity and temporal nature of autophagy, a 
process that plays critical roles in response to drug treatments, aging, and disease. 
6.1. Introduction 
Autophagy is a cellular pathway responsible for the degradation of intracellular 
components involving phagophores, autophagosomes, amphisomes, and autolysosomes 
(Figure 6.1). All these organelles have the protein LC3-II localized on their membrane, 
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which requires lipidation of the cytosolic LC3-I, a process occurring during the initial 
formation of phagophores.
57, 257, 258
 Because of ubiquitous nature in autophagy organelles, 
LC3-II has been extensively used as an autophagy marker. However, this marker is 
present in phagophores that form around intracellular components to be degraded, in 
autophagosomes that form from phagophores, and in autolysosomes that form from 
fusion of autophagosomes with lysosomes.
63, 64
 There is also an alternate route of which 
up to 5% of autophagosomes fuse with endosomes to form amphisomes that then mature 
into autolysosomes.
81, 82
 Defects in autophagy have been associated with aging, cancer, 
and neurodegenerative diseases.
10
  
 
Figure 6.1. Autophagy Degradation of Intracellular Contents. Phagophores engulf 
intracellular components such organelles (pentagons) and have LC3-II localized on their 
membrane (triangles). Phagophores mature into autophagosomes. Autophagosomes either 
mature into autolysosomes by direct interaction with lysosomes or into amphisomes by 
fusing with endosomes. Because amphisomes are a small fraction (<5%), they will not be 
explicitly mentioned in this report. Autolysosomes degrade the components sequestered 
in autophagosomes and then are recycled to form lysosomes.
67
 Treatment with 
vinblastine halts formation of autolysosomes, while rapamycin enhances the overall 
autophagy process.
81
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Several techniques such as Western blotting, fluorescence confocal microscopy, 
transmission electron microscopy and flow cytometry have been used to monitor 
autophagy. Western blots determine bulk amounts of LC3-II relative to LC3-1 or GFP-
LC3-II relative to free GFP.
58, 259
 Increased levels of LC3-II or free GFP indicate 
increased autophagy or degradation of intracellular components, respectively. Similarly, 
fluorescence confocal microscopy determines the number of fluorescently-labeled LC3-II 
organelles
30, 260-262
 or fluorescently-labeled LC3-II organelles that are colocalized with 
fluorescently-labeled lysosomes. Transmission electron microscopy can also be used to 
evaluate autophagy based on the number of observed autophagosomes.
82
 Lastly, flow 
cytometry determines levels of fluorescently labeled LC3-II in whole cells after the 
extraction of LC3-I with saponin treatment.
33
 Overall, these techniques use LC3-II levels 
or organelle numbers to examine the extent of autophagy, or steady state, but additional 
observations are required to determine the rate at which autophagy occurs (i.e. autophagy 
flux), which is critical to understand cell function and disease.
29, 263
 Ultimately, temporal 
measurements would tremendously benefit from analytical strategies that account for the 
temporal status of the autophagy process.  
Inhibitors that halt autophagy at specific points of its pathway have been used to 
evaluate autophagy flux previously (Figure 6.1).
81, 82
 This leads to accumulation of 
organelles upstream of the blockage point and degradation of organelles downstream 
from the blockage point during the duration of the inhibitor treatment. For instance, 
vinblastine treatment leads mainly to the accumulation of autophagosomes and the 
disappearance of autolysosomes.
81, 82
 Measurements of samples with or without blockage 
by vinblastine are used to determine differences between accumulation and disappearance 
of the numbers and properties of autophagy organelles, providing an assessment of 
autophagy flux.
83
 Both Western blotting and flow cytometry of whole cells have been 
used previously to estimate autophagy flux.
33, 83
 Unfortunately, these approaches cannot 
provide a detailed account on whether changes are the result of different organelle 
numbers or changes in individual organelle properties (e.g. individual organelle content 
of LC3-II). 
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Capillary electrophoresis coupled to laser induced fluorescence detection (CE-
LIF) is a technique previously used to determine the numbers and properties of 
individual, fluorescently-labeled organelles such as mitochondria, 
93, 264
 nuclei,
104
 
endosomes, and acidic organelles.
48, 107
 Due to its excellent limits of detection,
48, 94, 104
 
CE-LIF can detect individual organelles tagged with low levels of a fluorescent marker. 
This technique has not been used to examine temporal changes such as those needed to 
assess autophagy flux.  
This chapter describes the first use of individual organelle analysis by CE-LIF in 
combination with a treatment that halts autophagy (i.e. vinblastine) to determine time-
dependent changes in number and properties of autophagosomes under basal and 
rapamycin-enhanced autophagy conditions.  Relative to basal autophagy, rapamycin 
treatment resulted in the detection of a higher number of autophagy organelles at steady 
state, which is in agreement with rapamycin’s effect previously observed through bulk 
measurements of autophagy markers. For temporal dependent measurements at basal 
autophagy, we observed a net accumulation of autophagy organelles (i.e. rate of 
appearance of autophagosomes exceeds that of disappearance of autolysosomes), with 
accumulated organelles having higher individual GFP-LC3 contents and more positive 
electrophoretic mobilities than those that disappeared. In contrast, under rapamycin-
enhanced autophagy conditions, there was a net disappearance of autophagy organelles, 
with remaining organelles having lower GFP-LC3 contents and more negative 
electrophoretic mobilities than those that disappeared. These unexpected results suggest 
that rapamycin may regulate autophagy at various points of this process, an observation 
that could not have been done with conventional technologies. Future applications of CE-
LIF combined with autophagy inhibitors could be used to examine autophagy flux under 
different conditions characterized by altered autophagy  such as neurodegenerative 
diseases
6, 8
 and aging.
6
 
6.2. Theory 
A sample collected at a given time contains a mixture of various autophagy 
organelle types (Figure 6.1). This mixture represents the steady state or snapshot of 
autophagy at a single time point. Comparison of two samples collected under different 
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conditions (e.g. basal versus rapamycin-enhanced) is commonly used to define 
differences between these two conditions such that 
         Equation 6.1 
where D is the difference in a measured property, iR is the property observed 
under a given treatment (e.g. rapamycin treatment) and iB is the corresponding basal 
condition. Bulk differences between two conditions can easily be determined by applying 
this equation to existing assays (e.g. Western blots). In this study we extend the use of 
this equation to the number of organelles, individual organelle GFP-LC3-II contents, and 
individual organelle electrophoretic mobilities. 
To determine autophagy flux associated with a given condition, one approach is 
to measure the difference in organelle numbers before and after halting autophagy. Under 
steady state conditions discussed previously, the rate of appearance of a given type of 
autophagy organelle equals the rate of disappearance of a given type of autophagy 
organelle. That is,   
                                      Equation 6.2 
where Ф is autophagy flux, RA is the rate of appearance and RD is the rate of 
disappearance. When flux is blocked, for instance when vinblastine halts autolysosome 
formation, the rate of accumulation (RA) and rate of disappearance (RD) can be related to 
the number of detected organelles as follows: 
                                      Equation 6.3 
where No is the number of detected organelles before vinblastine treatment, NT is 
the number of detected organelles after vinblastine treatment, and t is the duration of the 
treatment. The difference between the rate of accumulation and rate of disappearance of 
detected organelles can then be calculated as,  
       
     
  
    Equation 6.4 
When RA - RD is positive, the rate of formation of autophagosomes, and to a lesser 
extent phagophores and amphisomes, exceeds the rate of disappearance of 
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autolysosomes. When this difference is negative, the rate of disappearance of 
autolysosomes exceeds the rate of formation of the other autophagy organelles.  
A similar calculation determines changes in properties of individual organelles, 
   
     
  
    Equation 6.5 
where D is the difference of the property of interest it, measured at time t, and the 
property io measured at the onset of autophagy blockage, divided by the duration of the 
autophagy blockage (t). In this study we used this equation to determine time-dependent 
changes in individual organelle contents of GFP-LC3-II and their electrophoretic 
mobilities. A similar interpretation to Equation 6.4, when D is positive in Equation 6.5, 
the property of interest is higher for forming organelles than for disappearing 
autolysosomes. When D is negative, the reverse is true.  
Because individual organelle measurements are commonly represented as distributions, 
Equation 6.5 can be modified to compare the x
th
 percentile of two distributions as  
    
        
  
                Equation 6.6 
where Dx is the difference at the x
th
 percentile, ix,t and ix,o are values at x
th 
percentile for the property of interest measured at a given time, t, and at the onset of  
autophagy blockage, respectively. This equation was applied to individual organelle 
contents of GFP-LC3-II and their electrophoretic mobilities. The interpretation of 
Equation 6.6 is similar to that of Equation 6.5, but extends the concept to percentiles of 
individual organelle measurements.   
6.3. Experimental 
6.3.1 Materials, Reagents, and Buffers 
Sucrose, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
ethylenediaminetetraacetic acid (EDTA), vinblastine, rapamycin from Streptomyces 
hygroscopicus, gentamycin, protease inhibitor cocktail, Triton X-100, poly-L-lysine, and 
poly(vinyl alcohol) (99%+ hydrated, molecular weight 89,000 to 98,0000) were obtained 
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from Sigma Aldrich (Atlanta, GA). Rabbit polyclonal LC3 antibody was obtained from 
Novus Biologicals (Littleton, CO). Fluorescein, prolong gold antifade reagent with 4’,6’-
diamidino-2-phenylindole (DAPI), goat anti-rabbit AlexaFluor568 polyclonal antibody, 
AlignFlow flow cytometry beads (2.5 μm) and lipofectamine 2000 reagent were obtained 
from Invitrogen (Carlsbad, CA). Hydrochloric acid was obtained from Mallinckrodt 
(Phillipsburgh, NJ). Fetal bovine serum was obtained from Omega Scientific (Tarsana, 
CA). Dubelcco’s Modified Eagle Medium (DMEM) high-glucose cell medium and 
geneticin were obtained from Gibco (Carlsbad, CA). D-Mannitol was obtained from 
Riedel-de Håen (Atlanta, GA). Sodium hydroxide was obtained from Fluka (Seelze, 
Switzerland). Phosphate buffered saline (10× concentration, 1.37 M NaCl, 27 mM KCl, 
80 mM Na2HPO4, and 20 mM KH2PO4, pH 7.4) was obtained from BioRad (Hercules, 
CA). 0.5% trypsin-EDTA (10× concentration, no phenol red) was obtained from Life 
Technologies (Grand Island, NY). Formaldehyde and sodium chloride were obtained 
from Fisher Scientific (Pittsburgh, PA). Bovine serum albumin fraction V, heat shock, 
fatty acid free was obtained from Roche (Basel, Switzerland). Water was purified with a 
Millipore Synergy UV system (18.2 mΩ/cm, Bedford, MA). 
Homogenization buffer was made by adding 11.99 g sucrose (70.0 mM), 19.52 g 
mannitol (214 mM), 611 mg HEPES (4.31 mM), and 724 mg EDTA (4.94 mM) to 500 
mL deionized water and brought to pH 7.2 with 0.1 M HCl and 0.1 M NaOH. Capillary 
electrophoresis (CE) buffer was made by adding 42.88 g sucrose (250 mM), and 1.18 g 
HEPES (10.0 mM) to 500 mL deionized water and brought to pH 7.2 with 0.1 M HCl and 
0.1 M NaOH. The CE buffer was photobleached with 120-mW LED lights with a λmax at 
472 nm for 72 h to reduce background fluorescence intensity.
103
 
6.3.2 Cell Culture 
To create the L6 cell line expressing GFP-LC3, transfections were done with a 
plasmid containing the EGFP-LC3 gene (plasmid 11546, Addgene)
265
  and selected by 
fluorescence activated cell sorting. In brief, L6 cells (ATCC, Manassas, VA) were 
cultured to 70-90% confluence in a 24-well plate. DMEM medium volume was adjusted 
to 500 μL in each well. Both Lipofectamine 2,000 (Life Technologies, Grand Island, NY) 
transfection reagent (2.4 μL) and plasmid (800 ng) were diluted separately in 50 µL of 
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Opti-MEM medium each, and then mixed. After five minutes, this mixture was added to 
wells containing L6 cells and incubated for 48 h, collected by centrifugation at 1,000g for 
10 min, and diluted to 2.5 × 10
6
 cells/mL in 1× PBS containing 0.5% w/v bovine serum 
albumin. Non-transfected L6 cells were used as a control. Cells expressing GFP-LC3 
were selected using fluorescence activated cell sorting (FACS) with a BD FACSAria 1 
flow cytometer (BD Biosciences, San Jose, CA) using a 130-μm nozzle and a 20 mW, 
488 nm-argon ion-laser. Only 32% of the cells were fluorescent. Thus, FACS was used a 
second time to sort one cell per in each well of 24-well plates. Fluorescent microscopy 
was used for up to one week following sorting to select fluorescent cell clones. 
Transfected cells were frozen for future use in liquid nitrogen at -80° C. The studies 
reported here used the same cell clone. 
 The original L6 cells and the clone expressing GFP-LC3 were maintained at 
37°C, 5% CO2 in DMEM supplemented with 10% fetal bovine serum containing either 
100 µg/mL gentamycin or 150 µg/mL of each gentamycin and geneticin, respectively,. 
For maintenance, cells were released with trypsin in PBS (0.5% v/v) from T-flasks and 
then split 1:40 (v/v) into new flasks. 
6.3.3 Autophagy Treatments 
Once cells reached ~90% confluence, cells were treated with vinblastine, 
rapamycin, or both. For basal autophagy experiments, two different treatments were 
performed: One flask was treated with 50 µM vinblastine for two hours, while the second 
flask was untreated. For rapamycin-induced autophagy experiments, both flasks were 
treated with 267 µM rapamycin for 3 hours; one hour into this treatment, one flask was 
treated with 50 µM vinblastine for the remaining two hours, while the second one 
remained free from vinblastine. For both basal and rapamycin-induced autophagy 
experiments, cells were harvested by differential centrifugation at 1,000g for 10 minutes 
and then washed once by suspending in homogenization buffer and differential 
centrifugation at 1,000g for 10 minutes. 
6.3.4 Organelle Isolation and Release 
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Post-nuclear fractions from GFP-LC3 expressing L6 cells (passages 14-24, 10
6
-
10
7
 cells) were prepared. Cell disruption was done in an ice-cooled cell disruption bomb 
(Parr Instrument Co., Moline, IL) charged to 500-600 psi with nitrogen gas for a 
minimum of 15 min prior to pressure release. The lysate was collected in a 50-mL falcon 
tube. Unbroken cells and nuclei were removed by differential centrifugation at 600g for 
10 minutes. Organelles were collected by differential centrifugation at 14,000g for 45 
minutes. The organelle pellet was reconstituted with homogenization buffer, and 
centrifuged at 14,000g for 30 minutes. The organelle pellet was reconstituted with CE 
buffer (100 μL) and was resuspended with a 1.00-mL syringe (Hamilton, Reno NV) to 
break up the organelle pellet and minimize organelle aggregation. Protein concentrations 
were determined using the bichinchoninic acid protein assay according to the 
manufacturer (ThermoScientific, Wilmington, MA). 
6.3.5 CE-LIF Instrumentation and Alignment 
Poly-vinyl alcohol (PVA) coating of fused silica capillaries (150-μm outer 
diameter, 30-μm inner diameter, Polymicro, Phoenix, AZ) was done as previously 
described.
266
 PVA was used to decrease non-specific binding of organelles to the fused 
silica capillary.
91
 The current monitoring method was used to estimate the reduction of 
electroosmotic flow relative to an uncoated capillary.
267
 Residual electroosmotic flows 
were 17 - 22% of that of uncoated capillaries. Capillaries were no longer used when GFP-
labeled biological material began adhering to the outlet of the capillary. Prior to storage 
at room temperature, capillaries were flushed with methanol, deionized water, and air. 
A previously described, a custom-built CE-LIF instrument
89
 was used to 
determine numbers of autophagy organelles, individual autophagy organelle GFP-LC3-II 
levels, and individual autophagy organelle electrophoretic mobility. Briefly, a 488-nm 
argon-ion laser (10 mW) was used for fluorescence excitation. A 530 (± 17.5)-nm filter 
collected GFP and fluorescein fluorescence. The polyimide coating on the outlet of the 
capillary was burned to decrease fluorescence from this coating. Fluorescence was 
detected by a photomultiplier tube (R1477, Hamamatsu Corp., Bridgewater, NJ, 1 kV). 
Data were collected at 200 Hz and digitized by a NiDaq I/O data board (PCI-MIO-16XE-
50, National Instruments, Austin, TX) controlled with Labview 5.1 software (National 
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Instruments). The limit of detection for a fluorescein standard was 11 ± 8  zmol (Ave ± 
St. Dev., n = 12). Capillary electrophoresis separations were performed at -297 V/cm for 
~30 minutes. Hydrodynamic injection (104-cm height, 10 s injection) was used for 
sample introduction. In between separations, the capillary was washed with methanol and 
CE buffer for 5 minutes each. Methanol removed any remaining biological material and 
CE buffer re-equilibrated the capillary. For alignment of the instrument, please see 
Section D.3. 
6.3.6 Data Analysis 
CE-LIF data was analyzed using Igor Pro (WaveMetrics, Inc., Lake Oswego, OR) 
as previously described. 
48
 Organelle peaks were selected according to a threshold value 
defined as follows: 
                                   Equation 6.7 
where   is the average background intensity and   is the standard deviation of the 
background intensity. This threshold eliminated at least 95% of background intensity 
peaks (seen with a threshold of   + 6 ). 
In order to account for variations in contents of each sample, the number of 
organelle peaks was then normalized to the amount of protein in the sample injected, 
calculated as follows: 
                                          Equation 6.8 
where Vi is the volume injected and [protein] is the protein concentration of the 
biological sample determined by the BCA assay.  
Random non-specific events, which are detected prior to the time required by 
organelles to reach the detector appeared from 0 to ~ 450 – 500 s, which is termed pre-
migration window. The number of peaks detected in the pre-migration window was 0.02 
± 0.02 peaks/s (Ave ± St. Dev., n = 12 runs). These events in the pre-migration window, 
were removed from further analysis. To determine the contribution of native fluorescence 
to GFP fluorescence detection organelles of non-transfected L6 cells were also examined 
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in the migration window that begins at 400 -500s (Figure 6.2A.). The number of detected 
peaks per ng protein in the sample was 6 ± 0 (Ave. ± St. Dev., n = 2 runs), while this 
number was 252 ± 78 events (Ave. ± St. Dev., n = 3 runs) in the sample from GFP-LC3 
expressing cells. This suggests that 2% of the detected events in electropherograms of 
autophagy organelles from GFP-LC3 transfected cells were due to native fluorescence.    
When samples have a large number of organelles, two or more organelles may 
produce one single detected event. Statistical overlap theory (SOT) was used to predict 
overlap of individual autophagy organelle events (See Appendix, Table D.3.).
268, 269
 
There is a saturation limit above which overlap precludes an accurate count of events. In 
regions of the electropherogram (bins) in which the number of the events exceeded the 
saturation limit, previously defined as ‘m’,41, 42 m was used as a conservative number of 
events in the bin (See Appendix, Table D.3.). This saturation value was determined as 
described previously and is based on    
 
 
 where σ is the peak width and X is the 
duration of the bin in seconds.
164
 
Because the detector sensitivity varies from day-to-day, we corrected for 
variations in instrument sensitivity to allow for comparison of individual autophagy 
organelle fluorescence levels in separations performed on different days. This correction 
used the background intensity (c.f. Equation 6.7), assumed proportional to the LIF 
detector sensitivity. All the signal intensities of the detected peaks were normalized to 
that with the lowest background intensity level. This correction is particularly important 
because each condition (basal autophagy, untreated; basal autophagy, vinblastine-treated; 
rapamycin-induced autophagy, untreated; and rapamycin-induced autophagy, vinblastine-
treated) was done on different days. Please see Supplementary Information Section D.3. 
for further information.  
The electrophoretic mobilities of detected organelles (µ) are affected by run-to-
run fluctuations. We used the observed (µFlu,o)  and known (µFlu,r) electrophoretic 
mobilities of fluorescein to determine the electrophoretic mobilities of observed events 
(µorganelle) as follows:  
μ
         
 
  
        
  μ
          
                Equation 6.9 
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             Equation 6.10 
where μorganelle is the mobility of a detected organelle, L is the length of the 
capillary, t is the organelle migration time, V is the separation voltage, μFlu,o is the 
observed fluorescein electrophoretic mobility, and μFlu,r is the reported electrophoretic 
mobility of fluorescein in a PVA-coated capillary.
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Quantile-quantile plots (QQ plots) were used to compare, in increments of 5%, 
the 5
th
 through 95
th
 percentiles of distributions of individual organelle fluorescence levels 
and electrophoretic mobilities. Comparisons of these distributions included (1) basal and 
rapamycin-enhanced autophagy steady states, and (2) vinblastine treated and untreated 
cells under basal and rapamycin-enhanced autophagy. If the two distributions are similar, 
their QQ plot approaches a diagonal line with slope equal to one. (i.e., line y = x). The 
distances between percentiles was also plotted to better understand the difference in 
percentiles. 
6.3.7. Safety Considerations 
Biosafety level 1 was observed for all procedures using L6 cells. Biological waste 
was treated with bleach for 30 min prior to disposal. Used cell culture supplies were 
autoclaved prior to disposal. 
6.4. Results & Discussion 
6.4.1. Detection of Individual Autophagy Organelles by CE-LIF 
The first focus of this study was to determine the suitability of CE-LIF to measure 
the properties of autophagy organelles. Prior work demonstrated the use CE-LIF to 
determine the numbers and properties of other types of individual organelles.
48, 93, 104, 107, 
264
 To evaluate the utility of GFP-LC3 as a label for autophagy organelles, fluorescence 
confocal microscopy confirmed colocalization of GFP and anti-LC3 antibody at puncta 
(Section D.1.), which indicated GFP-LC3 is a suitable marker to monitor autophagy 
organelles by CE-LIF.   
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The CE-LIF analysis of organelles isolated from GFP-LC3 expressing L6 cells 
under conditions of basal autophagy, treated with vinblastine, treated with rapamycin, or 
treated with both rapamycin and vinblastine demonstrated detection of individual 
autophagy organelles (Figure 6.2).  Representative electropherograms of individual 
organelles showed narrow peaks, (FWHM = 36 ± 16 ms (Ave ± St. Dev, n =12,567 
peaks), a width defined by the organelle’s travel time through the laser beam of the LIF 
detector (Figure 6.2F). These narrow events are expected when a fluorophore (i.e. GFP-
LC3-II) is bound to an organelle. On the other hand, GFP-LC3-I, which is cytosolic, 
would be free in solution and would be detected as a band with broadening defined by 
diffusion and other band broadening effects.
103
 A broad peak from GFP-LC3-I was not 
detected, because GFP-LC3-I was lost during removal of the cytosol by differential 
centrifugation during the fractionation procedure.
271
 Because GFP-LC3-I does not 
interfere in the CE-LIF results, here we refer to GFP-LC3-II, the organelle bound form, 
as GFP-LC3. Lastly, to eliminate the possibility that the observed events were attributed 
to native fluorescence, we analyzed organelles isolated from L6 cells not expressing 
GFP-LC3 (Figure 6.2.A). The low number of detected organelle peaks in this control 
(Figure 6.2A) relative to analyses of GFP-LC3 expressing cells (Figure 6.2B-E) 
confirmed that the observed events are mainly due to GFP-LC3 fluorescence and not to 
autofluorescence or light scattering by organelles. Together, these results confirm that 
GFP-LC3 labeled organelles can be monitored by CE-LIF. 
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Figure 6.2. Electropherograms of L6 cells expressing GFP-LC3. (A) Non-transfected 
cells. (B)-(F) GFP-LC3 expressing cells. (B)  Basal autophagy. (C) Basal autophagy after 
vinblastine treatment. (D) Rapamycin enhanced autophagy. (E) Rapamycin enhanced 
autophagy after vinblastine treatment. The broad peaks at ~1,000 s in (A)-(E) are 
fluorescein peaks. (F) Expansion of individual organelle detected events from (E). CE 
buffer: 250 mM sucrose, 10 mM HEPES, pH 7.2; -297 V/cm in a PVA coated capillary. 
Fluorescence detection at 530 ± 18 nm.  
Next, we assessed the reproducibility of the individual organelle fluorescence 
intensity and electrophoretic mobility distributions obtained from replicate CE-LIF 
analysis of the same sample. QQ plots confirmed that both properties had adequate 
reproducibility (See Appendix, Figure D.3).
91, 93
 Further improvements in reproducibility 
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of individual organelle properties may be attained as techniques for reproducible cell 
disruption and organelle isolation become available. Another option to enhance 
comparisons of distributions is to pool data from several replicates as previously done.
91, 
93
 This approach provided the means to compare distributions of individual organelle 
GFP-LC3 fluorescence intensities and electrophoretic mobility distributions resulting 
from the CE-LIF of basal and rapamycin enhanced autophagy. 
6.4.2 Individual Organelle Comparisons of Autophagy Steady States 
Individual organelle measurements were used to compare the steady states 
(snapshots) of basal and rapamycin-enhanced autophagy (c.f. Equation 6.1). These 
snapshots include: (1) the number of organelles present in the respective samples, (2) the 
distribution of individual organelle GFP-LC3 intensities, and (3) the distribution of 
individual organelle electrophoretic mobilities.  
Samples from rapamycin-treated cells had higher numbers of autophagy 
organelles than untreated cells (174 ± 31 and 71 ± 15, events/ng protein, respectively; 
Avg. ± St. Dev., n = 3 runs). These results are in agreement with previous observations 
done by confocal fluorescence microscopy in which rapamycin-treatment increased the 
number of autophagy organelles detected in primary cortical neurons
272
 and in normal rat 
kidney cells
260
 relative to those numbers in untreated cells. 
Surprisingly, when we analyzed the steady state contents of GFP-LC3 levels in 
individual autophagy organelles, the distributions of rapamycin-enhanced and basal 
autophagy were remarkably similar (Figure 6.3). This suggests that, although rapamycin 
enhances autophagy, the GFP-LC3 contents in autophagy organelles and the proportions 
of the various types of autophagy organelles at steady state remain about the same.  
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Figure 6.3. (A) QQ plot of individual GFP-LC3 fluorescent intensity distributions. 
Comparison of steady state distributions of individual GFP-LC3 levels under basal (x-
axis) and rapamycin-enhanced (y-axis). Markers represent 5, 10, 15…95th percentiles. 
For percentiles with y = x, their intensity value is the same. (B) Changes in the 
distributions of individual GFP-LC3 levels. The change for a given percentile was 
calculated according to Equation 6.6. 
Electrophoretic mobility has been associated with the surface charge of 
organelles.
93
   Because individual organelle CE-LIF analysis reports individual 
electrophoretic mobilities (c.f. Equation 6.9), this technique is suitable to compare 
surface composition of individual organelles from cells with rapamycin-enhanced and 
basal autophagy. The electrophoretic mobilities of autophagy organelles were, in general, 
more positive when cells were treated with rapamycin relative to untreated cells (25
th 
-
80
th
 percentiles in Figure 6.4.). These observations suggest that rapamycin treatment not 
only enhances the number of autophagy organelles present at a given time but it is 
associated with a change in surface composition, which reflects on the sources of material 
that make up the surface of autophagy organelles and on interactions with other organelle 
types. 
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Figure 6.4. (A) QQ plot of individual autophagy organelle electrophoretic mobility 
distributions. Comparison of steady state distributions of individual electrophoretic 
mobility under basal (x-axis and rapamycin-enhanced (y-axis). Markers represent 5, 10, 
15…95th percentiles. For percentiles with y = x, their electrophoretic mobility value is the 
same. (B) Changes in the distributions of individual autophagy organelle electrophoretic 
mobility. The change for a given percentiles was calculated according to Equation 6.6. 
While bulk measurements (e.g. Western blot) are adequate to compare total 
marker levels (e.g. LC3-II levels) of various autophagy regimens, individual organelle 
CE-LIF analysis provides a more extensive description of the autophagy regiments. 
Using this technique, steady states (snapshots) of autophagy in cell cultures expressing 
GFP-LC3 we were able to count organelles as well as determine distributions of 
individual GFP-LC3 intensities and individual electrophoretic mobilities. Comparison of 
basal and rapamycin-enhance autophagy using individual organelle CE-LIF demonstrated 
that increases in autophagy markers are caused by a larger number of autophagy 
organelles and not by increase in the individual organelle GFP-LC3 contents. The 
analysis also suggests that surface composition and likely the origin of the biomolecules 
forming the surface of autophagy organelles are different for basal and rapamycin-
enhanced autophagy. 
6.4.3 Temporal Changes in Individual Autophagy Organelle Properties  
We investigated autophagy dynamics in L6 cells undergoing either basal or 
rapamycin-enhanced autophagy. Treatment with vinblastine halts formation of 
autolysosomes by blocking fusion of autophagosomes and lysosomes,
81
 leading to 
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accumulation of mostly autophagosomes and degradation of the autolysosomes which are 
formed prior to vinblastine treatment. Comparison of individual autophagy organelle 
properties in the presence and absence of vinblastine treatments allowed us to assess the 
dynamics associated with autolysosome formation (c.f. Equation 6.4). We characterized 
temporal changes in numbers of individual autophagy organelles that accumulate or 
disappear as well as the temporal changes in the distributions of individual organelle 
GFP-LC3 fluorescence and electrophoretic mobilities.  
For basal autophagy, the numbers of detected organelle events were 107 ± 23 and 
230 ± 59 events/ng protein (Avg. ± St. Dev., n = 3 run) for untreated and after a 2-hour 
vinblastine treatment, respectively. Using Equation 6.3, the calculated temporal change 
was 62 ± 32 events/(hour × ng protein). These results indicate that autophagosome 
formation is faster than disappearance of autolysosomes under basal autophagy 
conditions. Similarly for rapamycin-enhanced autophagy, the number of detected 
organelle events were 174 ± 31 and 49 ± 20 events/ng protein (Avg. ± St. Dev., n = 3 
runs) for untreated and after a 2-hour vinblastine treatment, respectively; the temporal 
change in the number of detected organelle events was -63 ± 18 events/(hour × ng 
protein). The faster disappearance of autolysosomes relative to the rate of appearance of 
autophagosomes under conditions of rapamycin-enhanced autophagy suggests a rapid 
degradation of the autolysosome cargo. In agreement, previous studies reported increased 
levels of free GFP and free LC3 upon rapamycin treatment of HeLa cells expressing 
GFP-LC3
273
 and increased levels of colocalization between DsRed-LC3 puncta and 
cathepsin D, a lysosomal protein, following rapamycin treatment in cortical neurons.
272
 
Thus, the study reported here provides evidence that the major effect of rapamycin is to 
increase the rate of degradation of autolysosome cargo. 
Temporal changes in individual autophagy organelle GFP-LC3 distributions can 
be represented as QQ plots. In Figure 6.5.A the series of markers represent the 5, 10, 
15… 95 percentiles of two distributions: organelles from cells treated with vinblastine (y-
axis) and from untreated cells (x-axis). The diagonal indicates the location of the markers 
for identical distributions. Vertical deviations from the diagonal correspond to changes 
that occur during the vinblastine treatment.   For basal autophagy, the organelles that 
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accumulate tend to have higher individual GFP-LC3 fluorescence signals than 
autolysosomes that are being degraded (Figure 6.5). In contrast, for rapamycin-enhanced 
autophagy, organelles that accumulate have lower individual GFP-LC3 fluorescence 
signals than autolysosomes that are being degraded.  
 
Figure 6.5.  (A) Temporal changes in the distributions of individual GFP-LC3 levels. (B) 
Changes in the distributions of individual GFP-LC3 levels. The change for a given 
percentiles was calculated according to Equation 6.6. 
Previous studies reported an increase in LC3-II signal when autophagosomes are 
accumulated upon autophagy blockage.
33, 84
 In agreement with these studies, we observed 
an increase in the individual organelle GFP-LC3 distributions (c.f. Figure 6.5). 
Phagophores and autolysosomes may be represented by the lower percentiles in the QQ 
plots because: (1) phagophores are the first autophagy structures formed, which suggest 
lower GFP-LC3 levels and fluorescence than autophagosomes,
274
 and (2) autolysosomes 
experience cleavage and degradation of GFP-LC3-II as the autolysosome matures and for 
GFP-LC3-II localized in the autolysosomal lumen, the low pH decreases the GFP 
fluorescence quantum efficiency.
67, 275, 276
 Thus, it is not surprising that under basal 
conditions individual fluorescence GFP-LC3 levels increase upon vinblastine treatment, 
suggesting that the observed temporal changes are mainly due to the accumulation of 
autophagosomes. 
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In contrast, under rapamycin-enhanced autophagy conditions there was a partial 
decrease in the individual GFP-LC3 fluorescence intensity (50th to 95th percentile, 
Figure 6.5) during the duration of the vinblastine treatment. This change cannot be 
explained on the basis of low GFP-LC3 fluorescence intensities of phagophores or 
autolysosomes as autophagosomes still continue forming and accumulating during the 
vinblastine treatment. Consistent with our findings, others have observed decreased GFP-
LC3-II levels by Western blotting,
83
 but these studies did not reveal that only a subset of 
individual organelles (i.e. 50 to 95
th
 percentile) showed this trend. Therefore, this CE-LIF 
individual organelle measurement confirms these bulk studies and defines that 
autophagosomes formed under rapamycin treatment have lower GFP-LC3-II contents.   
Temporal changes in individual electrophoretic mobility distributions of 
autophagy organelles can be represented as QQ plots. Based on liposome models, we 
previously attributed electrophoretic mobility to variations in surface charge composition 
and not liposomal size.
93
  Therefore we used QQ plots to gain an insight of temporal 
variations in surface compositions of autophagy organelles represented by their 
respective electrophoretic mobilities.  
For basal conditions, vinblastine treatment revealed that the accumulated 
autophagy organelles (autophagosomes) had more positive electrophoretic mobility 
distribution than disappearing autolysosomes (Figure 6.6.). In contrast, for rapamycin-
enhanced autophagy conditions, the accumulated organelles (autophagosomes) had a 
more negative electrophoretic mobility distribution than disappearing autolysosomes 
(Figure 6.6.). These changes, expressed as mobility units (cm
2
/(V  s) per length of 
vinblastine exposure (h), are more clearly represented in Figure 6.6, where each 
percentile have different degrees of variation. Because phagophores continue forming 
and being transformed into autophagosomes during vinblastine treatment and amphisome 
numbers are low compared to autophagosomes,
81
 the electrophoretic mobility changes 
observed are mainly attributed to autophagosome formation and disappearance of 
autolysosomes. Thus in regards to electrophoretic mobility, autophagosomes are more 
positive than autolysosomes under basal conditions while the opposite is observed under 
rapamycin-enhanced conditions. 
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Figure 6.6. (A) Temporal changes in the distributions of individual electrophoretic 
mobilities. (B) Changes in the distributions of individual electrophoretic mobilities. The 
change for a given percentiles was calculated according to Equation 6.6. 
Both lipid and protein compositions define the surface of autophagosomes and 
contribute to their surface charge and, in turn, to their electrophoretic mobilities. 
Considering the multiple sources of autophagosomes membrane components such as the 
plasma membrane, Golgi, ER, and mitochondria,
251, 277, 278
 it is not surprising to observe 
highly heterogeneous individual electrophoretic mobilities. On the other hand, the 
dramatic temporal changes observed as a result of vinblastine treatment (Figure 6.6), 
correspond to differences in surface compositions of autophagosomes and autolysosomes. 
As autophagosomes accumulate and autolysosomes disappear these marked differences 
in become more pronounced with time. These differences suggest that forming 
autophagosomes have positive surface charges relative to autolysosomes under basal 
autophagy conditions, but this relationship reverses under rapamycin-induced autophagy 
conditions. These results suggest that the make up the membranes of autophagosomes 
and autolysosomes is dependent on the status of autophagy in the cell. In agreement, 
under starvation-enhanced autophagy, the omegasome forms in ER instead of the 
Golgi.
277
 The omegasome is one source for autophagosome membrane components. 
Similarly, starvation induces use of outer mitochondrial membrane as a source 
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autophagosome membrane components.
62, 279
 Together, these results imply that individual 
electrophoretic mobility changes are associated with differences between autophagy 
organelle types (autophagosomes and autolysosome) as well as with the sources of 
materials that make up the organelle membranes. 
6.5. Conclusions 
This study demonstrated that CE-LIF can be used to detect individual autophagy 
organelles based on the GFP-LC3-II label. Individual detection eliminates biases caused 
by cytosolic GFP-LC3-I, which is eliminated during sample preparation. Both individual 
GFP-LC3 fluorescence and electrophoretic mobilities are directly determined from CE-
LIF data, which made possible comparisons of basal and rapamycin-enhanced autophagy 
as well as temporal changes reflected by accumulation autophagosomes and degradation 
of autolysosomes. 
Comparison of snapshots of autophagy steady states revealed an increased 
number of autophagy organelles under rapamycin-enhanced conditions, fairly consistent 
levels of GFP-LC3 between the two states, and a more positive electrophoretic mobility 
for rapamycin-enhanced autophagy, which suggest a more positive surface charge. 
Temporal changes observed by inhibiting autophagy with vinblastine reveal that (1) 
autolysosome degradation is faster than autophagosome formation under rapamycin-
enhanced autophagy; (2) autophagosomes have higher levels of GFP-LC3 than other 
organelles under basal autophagy but lower ones under rapamycin-induced autophagy; 
and (3) autophagosomes have more positive electrophoretic mobilities than the rest of the 
autophagy organelles under basal conditions, but a more negative electrophoretic 
mobilities than the rest of the autophagy organelles under rapamycin-enhanced 
autophagy.  
Future developments will include use of fluorescent labels specific for 
autolysosomes and phagophores to obtain a more comprehensive description of the 
dynamics of autophagy. In addition, labeling of other organelle types may aid at 
monitoring autophagy sub-types such as mitophagy (degradation of mitochondria) and 
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pexophagy (degradation of peroxisomes). These advancements respond to a critical need 
for tools to investigate the role of autophagy flux in disease and aging.
6, 8, 9
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Chapter 7 
Conclusions 
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The work described in this thesis provides new techniques for the high enrichment 
of endocytic organelles and determination of both endocytic organelle and autophagy-
related organelle properties. Endocytic organelles were enriched using magnetic 
separation, allowing for the determination of the biotransformation of the prodrug N-L-
leucyldoxorubicin (LeuDox) into the product doxorubin (Dox). The first untargeted 
determination of small molecules enriched in autophagosomes fractions was performed 
by UPLC-MS
e
. This resulted in preliminarily identifications of compounds that will 
continue to be studied for their importance in maintaining proper autophagosome 
function and autophagy flux. Finally, the first technique was developed to determine 
temporal changes in the number and properties of accumulated autophagosomes and 
phagophores under basal and rapamycin enhanced autophagy by CE-LIF.  
Current techniques for the enrichment of endocytic organelles do not result in 
fractions both free of unwanted organelles and with intact endocytic organelle 
membranes.
11, 13, 15, 213
 The work described in Chapter 3 describes the enrichment of 
magnetically labeled endocytic organelles. Enriched fractions had no detectable 
mitochondria and peroxisomal activity when compared to endocytic organelle enriched 
fractions from differential centrifugation. Using capillary cytometry to detect individual 
endocytic organelles, a majority of enriched endocytic organelles maintained their acidic 
pH indicating the enriched organelles had intact membranes.  This technique can be used 
to prepare endocytic organelle fractions to determine their properties such as small 
molecule composition and pH.  
Magnetically enriched endocytic organelle fractions described in Chapter 3 were 
then used to determine the biotransformation of LeuDox to Dox specific to those 
fractions (work described in Chapter 4). About 10% of LeuDox was biotransformed to 
Dox in the enriched acidic organelle fraction accounting for ~45% of the total 
biotransformation detected in the post nuclear fraction. The remaining biotransformation 
of LeuDox to Dox occurred in the non-enriched fraction containing remaining endocytic 
organelles, other organelles, and cytosol. This suggests that endocytic organelles may 
play an important role in intracellular biotransformation of LeuDox to Dox in addition to 
the previously reported extracellular biotransformations.
49
 This technique allows for the 
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determination of intracellular biotransformation of drugs and prodrugs and can be applied 
to other prodrugs that may not only be activated both extracellularly and intracellularly. 
Furthermore, this technique may be useful to determine other biotransformations that are 
attributed to lysosomes and other endocytic organelles. 
New methods were also developed for determining the properties of 
autophagosomes. The small molecule composition of autophagosomes had previously not 
been determined including using non-targeted methods by liquid chromatography 
coupled to mass spectrometry. Preliminary identifications were assigned to features 
enriched or unique to autophagosomes by UPLC-MS
e 
(work described in Chapter 5). A 
rigorous data analysis procedure was developed to both select features that had extracted 
ion chromatograms with chromatographic peak profiles and to ensure daughter ions from 
high-collision energy mass spectra possessed matching extracted ion chromatograms with 
its parent ion. Enriched autophagosome fractions from rat myoblast cell culture and liver 
tissue had 187 features detected and 34 high confidence preliminary identifications. 
Many of the preliminary identifications made, such as PE(16:0/0:0) and sphinganine, 
have previously been associated with autophagy and autophagosomes indicating that the 
preliminary identifications made are of high-relevance to autophagy. In the future, 
identifications will be validated and investigated for their role in autophagy and proper 
autophagosome function. 
The work described in Chapter 6 uses the labeling of autophagy organelles with 
GFP-LC3 to determine temporal changes in the number and properties of individual 
autophagy organelles by CE-LIF. The dynamic nature of autophagy and the multiple 
autophagy organelles involved make bulk measurements, such as those done by Western 
blotting, inadequate to understand autophagy and its roles in aging and disease. L6 cells 
expressing GFP-LC3 were treated with vinblastine, which halts autophagy just before 
formation of autolysosomes, to accumulate autophagosomes and phagophores from basal 
and rapamycin enhanced autophagy flux. Comparison of organelle numbers and changes 
in GFP-LC3 fluorescence intensities or electrophoretic mobilities of individual 
organelles, that either accumulated or disappeared during vinblastine treatment, provides 
individual-organelle level detail of the autophagy process. Under basal autophagy 
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conditions, there was a net accumulation of organelles, which mostly represent 
autophagosomes; because autolysosomes also degrade, the higher GFP-LC3 fluorescence 
and more positive electrophoretic mobility of individual organelles likely represent 
differences between these two organelle types. When autophagy was enhanced by 
rapamycin treatment, disappearance of autophagy organelles (autolysosomes) prevailed 
over formation of other autophagy organelles, the GFP-LC3 fluorescence of individual 
organelles decreased suggesting accumulation of organelles with lower levels of this 
marker, and the individual electrophoretic mobilities were more negative suggesting that 
organelles formed have a different surface composition.  The dramatic contrast between 
time dependent changes in individual organelle properties between basal and rapamycin-
driven conditions demonstrates an anticipated complexity of autophagy flux which likely 
plays critical role in response to drug treatments, aging, and disease.  
The developments described in this thesis are new, improved methods for 
enriching endocytic organelles and new methods for investigating autophagosome 
composition and autophagy flux. Development of these techniques may lead to additional 
follow-up experiments to further increase our understanding of endocytic and 
autophagosome organelle properties in biological systems. Improved understanding of 
the properties of endocytic and autophagy organelles from biological systems of diseased 
states is needed. This may help determine and develop new therapeutic strategies that 
could compensate for dysfunctional autophagy flux or modified levels of 
autophagosome-enriched molecules. Improving the design of anti-cancer drugs to 
account for organelle-specific biotransformations can improve their efficacy. Developing 
new therapies for diseases with diminished or increased autophagy levels can be done by 
improved understanding of the composition of these organelles and their properties. 
Ultimately, the methodologies described in this thesis aim to improve the quality of life 
of patients receiving anti-cancer drugs and with autophagy-related diseases.  
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Chapter 8 
Future Work 
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8.1. Introduction 
 The work described in the prvious chapters of this thesis points to future 
developments that could further optimize the new techniques described in the thesis, 
validate results, or apply this work to new biological systems. Experiments are discussed 
in this chapter that can lead to magnetically enriched autophagosome fractions (work 
described in Chapter 5), validation of preliminary identifications from enriched 
autophagosome samples (work described in Chapter 5), and detection of specific 
autophagy-related organelles to determine their properties for different autophagy 
conditions and to monitor organelle-specific autophagy (work described in Chapter 6). 
8.2. Improving yield of endocytic organelle enrichment 
 In the work described in Chapter 3, enriched endocytic organelle fractions had a  
relatively low yield of lysosomes when compared to differential centrifugation (18 ± 6% 
vs. 42 ± 10%, based on lysosome enzymatic activity in the enriched fraction compared to 
whole cell lysate, avg. ± st. dev., n = 3). While the technique was sufficient to determine 
lysosomal enzymatic activity (work described in Chapter 3) and endocytic organelle-
specific biotransformation (work described in Chapter 4), other methodologies could also 
be done following the development of methodologies that increases the endocytic 
organelle yield. For example, compositional studies of endocytic organelles would 
benefit as increased levels of endocytic-organelles would increase the detection of low-
abundance endocytic organelle-enriched features (a sample-specific chemical entity 
characterized by a unique constitution of chromatographic retention time, m/z and 
intensity).  
 Increased endocytic organelle yield can be obtained by modification of the 
geometric arrangement of the PEEK tubing and its placement in the cavity of the home-
built magnetic device. In the work described in Chapters 3 and 4, a single, linear section 
of PEEK tubing was held in the cavity of the home-built magnetic device. This 
geometrical arrangement guaranteed that PEEK tubing passed through the location of the 
device with maximum field strength (Figure 3.1, 8.1.A). The relatively small section of 
PEEK tubing held in the cavity, however, allowed for the collection of a relatively 
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decreased amount of the cell sample. This geometrical arrangement could be modified to 
increase the section of PEEK tubing to the magnetic cavity to capture additional 
magnetic-labeled organelles (Figure 8.1.B and 8.1.C). The geometries described in Figure 
8.1.B and 8.1.C are not the only possibilities for magnetic enrichment that can potentially 
increase endocytic organelle yield but were selected for their simplicity  to manipulate 
the PEEK tubing.
280
 
 
Figure 8.1. PEEK tubing geometries for magnetic enrichment. PEEK tubing is held in 
the magnetic cavity of a magnetic separator built with neodymium borate magnets 
(square blocks). The arrow depicts the magnetic field. (A) The geometric arrangement of 
PEEK tubing used in the work described in Chapter 3. (B-C) The geometric arrangements 
of PEEK tubing that could provide additional PEEK tubing and, therefore, capture 
increased volumes of magnetically labeled endocytic organelles and increase yield. 
 As indicated in Figure 3.1, the magnetic field is strongest in the middle of the 
magnetic setup (indicated by arrow in Figure 8.1.). PEEK tubing setups B and C increase 
the length of PEEK tubing and, therefore, the volume of biological sample that can be 
captured. However, the magnetic field strength is weaker in these positions. To capture 
magnetically labeled organelles in tubing located in areas of weaker magnetic field 
strength, either the applied fluid flow may need to be decreased, the magnetic strength of 
the magnetic field may need to be increased, or a combination of both. Equation 8.1 
describes the forces (μ) of a magnetic particle in a tube:281 
                    Equation 8.1. 
 When the total force becomes 0, Equation 8.1 indicates that the magnetic force 
and the fluid flow force are equal and the particle is held at a single location in a 
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magnetic field. Modeling can be performed to examine the optimized fluid flow for an 
applied magnetic field and a particle with a given magnetically susceptibility. The 
Arriaga lab is well equipped to perform these studies and optimization due to the 
availability of computer software to model magnetic fields and expertise in organelle 
enrichment. Following modeling to determine an initial set of parameters based on the 
PEEK tubing geometry, fluid rate, and magnetic field strength, initial parameters can be 
further optimized using the home-built magnetic device and liposomes containing 
magnetic nanoparticles.
89
  
 An additional modification of the procedure developed in Chapter 3 is to modify 
the duration of the treatment of cells with the dextran-coated iron oxide nanoparticles. 
This will allow for the targeting of lysosomes over late endosomes. In different types of 
cell culture, dextran traffics to cells and within cells at different rates. In the procedure 
described in Chapter 3, cells were treated for 30 min with dextran-coated nanoparticles 
followed by cell harvest. Previously in the literature, dextran targeting to lysosomes has 
been done with 30 min pulse with no chase,
282-284
 1 hr pulse and 1 hr chase,
285
 and 4 hr 
pulse and 20 hr chase.
286
 Lysosome enrichment may be maximized by ensuring dextran 
coated magnetic nanoparticles are localized in lysosomes (compared to late endosomes). 
Different pulse-chase combinations, such as those described above, can be used for the 
treatment of cells with dextran coated magnetic nanoparticles. To determine if increased 
numbers of lysosomes have been captured, tetramethylrhodamine- and fluorescein-
labeled dextran will also be endocytosed and individual organelle pH will be determined 
by either capillary cytometry as described in Chapter 3
88
 or CE-LIF.
48
 If more lysosomes 
are captured following magnetic enrichment, histograms of organelle pH will show 
increased acidity (Figure 8.2.). In addition to treatment times for the pulse-chase, other 
factors such as additives to the cellular media and the coating of the nanoparticle may 
need to be considered as well. 
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Figure 8.2. Hypothetical histograms indicating increased lysosomes have been captured 
due to a different pulse-chase treatment of dextran-coated nanoparticles. If a second pulse 
chase treatment (B) has a higher relative abundance of pH 4-5 organelles than an original 
pulse chase treatment (C), this suggests more lysosomes, with increased acidity, have 
been magnetically enriched. 
8.3. Magnetic enrichment of autophagosomes 
 Organelle enrichment methods are still needed to enrich autophagosomes in high 
purity, high yield, with intact organelle membranes.
85
 Chapter 5 describes the enrichment 
of autophagosomes from tissue and cell culture. Density gradient centrifugation provided 
an excellent purity of autophagosomes. Since cell culture was used instead of starting 
material as tissue, density gradient centrifugation could not be used for autophagosome 
enrichment.
8830, 281
 It is difficult to increase the amount of starting material from cell 
culture when expensive pharmacological treatments such as vinblastine or when 
expensive SILAC-reagents are used to treat cell culture. To enrich autophagosomes from 
cell culture, vinblastine treatment was used to increase the yield of autophagosomes
81
 and 
several steps were taken to remove unwanted organelles such as treatment with glycyl-L-
phenyl-2-naphthylamine to osmotically lyse lysosomes and magnetic immunoenrichment 
to remove mitochondria.
81
 While autophagosomes were enriched and lysosomes and 
mitochondria were not detected in the enriched fraction, other organelles that were not 
examined for their presence could remain in the autophagy-enriched fraction. While low 
levels of these organelles could be present due to macroautophagy of organelles, their 
enrichment levels should be diminished compared to autophagosomes.
75
 Techniques are 
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needed to enrich autophagosomes from biological samples and cell culture by specifically 
selecting autophagosomes instead of the de-enrichment of other organelles. 
 Magnetic immunoenrichment of autophagosomes would provide a technique to 
enrich autophagosomes from tissue and cell culture. Magnetic immunoenrichment is 
described in Section 2.4. In brief, a magnetic nanoparticle is coated with an antibody for 
an organelle-specific protein. Following binding between the antibody and protein, an 
external magnetic field can be used to separate the magnetic and non-magnetic fractions. 
The organelle of interest, bound to the antibody, should be enriched in the magnetic 
fraction. Autophagosomes have a well-established protein marker, LC3-II, with many 
commercially available antibodies. Previous magnetic immunoenrichment techniques for 
organelles have been developed in the Arriaga lab resulting in organelle fractions that 
have intact membranes.
85, 213, 287
  
 Magnetic cell sorting has been thoroughly introduced and discussed in the 
literature. The technique separates magnetically labeled cells from non-labeled cells.
207, 
281, 288-295
 Cells are labeled with magnetic particles coated with antibodies against cellular 
surface proteins which cause magnetically-labeled cells to flow to different outlets due to 
an applied magnetic field. The techniques used in magnetic cell sorting can be used for 
organelle magnetic immunoenrichment to allow simultaneous enrichment of different 
types of magnetic, immunolabeled organelles. To perform magnetic immunoenrichment 
of organelles, proteins specific to an organelle must be identified (Table 8.1), antibodies 
for the organelle-specific proteins must be either commercially available or developed, 
and antibodies must be conjugated to the magnetic particles.
213, 287
 Due to the availability 
of antibodies for autophagy-related organelle marker proteins, magnetic immuno-
enrichment could be applied for the magnetic immunoenrichment of autophagy-related 
organelles. Organelles may be labeled with antibody-coated magnetic particles with 
varying magnetic susceptibility.
281, 288, 293, 295
 This will allow organelles to be directed to 
different outlets in a magnetic separator when an external magnetic field is applied 
(Figure 8.3).
 21, 26, 27, 29
 In the event that an organelle can bind multiple antibody-bound 
magnetic particle, controls will be needed to determine the resolution of magnetic 
separation of organelle types. Continuous separation would allow for increased yield of 
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magnetically separated organelles. Two different magnetic separator designs have been 
previously designed for cells that are capable of separating cells and particles with greater 
than 90% purity of the eluted fraction (Figure 8.3.) making these magnetic separators 
excellent candidates for organelle magnetic immunoenrichment.
281, 288
 
Organelle Marker Protein 
Phagophore LC3,
296
 Beclin 1
297
 
Autophagosome LC3, GATE-16
296, 298
 
Amphisome LC3, Mannose-6-phosphate receptor
299
 
Autolysosome LC3, LAMP1
300
 
Lysosome LAMP1
300
 
Late Endosome Mannose-6-phosphate receptor
299
 
Table 8.1. Autophagy-related organelle proteins for fluorescent labeling. 
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Figure 8.3. Organelle magnetic immunoenrichment design. (A) Buffer flow is 
perpendicular to the magnetic field. Magnetically labeled autophagy-related organelles 
(hexagons, squares, and spheres) are separated based on their magnetic susceptibility in 
the flow device. Outlets are built along the length of the flow channel.
288
 (B) Similar to A 
except all outlets are at the end of the separation device.
281
 
8.4. Building online databases to improve number of preliminary identifications 
 As described in Chapter 5, UPLC-MS
e
 was used to make preliminary 
identifications of features from an enriched autophagosome fraction. These features and 
preliminary identifications may be important to maintain proper autophagosome function 
and autophagy flux. Of the 185 features detected with the workflow from enriched 
autophagosome fractions, 153 were not identified with online database searches. 
Increasing the number of entries of small molecules in mass spectrometry databases will 
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increase the number of additional preliminary identifications and will decrease the 
experimental time needed to validate preliminary identifications. 
 LipidMAPS, Chemical Entities of Biological Interest, and the Human 
Metabolome Database are databases used for making preliminary identifications of 
features from biological samples, including features of organelles, and together contain 
over 75,000 biologically-relevant small molecules. Additional database entries produced 
by the LC-MS community will increase the numbers of database entries and can lead to 
increased number of preliminary identifications in future studies and retroactive searches 
of completed studies. Making additional preliminary identifications will lead to increased 
numbers of validated identifications and lead to increased understanding of 
autophagosomes and endocytic organelles. 
 Additional evidence supporting preliminary identifications would provide 
increased confidence in database identification. In the workflow described in Chapter 5, 
theoretical fragments are predicted with MassFragment software and compared to 
detected fragments. Currently, only predicted high-collision energy mass spectra can be 
used for structure elucidation for high-accuracy mass spectra. The METLIN database 
contains about 11,000 high-resolution MS
2 
metabolites.
301
 There are no online databases, 
however, that combine high-mass accuracy mass spec and MS
2 
for database 
identifications of features. Comparing detected daughter ions from high-collision energy 
mass spectra to online databases that have parent and daughter mass spectra standards 
would provide increased confidence in a preliminary identification when compared to 
theoretical fragmentation.  
 Building databases will likely require the scientific community as a whole and 
would make additional preliminary identifications difficult to perform quickly. 
Furthermore, it is difficult to learn of updates for online databases. Mass spectra of 
chemical standards can be used to determine if potential identifications made from 
databases are correct, however, this could prove to be expensive and time-consuming. 
Alternative methods of mass spectrometry, such as targeted methods like MS
2
, could be 
used to collect mass spectra of features. Fragments of small molecules can be identified 
to determine the identity of an unknown compound. For example, the identifies of 
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triglycerides could be determined by first identifying the compounds of the side chain 
fatty acids. 
8.5. Validation of preliminary identifications 
 The work described in chapter 5 concludes by making several preliminary 
identifications of features enriched in autophagosomes. Validation of preliminary 
identifications is always needed to confirm the identification.
302
  Validation with 
commercial standards is relatively straightforward if high quality commercial standards 
are available. The standard is examined using the same methodology used for examining 
the feature located in the biological sample. This includes comparison of extracted ion 
chromatograms, low energy mass spectra, and high energy mass spectra. If the 
preliminary identification is correct, the mass spectra of the biological feature and the 
commercial standard should be very similar. The Arriaga lab is equipped to perform these 
experiments in the chemistry department’s mass spectrometry facility provided standards 
can be acquired (such as the commercial standard for sphinganine (Avanti Polar lipids, 
Alabaster, AL). 
 Validation can also be done while comparing autophagosomes samples from 
different autophagy flux conditions. For enriched autophagosome samples, a 
pharmacochemical treatment can be used to increase the number of autophagosomes
81
 
and therefore increase the concentration of autophagosome-specific compounds. 
Likewise, siRNA techniques could be used to decrease the number of autophagosomes
303
 
and therefore decrease the concentration of autophagosome-specific compounds. Tandem 
mass spectrometry can be performed with a triple quadrupole mass spectrometer to 
monitor a specific parent ion and specific daughter fragments.
304
 The autophagosome 
sample can be spiked with an isotope-labeled standard and run simultaneously. The 
detected daughter m/z fragments should be similar between the isotope standard and the 
biological feature, however, the m/z values will be different due to the isotope labeling. 
Features associated with autophagosomes will have increased levels for biological 
systems with accumulated autophagosomes when compared to a control sample. Features 
not associated with autophagosomes will have decreased levels for biological systems 
without autophagosomes. Using isotopically labeled standards to validate preliminary 
 132 
identifications made in the work described in Chapter 5 will both validate and provide 
associations between the validated compounds and different autophagy flux conditions.  
8.6. Determination of selective autophagy with CE-LIF 
 Chapter 6 presents the first study of temporal changes of individual organelle 
numbers, GFP-LC3-II levels, and electrophoretic mobility of accumulated 
autophagosomes and phagophores following pharmacological treatment of basal 
autophagy and rapamycin enhanced autophagy levels by CE-LIF. One drawback of this 
study, however, is that the properties of different types of autophagy-related organelles 
could not be directly determined because LC3 is localized in phagophores, amphisomes, 
autolysosomes, and autophagosomes.
305
 
 Autophagy-related organelles (phagophores, autophagosomes, amphisomes, and 
autolysosomes) have unique combinations of proteins that could be used for their specific 
detection (Table 8.1.).
57
 Laser induced fluorescence detectors can be set up to detect four 
fluorescently labeled proteins specific for an organelle type (one laser induced 
fluorescence detector per protein). This instrument is depicted in Figure 8.4. Up to four 
different organelle-specific proteins can be detected allowing specific autophagy-related 
organelles to be detected. This may determine specific autophagy organelle properties 
such as marker protein levels and electrophoretic mobilities from biological systems with 
different autophagy levels. Furthermore, this could determine if specific autophagy 
organelles have increased numbers under different autophagy levels. 
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Figure 8.4. CE-LIF instrument with four LIF detectors. Thus allows detection of four 
fluorescently labeled organelle-specific proteins. Two excitation lasers can be focused on 
the sheath flow cuvette to excite four fluorescently-labeled proteins specific for four 
different organelles. Four different bandpass filters will be used to detect four different 
fluorophores.  
 Determination of autophagy levels of organelle-specific autophagy levels such as 
lipophagy (lipid droplets),
306
 mitophagy (mitochondria),
307
 pexophagy (peroxisomes),
308
 
reticulophagy (endoplasmic reticulum),
309
 and ribophagy (ribosomes),
309
 is determined 
with multiple measurements of the levels of autophagosome and the autophagocytosed 
organelle by Western blotting, fluorescence confocal microscopy, and transmission 
electron microscopy.
29, 310
 Similar to macroautophagy, however, temporal changes of 
individual organelle numbers, GFP-LC3-II levels, and electrophoretic mobility of these 
organelles are still unknown. Therefore, a need exists to determine organelle-specific 
autophagy organelles properties similar to the work described in Chapter 6.  
 134 
 To determine temporal changes associated with the organelle-specific 
accumulation of individual autophagy organelles from different autophagy levels, 
individual autophagy organelle numbers and properties will be determined. 
Fluorescently-labeled proteins can be used to label autophagocytosed and non 
autophagocytosed organelles in organelle-specific autophagy pathways. Proteins unique 
to autophagy-targeted organelles and to the non autophagy-targeted organelle can be 
labeled (Table 8.2.). Increased and decreased organelle-specific autophagy can be 
triggered using multiple techniques such as increased Parkin levels by cellular 
transfection to increase mitophagy
311
 and 3-methyl adenine to decrease mitophagy.
76
 
Organelle Marker Proteins Reference 
Lipid Droplet Perilipin-2 
312
 
Autophagy-targeted 
Mitochondria 
PINK1, Parkin, VDAC1, 
TOM22 
76, 313-315
 
Non Autophagy-
targeted 
Mitochondria 
VDAC1, TOM22 
42, 44-46
 
Peroxisome Pex14 
316
 
Endoplasmic 
Reticulum 
p28 
317
 
Ribosome S6 
318
 
Table 8.2. Organelle-specific proteins for monitoring selective autophagy. 
 Properties will be determined such as the numbers of autophagosome events with 
internalized, autophagocytosed organelles such as mitochondria, fluorescent protein 
levels of autophagy organelles such as LC3-II, fluorescent protein levels of 
autophagocytosed organelles such as Parkin, and electrophoretic mobility of autophagy 
organelles and non-autophagocytosed organelles. The number and properties of non 
autophagy-targeted organelles, such as mitochondria not undergoing mitophagy, will also 
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be determined. The instrumental setup proposed for detecting different autophagy-related 
organelles can also be used to monitor selective autophagy pathways. 
8.7. Conclusion 
 This chapter describes additional work needed to advance the enrichment and 
analysis of endocytic organelle and autophagosome fractions. Increasing the yield of 
endocytic organelles will allow for additional applications of the technique, such as 
determining features unique or increased in lysosomes by UPLC-MS.  Magnetic 
immuno-enrichment of autophagosomes and autophagy-related organelles may provide a 
highly enriched sample that is prepared relatively quickly and can be used to determine 
autophagosome properties. Making additional database identifications and validating 
identifications from autophagosome enriched fractions will provide new insights into 
how autophagosomes function. Finally, labeling of specific autophagy-related organelles 
will allow for the determination of the temporal changes of specific autophagy organelles 
and insight into organelle-specific autophagy such as mitophagy. These advancements 
will provide new insights to the work described in the thesis by expanding the 
applications of the highly enriched organelle fractions, confirm the preliminary 
identifications of autophagosomes providing new chemical markers for future studies of 
autophagy, and understanding of the properties of each autophagy organelle e.g. 
phagophores, autophagosomes, amphisomes, and autolysosomes, for different autophagy 
levels and organelle-specific autophagy levels. These will be new markers and properties 
to study lysosome- and autophagosome-associated disorders.  
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Supplementary Material to Chapter 3 
Individual organelle pH determinations via laser-induced fluorescence detection of 
magnetically-enriched endocytic organelles 
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A.1. Imaging 
Fluorescent regions were defined by those pixels with fluorescence intensities 
above the threshold, defined as the background plus five times the standard deviation of 
the background. Cross-talk caused by detection of Lysotracker Red and AlexaFluor488-
FeDex in the wrong imaging setting was calculated by treating cells with only one 
fluorescent label and observing the preparation with the two fluorescence microscope 
filter sets. When cells were treated with only LysoTracker Red, pixels in the green image 
had on average 9.1% of cross-talk from the red image. This factor was subtracted from 
the green image to obtain a corrected fluorescence representative of AlexaFluor488-
FeDex. There was no detectable cross-talk from the AlexaFluor488-FeDex into the red 
image. 
Manders coefficients M1 and M2 were used to evaluate colocalization of 
fluorophores in image overlays (Figure 3.3, Figure A-1). These coefficients were 
calculated as: 
   
         
   
    Equation A.1. 
   
         
   
    Equation A.2. 
where Ri,coloc = 1 for any pixel with LysoTracker Red fluorescence that also has 
colocalized AlexaFluor 488 fluorescence, Gi,coloc = 1 for any pixel with AlexaFluor488-
FeDex fluorescence that also has colocalized LysoTracker Red fluorescence, Ri is total 
number of pixels showing Lysotracker Red fluorescence, and Gi is the total number of 
pixels showing AlexaFluor 488 fluorescence. 
The intensity correlation quotient (ICQ) was used to compare the trends of 
fluorescence intensities of AlexaFluor 488 and LysoTracker Red in image overlays. The 
ICQ was calculated as: 
     
                          
 
      Equation A.3. 
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where Ri and Gi are the LysoTracker Red and AlexaFluor488-FeDex fluorescence 
at pixel (i), respectively, Rav and Gav are the respective average intensities for N pixels 
with colocalized fluorescence, while sign(Ri > Rav) and sign(Gi > Gav) represent the sign 
(i.e. positive or negative) resulting from comparing the pixel (i) fluorescence intensity 
relative to the average fluorescence intensity. When both signs are the same, a value of 
“1” is added. ICQ values range from 0.5 (direct correlation) to -0.5 (inverse correlation). 
A.2. Determination of the pH of individual organelles 
A.2.1. Synthesis of liposomes used as pH standards 
Aliquots of 187 μL of 1.29 × 10-2 M phosphatidylcholine, 169 μL of 1.3 × 10-2 
M phosphatidylethanolamine, 30 μL of 2.5 × 10-2 M cholesterol, and 9 μL of 2.3 × 10-2 
M phosphatidylserine (all in chloroform) were added and mixed in a 5 mL round bottom 
flask.
48
 The mixture was swirled and concentrated under a stream of nitrogen gas. The 
sample was dried overnight in a dessicator. Aliquots of 500 μL of various buffers 
representing various pHs were added to separate round bottom flasks: 10 mM HEPES 
(pH 7.92), 4 mM phosphate (pHs 7.45 & 6.87), 4 mM succinate (pH 5.89), and 4 mM 
citrate (pHs 5.05, 4.02, and 3.07). To each flask, Fluorescein-TMRM-conjugated dextran 
was added to the buffer in the flask (0.4 mg/mL HEPES, 0.4 mg/mL phosphate, 0.5 
mg/mL succinate, 1.0 mg/mL 5.05 citrate, 1.9 mg/mL 4.02 citrate, and 3.5 mg/mL 3.07 
citrate) and vortexed 5 minutes to form liposomes. After two hours swelling at 4°C, 
liposomes were centrifuged at 13,200g and washed with their respective buffer. 
Liposome sample was diluted 1,000x v/v with buffer M and analyzed as described in 
Chapter 3. Liposomes were analyzed within 48 hours to avoid degradation. 
A.2.2 LIF detection of liposomes 
Liposomes were delivered to the LIF detector using the same conditions described 
in the Experimental for the delivery of organelles. Coincidence peaks were identified as 
described previously.  An x-y plot was used to determine the slope (R) of the fluorescein 
fluorescence intensity versus the TMRM fluorescence intensity for each pH tested. This 
slope is unique for each pH and is represented as “R”. The R values for each pH yield the 
calibration curve: 
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                                   Equation A.4. 
where the errors of the slope and the intercept are determined from the linear fit.  
The data for this calibration curve are shown in Figure S.3. Since there is also an error 
associated with “R”, we used the maximum error of “R” (i.e., (R = 0.05 at pH 7.9) in 
combination with the errors of the slope (m) and the intercept (b) to estimate the error 
of each pH (pH) determined from the calibration curve. The expression used to 
determine pH is: 
       
 
       
 
 
 
  
  
 
 
 
         
  
  
 
 
 
   Equation A.5. 
A.3. Figures 
 
Figure A.1. Confocal microscopy imaging colocalization (A) AlexaFluor488-FeDex 
detection. (B) LysoTracker Red detection. (C) Overlay. This method was done to create 
Figure 3.3. in Chapter 3 and perform M1, M2, and ICQ analysis. Scale bar = 10 μm 
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Figure A.2. Selection of washing flow rates. The pNPP (lysosomal), catalase 
(peroxisomal), and DCIP (mitochondrial) assays were used to determine the composition 
of the magnetically retained material. All assays were done in triplicate. Thin bars are one 
standard deviation. 
 
Figure A.3. Calibration curve for pH of individual organelles. Liposomes used as 
standards contained fluorescein/TMRM-bound dextran. The error bars correspond to the 
standard deviation of the slope determined from the x-y plot for each pH. 
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Figure A.4. Raw data from LIF detection shown in Figure 3.4. 
 
Figure A.5. Comparisons of individual organelle pH values. (A) Q-Q plot comparing pH 
of unretained organelles from cells not exposed (x-axis) and treated with nigericin (y-
axis). (B) Q-Q plot comparing unretained organelles from cells not exposed to FeDex (x-
axis) and exposed to FeDex (y-axis). This data was used to determine the correction 
factor (Table A.1). (C) Corrected data showing the number of unretained organelles 
within a given pH interval from cells treated with FeDex. 
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A.4. Tables 
Quantile (%) FeDex Treated Untreated Difference 
10 4.85 3.14 1.71 
20 5.52 3.88 1.64 
30 5.95 4.31 1.64 
40 6.30 4.63 1.67 
50 6.65 4.97 1.68 
60 7.01 5.28 1.73 
70 7.40 5.60 1.80 
80 7.86 6.15 1.71 
90 8.41 6.83 1.58 
100 10.60 8.69 1.91 
  Average 1.7 
  S.D. 0.1 
Table A.1. Corrections and controls of pH for organelles containing FeDex. The raw data 
for organelles containing both FeDex and fluorescein/TMRM-bound dextran (Figure S.4 
were corrected with a median filter to eliminate the broad band and to determine 
coincident events as described in the section A.5 (Figure 3.4). Shifting in pH could be 
caused by treatment with nigericin (Figure S.5A). This is expected because nigericin is a 
protonophore that dissipates the pH gradient. It was noticed that when FeDex was present 
all the pH values were shifted (Figure S.5B). Therefore the pH distributions of FeDex 
treated and untreated were compared quantile by quantile in increments of 10% (Table 
S.1).  The average difference, 1.7 ± 0.1 pH units, was used to adjust the pH of organelles 
treated with FeDex. An example of the corrected data is shown in Figure S.5C. 
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Supplementary Material to Chapter 4 
Magnetically Enriched Endocytic Organelles from Uterine Sarcoma Cells Biotransform 
the Prodrug N-L-Leucyldoxorubicin into Doxorubicin 
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B.1. Figures 
 
Figure B.1. Mass spectrometry of LeuDox. LeuDox sample analysis resulted in a clean 
mass spectrum with the major and minor peaks decreasing in magnitude during formation 
of Dox. When characterizing the LeuDox synthesis product, one other m/z value was 
detected by mass spectrometry that has the anthracycline ring and could be detected by 
fluorescent detection (m/z = 397). A Waters Acquity Triple Quadrupole instrument was 
used with electrospray ionization in positive ion mode.  Direct infusion of purified Leu-
Dox (10
-4 
M in methanol) resulted in the expected m/z value of the parent ion (m/z = 657).  
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Supplementary Material to Chapter 5 
UPLC-MSe, Chemometrics, and Mass Spectral Evaluation Criteria for Preliminary 
Identification of Chemical Entities Specific to Enriched Autophagosomes and Activated 
Mast Cells 
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C.1. Tables 
System
1
 Ext
2
 ESI
3
 
Potential 
Features 
Candidate 
Features 
Confirmed 
Features 
% CF
4
 
Potential 
IDs 
Preliminary 
IDs 
Liver Polar + 2086 62 45 11 28 14 
Liver NP + 1045 49 28 23 18 9 
Liver NP - 437 3 3 0 0 0 
Myoblast Polar + 1440 56 51 19 37 7 
Myoblast NP + 2008 55 45 22 28 3 
Myoblast NP - 1624 19 16 19 4 2 
MCN (vs. MCX) NA - 4765 10 10 39 1 0 
MCCX (vs. MCN) NA - 4765 11 8 0 6 0 
MCN (vs. MCTN) NA + 1914 398 286 23 3 1 
MCTN (vs. MCN) NA + 1914 181 136 50 24 6 
MCN (vs. MCTN) NA - 2843 487 186 3 12 1 
MCTN (vs. MCN) NA - 2843 266 102 41 23 2 
MCB (vs. MCCX) NA + 1804 187 168 13 19 3 
MCCX (vs. MCB) NA + 1804 449 431 33 2 0 
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MCB (vs. MCCX) NA - 2985 248 148 4 20 1 
MCCX (vs. MCB) NA - 2985 418 186 15 4 0 
Table C.1. Summary of workflow. 
1
- Liver = enriched autophagosomes from liver; myoblast = enriched autophagosomes from rat 
myoblasts; MCN = mast cells, non-activated; MCTN = TNPova-activated mast cells; MCCX = CXCL10-activated mast cells; MCB = 
Both CXCL10- and TNPova-activated. 
2
- Extractions performed were either nonpolar (NP) or polar (see materials & methods). NA = 
no extraction made. 
3
- ESI analysis was performed in positive (+) and negative (-) ionization modes. 
4
- % C.F. = the percentage of 
common confirmed features detected in a system by OPLS-DA and either LMM or t-test.
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C.2. Figures 
 
Figure C.1. Western blots of rat liver autophagosome-enriched fractions revealed the 
autophagosome fraction was free of contamination from other organelles. From rat liver 
homogenate (HOM), a pellet containing the nuclear fraction and (up to 30%) unbroken 
cells was produced. The supernatant was centrifuged at 17000g and the pellet is enriched 
in autophagosomes, lysosomes and mitochondria. The supernatant was centrifuged at 
100000g and the pellet contains the vesicles in the non autophagosome, endoplasmic 
reticulum enriched fraction (ER). From the 17000g pellet fraction, autophagosome (A), 
lysosome (L), and mitochondria (M) were separated by differential centrifugation in 
discontinuous density metrizamide gradients as described in the manuscript. 
Experimental antibodies were anti-LC3 (1:500 v/v dilution, rabbit, NB-2220, Novus 
Biologicals, Littleton, CO), anti-SEC61B antibody (1:2000 v/v dilutionb, rabbit, NB100-
74530) Novus Biologicals (Littleton, CO ), anti-LAMP1 antibody (1:1000 v/v, rabbit, 
ab24170, Abcam, Cambridge, MA), anti-Tom20 antibody FL-145 (1:500 v/v dilution, 
rabbit, sc-11415, Santa Cruz Biotechnology, Santa Cruz, CA), and anti-G3PD antibody 
(1:500 v/v dilution, rabbit, 600-401-A33, 600-401-A33, Rockland, Gilbertsville, PA). 
Anti-rabbit (R21459) or anti-mouse (G21234) IgG (H+L) horseradish peroxidase 
secondary antibodies (1:5,000 v/v dilution, goat, Invitrogen, Carlsbad, CA) were used for 
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chemiluminescence detection (Renaissance, NEN-Life Science Products). Membranes 
were exposed to BioMax Light Kodak films (Kodak Scientific Films) for increasing 
periods of time ranging from 5 s to 10 min.  
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Figure C.2. Western blots of autophagosome-enriched fractions from rat myoblasts show 
minimal mitochondria and lysosome contamination. Non-enriched, control organelle 
fraction (C), a semi-enrichment fraction (I), and the autophagosome-enriched fraction (A) 
were loaded onto a 15.0% “12+2” well SDS-PAGE gel (Criterion, Hercules, CA). 
Precision Plus Protein Dual Color standards (BioRad, USA) were used as a ladder for 
determination of molecular weights. The gel was run for 125 V for 60 min. Proteins were 
transferred onto a nitrocellulose membrane, 0.45 μm (BioRad, Germany). Transfer was 
done at constant voltage (100 V) for 2 h. Experimental antibodies were anti-LC3 (1:500 
v/v dilution, rabbit, NB-2220, Novus Biologicals, Littleton, CO), anti-LAMP1 antibody 
(1:1000 v/v, rabbit, ab24170, Abcam, Cambridge, MA), and anti-COX-IV (1:500 v/v 
dilution, mouse, ab14744, Abcam,Cambridge, MA). Antibodies were diluted in 4% skim 
milk (Nestle, Eden Prarie, MN) in TBS/T solution (BioRad, USA). Anti-rabbit (R21459) 
or anti-mouse (G21234) IgG (H+L) horseradish peroxidase secondary antibodies (1:5,000 
v/v dilution, goat, Invitrogen, Carlsbad, CA) were used for chemiluminescent detection. 
Membranes were imaged on a SRX-101A from Konica Minolta using Super Signal West 
Femto Maximum Sensitivity Substrate (Thermo Fisher, Rockford, IL). Glyceraldehyde 3-
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phosphate dehydrogenase (G3PD) was used as a positive control for the Western blotting 
system to ensure lanes contained protein. anti-G3PD antibodies were used for 
determination of G3PD as a loading control (1:500 v/v dilution, rabbit, 600-401-A33, 
Rockland, Gilbertsville, PA). 
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Figure C.3. Structures of preliminary identifications made for (A) rat liver 
autophagosomes, (B) rat myoblast autophagosomes, and (C) chemically activated mast 
cells. Two structural isomers of compound HMDB00269(*) were detected in enriched rat 
liver autophagosomes (Table 5.1.). 
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Describing the temporal nature of autophagy at the individual organelle level by 
Capillary Electrophoresis with Laser Induced Fluorescence Detection 
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D.1. Fluorescence Confocal Microscopy  
Preparation of cells for fluorescent confocal microscopy was done as previously 
described.
88
 Briefly, LabTek 4 chambered coverslips were incubated with poly-L-lysine 
(100 μL) for 30 min. prior to cell culture to improve cellular attachment to the coverslip. 
Cells were treated with vinblastine, rapamycin, or both vinblastine and rapamycin. Cells 
were fixed with 4% v/v formaldehyde in water, then permeabilized with 10% v/v Triton 
X-100 in water, and finally incubated with 5% w/v BSA to reduce non-specific binding 
of antibodies.
88
 Cells were then incubated with rabbit anti-LC3 antibody (1 μL in 250 μL; 
2% w/v BSA in 1× PBS) overnight. Cells were then washed with 1× PBS three times for 
5 minutes with PBS. Cells were then incubated with goat anti-rabbit AlexaFluor568 
secondary antibody specific to anti-LC3 antibody (1 μL in 250 μL; 2% w/v BSA in 1× 
PBS) for 1 hour. Cells were again washed with 1× PBS three times for 5 minutes to 
remove unbound antibody. 
Images were acquired with an Olympus IX81 inverted microscope (Melville, NY) 
as previously described.
88
 Data analysis of microscopy images was done with Simple PCI 
5.3 (Compix Inc., Cranberry Township, PA) as previously described.
88
 Colocalization 
was calculated between GFP-LC3 and anti-LC3 fluorescent signals using Equations D.1., 
D.2., D.3., and D.4.
86
 The M2 coefficient confirmed the GFP-transfected protein was 
LC3 (Table D.1). The R and ICQ coefficients indicated a 70-95% correlation between 
GFP and AlexaFluor568 (See Appendix, Table D.1). GFP-labeled organelles were 
observed in all samples with more intense organelles appearing in the vinblastine-treated 
samples (Figure D.1). 
D.2.Microscopy Correlation and Colocalization Equations 
Five regions of interest (ROIs) of the extracellular background were assessed to 
remove native fluorescence. The average ROI fluorescence (AveROI) and standard 
deviation ( ROI) were determined. To remove native fluorescence, the sum of AveROI and 
5 ROI were subtracted from each image. WCIF Image J-W, version 1.43s (National 
Institutes of Health) was used to calculate the Manders overlap coefficients (R, M1 and 
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M2), Pearsons Correlation Coefficient (r), and intensity correlation coefficient (ICQ). 
The Pearsons Correlation Coefficient was calculated as follows: 
    
                
         
          
 
     Equation D.1. 
where Ri is red fluorescence intensity in  pixel (i), Ra is the average red 
fluorescence intensity, Gi is green fluorescence intensity in pixel (i), Ga is the average 
green fluorescence intensity. This coefficient measures the linear relationship between 
the intensities of two fluorophores on a pixel-by-pixel basis. Its range is from -1 to +1. 
The Manders Overlap Coefficient (R) was calculated as follows: 
   
          
      
       
 
    Equation D.2. 
where the parameters are the same as those defined for the Pearson Correlation 
Coefficient. Its range is from 0 to +1. 
The M2 Coefficient gives the number of green fluorescence pixels (GFP) that also 
register red fluorescence (AlexaFluor568) was calculated as follows:  
    
         
   
    Equation D.3. 
where Gi,coloc is the number of green fluorescence pixels with colocalized red 
fluorescence, and Gi is the total number of pixels registering green fluorescence. Its range 
is from 0 to +1. 
The ICQ was calculated as follows: 
      
                
 
       Equation D.4. 
where the expression in the numerator refers to counting the number of pixels where both 
red (Ri) and green (Gi) fluorescence in pixel (i) are above or below their respective  
average, (Ra and Ga),  and N is the total number of pixels. The range of ICQ is from -0.5 
to +0.5. 
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 R R M2  ICQ 
Control 
(n=7) 
0.79 ± 
0.08 
0.57 ± 
0.15 
0.94 ± 
0.08 
0.24 ± 
0.15 
Vinblastine-
treated 
(n=6) 
0.84 ± 
0.08 
0.61 ± 
0.08 
1.00 ± 
0.00 
0.21 ± 
0.05 
Rapamycin-
treated 
(n=7) 
0.95 ± 
0.02 
0.78 ± 
0.08 
0.98 ± 
0.03 
0.32 ± 
0.06 
 
Table D.1. Summary of colocalization analysis of GFP and Immunolabeling with a 
secondary antibody labeled with AlexaFluor 569. 
 
Figure D.1. Exemplary fluorescence confocal microscopy of two different vinblastine-
treated L6 cells expressing GFP-LC3.  Green fluorescence is from GFP-LC3 and red 
fluorescence is from the secondary antibody labeled with AlexaFluor 586. (A) 
AlexaFluor 568 fluorescence of vinblastine-treated cell. (B) GFP fluorescence of 
vinblastine-treated cell. (C) Overlay of (A) and (B). (D) AlexaFluor 568 fluorescence of 
vinblastine-treated cell. (E) GFP fluorescence of vinblastine-treated cell. (F) Overlay of 
(D) and (E). Scale bar = 10 μm.  
D.3. Detector calibration and correction for variations in sensitivity and 
electrophoretic mobility.  
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To align the custom built instrument, AlignFlow flow cytometry alignment beads 
(Life Technologies, Grand Island, NY, 1:100 v:v in CE buffer) were used to align the 
PMT detector. (Figure D.2.). All relative standard deviations determined for the 
AlignFlow beads were below or equal to 27%, which is the manufacturer’s reported value 
(Table D.2.). This indicates the custom built instrument was aligned and that reproducible 
measurements of the fluorescence intensity of individual organelles can be made. Any 
detected changes in the GFP-LC3 levels of organelles on a given day can be attributed to 
differences in the autophagy organelles rather than the alignment. 
Changes in detector sensitivity were determined to correct for changes in 
organelle GFP-LC3 levels as described in Section 6.4.6. Since sensitivity can change 
from day to day, a correction factor needed to be applied for changing sensitivity so that 
organelle values are not biased because of a changed sensitivity on different days. In 
order to make this correction, we needed to confirmed that the alignment was the main 
source of any changes in detector sensitivity rather than changes in optics such as 
cleanliness and distances between optics. The expected decrease in standard deviation of 
the electropherogram background was calculated, which is proportional to the loss of 
background fluorescence signal. Overall, the percent difference between the calculated 
and observed standard deviation was between 2-14% for the four different days which 
separations were run. This difference suggests that the alignment of the custom-built 
instrument was the main cause for changing sensitivity and potential changes in GFP-
LC3 levels and confirms that the background can be used to make corrections. These low 
deviations suggest there may be a slight change in the cleanliness of the optics of the 
custom-built CE instrument and the proximity between the capillary tip and laser may 
have changed for separations done on different days.  
While individual autophagy organelle fluorescence levels were corrected for 
differences in sensitivity of the fluorescence detector, detection of low-intensity 
autophagy organelle events such as phagophores and autolysosomes may not be detected 
in some electropherograms due to changes in limits of detection. This can cause some 
comparisons of organelle quantiles to be slightly skewed due to the inability to detect all 
individual organelles. The two treatments that were the most affected by this are the 
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untreated and rapamycin-treated conditions. If we assume lower intensity events were not 
detected, detection of these low intensity events could lower the GFP-LC3-II values of all 
the percentile values (Figure 6.3). This would make the distance values between quantiles 
for the lowest percentiles larger in magnitude. The magnitude of this change in distance 
is undeterminable, if a change occurs. Overall, it is important to reiterate that when 
comparing percentiles of organelle events, these are comparisons of only the detected 
organelle events. Additional optimization of the custom-built CE-LIF instrument and 
development of new probes with increased fluorescence emission levels could optimize 
the detection of all autophagy organelle events. 
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Experiment %RSD Points Per Peak n 
Basal 15 10 212 
Vinblastine 13 15 154 
Rapamycin 26 15 199 
Both Vinblastine 
and Rapamycin 
13 12 145 
 
Table D.2. Alignment of CE-LIF detector prior to individual organelle detection. 
AlignFlow beads were delivered to the detector using 10psi to align the detector and 
minimize the relative standard deviation (%RSD) of peak intensities. The observed 
%RSD was comparable to the %RSD of the AlignFow beads provided by Life 
Technologies (28%) suggesting that the custom-built instrument was aligned to provide 
reproducible fluorescence intensity levels of particles or organelles. The points per peak 
values suggest particles were not undersampled and that reported %RSD values are 
accurate. To confirm that 10 psi provided a linear flow of beads similar to the separation 
voltage used for autophagy organelle separation, (-300 V/cm), alignment with AlignFlow 
beads was also done at -297 V/cm. This separation voltage resulted in a %RSD for bead 
intensity of 19.3% with 13 points per peak. These values are comparable to values 
obtained with 10 psi. AlignFlow Beads first appeared after ~275 sec when using 10 psi. 
Using the pre-migration window for autophagosomes (450-500 sec), we can estimate the 
linear flow from voltage-based alignment and separations to be 2-fold reduced compared 
to the linear flow from pressure-based alignment, however, this reduction does not appear 
to change the alignment values.  
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Figure D.2. Alignment of CE-LIF detector for individual organelle detection. AlignFlow 
beads were diluted in CE buffer (1% v/v) and were flowed through the capillary at 10 psi. 
The %RSD of the beads was 15% and the average points per peak was 10. 
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Basal autophagy, 
no vinblastine Trial 1 Trial 2 Trial 3 
mcritical 152 100 98 
α 0.13 0.17 0.17 
P 134 84 83 
X 97 67 77 
Bins 12 14 14 
BWO 0 3 5 
mdetected 
 
128, 135, 230,  
117, 167, 123, 
140, 157 
Basal autopahgy, 
vinblastine  Trial 1 Trial 2 Trial 3 
mcritical 197 182 196 
α 0.11 0.11 0.11 
P 177 163 175 
X 87.4 77.3 86.6 
Bins 15 20 17 
BWO 3 7 5 
mdetected 
322, 321, 
235 
299, 831, 683, 
414, 430, 278, 
464 
274, 364, 298, 
258, 294 
Rapamycin-
enhanced 
autophagy, no 
vinblastine Trial 1 Trial 2 Trial 3 
mcritical 251 284 281 
α 0.09 0.09 0.09 
P 229 261 257 
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X 107.6 104.6 128.1 
Bins 15 17 16 
BWO 2 3 1 
mdetected 399, 389 553, 684, 324 473 
Rapamycin-
enhanced 
autophagy, 
Vinblastine Trial 1 Trial 2 Trial 3 
mcritical 254 277 284 
α 0.09 0.09 0.09 
P 232 254 260 
X 109.4 125.6 130.1 
Bins 13 14 10 
BWO 0 1 0 
mdetected 
 
286 
  
Table D.3. Estimation of organelle events from observed peaks. A conservative number 
of organelles (mcritical) was used for bins showing saturation (mdetected > mcritical). Saturation 
is defined based on Statistical Overlap Theory, where mdetected is the number of observed 
peaks in a bin, mcritical is the maximum number of organelle events per bin that can be 
detected without predicted overlap, α is the type-1 error (Equation 6.9), X is the bin 
width in seconds, and BWO is the number of Bins With predicted Overlap. 
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Figure D.3. Reproducibility CE-LIF runs. QQ plots of each replicate (y-axis) versus the 
pooled data (x-axis). (A) GFP-LC3 fluorescence intensity, basal autophagy. (B) 
Electrophoretic mobility, basal autophagy. (C) GFP-LC3 fluorescence intensity, basal 
autophagy and vinblastine treatment. (D): Electrophoretic mobility, basal autophagy and 
vinblastine treatment. (E): GFP-LC3 fluorescence intensity, rapamycin-enhanced 
autophagy. (F) Electrophoretic mobility, rapamycin-enhanced autophagy. (G): GFP-LC3 
fluorescence intensity, rapamycin-enhanced 
